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Abstract
This thesis aims to investigate possible adverse side effects of antiretroviral therapy 
(ART) exposure in uninfected children bom to HIV infected women, and to explore 
potential strategies for monitoring the health of these children. Using data from the 
European Collaborative Study, an ongoing multi-centre cohort study of HIV infected 
women and their children, the association between ART exposure and health outcomes 
in uninfected children was investigated. ART exposure was not associated with 
congenital abnormalities, or serious clinical symptoms up to 18 months of age. Children 
exposed to combination therapy were more likely to be premature than unexposed 
children. There was a marginal but significant negative effect of combination therapy 
exposure on weight, height and head circumference up to 18 months of age, when 
compared to no or monotherapy exposure. The CHART study, a consented clinic-based 
follow-up of uninfected children bom in the UK, was conducted for three years to 
explore the feasibility of individualised follow-up to monitor adverse health events. The 
study was based on reports to obstetric and paediatric HIV surveillance, the National 
Study of HIV in Pregnancy and Childhood (NSHPC). Of 2104 eligible children, 33% 
were enrolled, 25% lost to follow-up, parents of 5% declined and the remainder could 
not be enrolled mainly because of resources or family circumstances. To obtain details 
on deaths and cancers among ART-exposed children over the long term, nearly 2200 
uninfected children reported to the NSHPC were identified on the National Health 
Service Central Register through an anonymous matching procedure. Three deaths and 
no cancers were notified by the end of 2005. A survey of 140 parents and carers of ART- 
exposed uninfected children was conducted to seek their views on the long-term follow- 
up of their children. Although most respondents were supportive of the rationale for 
follow-up, contradictory views were expressed on how contact should be maintained.
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Chapter 1 HIV infection in women and children
1.1 HIV infection
Acquired immune deficiency syndrome (AIDS) consists of a range of opportunistic 
infections and cancers that are associated with immunodeficiency. AIDS was first 
recognised in the USA in 1981 (Gottlieb et al. 1981). The causative agent of AIDS is the 
human immunodeficiency virus (HIV), which was identified in France in 1983 (Barre- 
Sinoussi et al. 1983).
HIV is a retrovirus belonging to the genus lentivirus. The most common species of HIV 
is HIV-1. The main target cell of HIV is the CD4+ T-lymphocyte (CD4 cell), a major 
cell of the immune system. HIV replication begins when a virion binds to a CD4 receptor 
and one of two co-receptors on the host cell (see Figure 1.1). After fusion with the cell, 
ribonucleic acid (RNA) from the virion is released into the cytoplasm. RNA is then 
converted to deoxyribonucleic acid (DNA), through reverse transcription. The DNA then 
enters the nucleus and is integrated into the cell DNA. Viral production begins when 
messenger RNA (mRNA) and genomic RNA are formed. mRNA is used to make viral 
proteins which are then split into smaller proteins by the enzyme protease. A progeny 
virion is assembled from the genomic RNA and the proteins; it is then ejected from the 
host cell (Phoolcharoen and Detels 2002).
HIV infection is associated with a progressive reduction in CD4 cells and a parallel 
increase in plasma HIV RNA (viral load). The clinical course of the infection typically 
includes three stages (see Figure 1.2). Primary infection is a period of rapid viral 
replication that persists for several weeks until an immune response occurs and HIV 
antibodies are produced (seroconversion).
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Figure 1.1 The replication cycle of HIV
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Although the following asymptomatic period can last for many years and is one of 
clinical latency, there is still continued viral turnover. Later in the course o f the infection, 
HIV symptoms develop, which include weight loss, fungal infections and fevers. This is 
followed by an AIDS diagnosis: an opportunistic infection, cancer, HIV dementia or 
wasting syndrome (Centers for Disease Control and Prevention 1992).
In developed countries, median time from primary infection to the development of AIDS 
in untreated individuals is around 10 years (Munoz et al. 1989, Goedert et al. 1989). 
Death then usually occurs within two years (Mocroft et al. 1997, Rothenberg et al.
1987).
CD4 cell count and viral load are used as prognostic indicators of HIV disease 
progression. The most widely used system for classifying HIV infection and AIDS in
22
adults was published by the Centers for Disease Control and Prevention in 1992 (Centers 
for Disease Control and Prevention 1992).
Figure 1.2 Changes in CD4 cell count and HIV RNA over time during the 
natural history of HIV infection
Initial infection
I Primaryinfection Asymptomaticinfection SymptomaticHIV/AIDS
CD4
HIV RNA
6 12
Weeks Years
Source: (Luzzi et al. 2003)
HIV RNA viral load in children with vertically-acquired HIV infection (see Section 1.5) 
peaks soon after birth and then gradually declines thereafter (Figure 1.3) (European 
Collaborative Study 2002). The slower decline in viral load in infants compared with 
adults is likely to be due to the immaturity of the infant immune system. In terms of CD4 
cell counts in HIV infected children, data from Europe have shown a peak at seven 
weeks of age, with a subsequent decrease over the first few years of life (European 
Collaborative Study 2003a).
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Figure 1.3 Log RNA viral load in HIV infected children by age, sex and
antiretroviral treatment
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1.2 Antiretroviral therapy
The first antiretroviral drug used for the treatment of HIV infection was zidovudine 
(ZDV), a nucleoside reverse transcriptase inhibitor (NRTI), made available in 1987 
(Fischl et al. 1987). Additional NRTIs and three further drug classes: non-nucleoside 
reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI) and fusion inhibitors 
(FI), were subsequently developed (Table 1.1).
Large randomised clinical trials in the mid 1990s demonstrated the clinical superiority of 
using double therapy over monotherapy (Delta Coordinating Committee 1996, Hammer 
et al. 1996). Highly active antiretroviral therapy (HAART) was later shown to delay HIV 
disease progression further (Collier et al. 1996). HAART consists of at least three 
antiretroviral drugs used in combination, usually including a PI or NNRTI with two 
NRTIs.
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Table 1.1 Principal antiretroviral drugs
Nucleoside reverse 
transcriptase 
inhibitors (NRTI)
Non-nucleoside 
reverse 
transcriptase 
inhibitors (NNRTI)
Protease inhibitors 
(PI)
Fusion inhibitors 
(FI)
zidovudine (ZDV) 
lamivudine (3TC) 
didanosine (ddl) 
zalcitabine (ddC) 
stavudine (d4T) 
abacavir (ABC)
nevirapine (NVP) 
efavirenz (EFV)
ritonavir (RTV) 
saquinavir (SQV) 
nelfinavir (NFV) 
atazanavir (ATZ) 
indinavir (IDV) 
amprenavir (AMP)
enfuvirtide (T-20)
HAART was introduced in 1996 and its use soon became widespread in Europe (Kirk et 
al. 1998, CASCADE Collaboration 2000, Mocroft et al. 1998). HAART has become the 
standard of care for HIV infected individuals in resource-rich settings (Gazzard 2005). 
Of over 41 000 patients seen for HIV care in the UK in 2004, 64% were receiving three 
or more antiretroviral drugs, compared with 1 % on monotherapy or double therapy; and 
a third of patients were not on therapy (The UK Collaborative Group for HIV and STI 
Surveillance 2005).
The use of HAART has consistently been shown to improve survival in HIV infected 
individuals in both clinical trials (Hammer et a l 1997) and observational studies 
(Murphy et al. 2001). An analysis of nearly 10 000 patients in the EuroSIDA study 
showed that there was a reduced risk of AIDS in the late HAART era (1998-2002) 
compared with the early HAART era (1996-1997) (Mocroft et al. 2003). European 
HIV/AIDS surveillance has shown a reduction in AIDS diagnoses and mortality 
associated with AIDS over the last 10 years (European Centre for the Epidemiological 
Monitoring of AIDS 2005).
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Initiation of antiretroviral therapy (ART) depends on clinical and immunological staging 
of HIV disease. The combination of antiretroviral drugs used depends on factors such as 
potential drug interactions, toxicity, resistance and adherence. Antiretroviral drugs delay 
progression of disease by interrupting HIV replication (see Figure 1.1). NRTIs resemble 
nucleotides that are used to form DNA during reverse transcription. When reverse 
transcriptase takes up an NRTI instead of a natural nucleotide, growth of the DNA chain 
ceases. NNRTIs bind directly to reverse transcriptase and prevent it from adding natural 
nucleotides to the DNA chain. Pis block the activity of protease, therefore preventing 
viral proteins from being split up, and ultimately halting the assembly of progeny virions. 
FIs prevent glycoproteins from attaching to the host cell, consequently averting fusion of 
the virion.
1.3 Epidemiology of HIV infection
By the end of 2005 an estimated 40.3 million people were living with HIV worldwide, 
just under half of whom were female. Two thirds of people living with HIV were in sub- 
Saharan Africa (25.8 million) (UNAIDS/WHO 2005).
In western Europe, over 20 000 newly diagnosed HIV infections, 35% of which were in 
females, were reported to European HIV/AIDS surveillance in 2004 (European Centre 
for the Epidemiological Monitoring of AIDS 2005). By the end of 2004, over 71 000 
HIV infections were known to have been diagnosed in the UK since the early 1980s; and 
the annual total increased from nearly 4000 in 2000, to just over 7000 in 2004 (The UK 
Collaborative Group for HIV and STI Surveillance 2005).
The main routes through which HIV is transmitted are: sexual contact, exposure to blood 
or blood products, and mother-to-child transmission (MTCT). Initially the majority of
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cases of HIV and AIDS were in homosexual males and injecting drug users. Globally, 
heterosexual contact is now the predominant mode of transmission, particularly in sub- 
Saharan Africa and areas such as South-East Asia (UNAIDS/WHO 2005). MTCT is the 
dominant type of acquisition for children (see Section 1.5). In western Europe, 56% of 
newly diagnosed HIV infections reported in 2004 were through heterosexual contact, 
30% were in homosexual or bisexual men, and 10% were in injecting drug users. Almost 
all women were infected through heterosexual contact (91%) (European Centre for the 
Epidemiological Monitoring of AIDS 2005). The increase in numbers of HIV diagnoses 
in the UK in recent years (see Figure 1.4), has been mainly due to increased diagnosis of 
infections acquired through heterosexual contact in high-prevalence areas, particularly 
sub-Saharan Africa (The UK Collaborative Group for HIV and STI Surveillance 2005).
Figure 1.4 HIV diagnoses by exposure group, UK: 1995-2004
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Source: (The UK Collaborative Group for HIV and STI Surveillance 2005)
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1.4 HIV infection in pregnant women
The prevalence of HIV infection in pregnant women, regardless of diagnosis status, can 
be assessed through unlinked anonymous (UA) testing of either blood samples from 
pregnant women or residual infant dried blood spots (for maternal HIV antibodies). In 
western Europe, reported prevalence of HIV infection in pregnant women between 1995 
and 2000 ranged from <0.02% (Finland, Sweden, Norway) to 0.15% (Spain) (European 
Centre for the Epidemiological Monitoring of AIDS 2001). Prevalence of HIV infection 
in women giving birth in England and Scotland has increased dramatically in recent 
years: from 0.09% in 2000 to 0.18% in 2004 (The UK Collaborative Group for HIV and 
STI Surveillance 2005) (Figure 1.5).
Figure 1.5 HIV prevalence1 among pregnant women by area of residence
(England and Scotland)
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HIV infected pregnant women are only able to access interventions to prevent MTCT 
(described in Section 1.5) when they are aware of their infection status. The estimated 
proportion of HIV infected pregnant women diagnosed before delivery in England and 
Scotland has increased from 71% in 2000 to 92% in 2004 (The UK Collaborative Group 
for HIV and STI Surveillance 2005). This is mainly due to the widespread offer and 
recommendation of routine antenatal HIV testing since 1999 (NHS Executive 1999), and 
the increase in the number of women already diagnosed becoming pregnant (Cliffe et al. 
2001).
1.5 Mother-to-child transmission of HIV infection
1.5.1 Rates and risk factors
MTCT (or vertical transmission) of HIV can occur during pregnancy, delivery or in the 
postnatal period through breastfeeding. Intrauterine transmission may occur due to fetal 
exposure to the virus in the amniotic fluid, or due to infection of placental cells and/or 
placental disruption. The main mechanism for intrapartum transmission is direct contact 
between the infant and maternal secretions during birth (Newell and Thome 2004). In 
non-breastfeeding populations, approximately three quarters of MTCT occurs around the 
time of delivery (Mock et al 1999). Before the introduction of interventions to reduce 
the risk of MTCT, rates reported from cohort studies varied between 15-20% in Europe, 
16-30% in the USA and 25-40% in Africa (The Working Group on Mother-to-Child 
Transmission of HIV 1995).
Maternal plasma HIV RNA level is the strongest independent risk factor for MTCT, and 
this has been shown both in cohort studies (Cooper et al. 2002, European Collaborative 
Study 2005c) and in clinical trials (Shaffer et al. 1999). Clinical risk factors such as 
AIDS are indirect markers for viral load (Newell and Thome 2004). Other risk factors
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for MTCT include CD4 cell count, obstetric factors such as vaginal delivery and 
prolonged rupture of membranes (Landesman et al. 1996, Kind et al. 1998), premature 
delivery (European Collaborative Study 1999) and breastfeeding (Dunn et al. 1992).
1.5.2 Interventions
Avoidance of breastfeeding significantly reduces the risk of MTCT; and HIV infected 
women in resource-rich settings are recommended to exclusively formula feed (Hawkins 
et al. 2005). ART prophylaxis is a highly effective intervention. Results from the 
Pediatric AIDS Clinical Trial Group (PACTG) 076 trial in the USA, published in 1994, 
showed that ZDV given to HIV infected pregnant women during pregnancy and delivery 
and to the neonate for six weeks, reduced the risk of MTCT by two thirds (Table 1.2) 
(Connor et al. 1994). The protocol was soon adopted as routine clinical practice across 
Europe (European Collaborative Study 2001). ART reduces the risk of MTCT by 
decreasing viral replication and therefore viral load in the pregnant woman, and acting as 
a prophylaxis for the neonate. Other clinical trials have shown the efficacy of more 
simple and less expensive strategies, such as short-course ZDV and single-dose 
nevirapine, for use in less developed countries (Table 1.2) (Shaffer et al. 1999, Guay et 
al. 1999, World Health Organization 2004).
Over the last 10 years, there has been a shift from ZDV monotherapy to HAART use for 
HIV infected pregnant women (Cooper et al. 2002). This has reflected changes in the 
management of HIV disease in adults (Mocroft et al. 2003, Kirk et al. 1998). Although 
never evaluated in a randomised placebo-controlled trial, HAART is effective in 
reducing the risk of MTCT by lowering viral load. Cohort studies have shown very low 
rates of MTCT in the HAART era (Cooper et al. 2000, European Collaborative Study 
2005c).
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Table 1.2 Clinical trials of antiretroviral therapy to prevent mother-to child transmission
Trial Reference Setting Trial design Infant
feeding
Therapy Transmission
rateAntenatal / intrapartum Neonatal
PACTG
076
1 USA & 
France
Randomised,
placebo-controlled
Formula AN: ZDV (from 14-34 weeks) 
IP: intravenous ZDV
ZDV for 6 
weeks
8.3% in ZDV arm 
versus 25.5% in 
placebo arm at 18 
months
Bangkok
short-
course
ZDV
2 Thailand Randomised,
placebo-controlled
Formula AN: ZDV (from 36 weeks) 
IP: oral ZDV
None 9.4% in ZDV arm 
versus 18.9% in 
placebo arm at 6 
months
ANRS
075
3 France Open label, non­
randomised
Formula AN: ZDV (from 14 weeks) + 
3TC (from 32 weeks)
IP: intravenous ZDV + oral 
3TC
ZDV + 3TC for 
6 weeks
1.6%
HIVNET
012
4 & 5 Uganda Randomised,
placebo-controlled
NVP versus ZDV
Breast AN: none
IP: oral sdNVP versus oral 
ZDV
sdNVP within 
72 hours of 
birth versus 
ZDV for 7 days
15.7% in NVP 
arm versus 25.8% 
in ZDV arm at 18 
months. Placebo 
arm stopped
PACTG, Pediatric AIDS Clinical Trial Group; ANRS, Agence Nationale de Recherches sur le SIDA; HIVNET, HIV Network for Prevention Trials;
AN, antenatal; IP, intrapartum; ZDV, zidovudine; sdNVP, single dose nevirapine; 3TC, lamivudine
References:
1) (Connor et al 1994)
2) (Shaffer et al. 1999)
3) (Mandelbrot et al. 2001)
4) (Guay et al 1999)
5) (Jackson et al 2003)
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Elective caesarean section before the onset of labour and rupture of membranes reduces 
the risk of MTCT compared with a vaginal delivery, as the procedure prevents contact 
between the fetus and maternal secretions. The protective effect of an elective caesarean 
section was reported in observational studies (Mandelbrot et al. 1998) and a randomised 
clinical trial (The European Mode of Delivery Collaboration 1999). However, the low 
MTCT rates achieved with HAART use during pregnancy have led to a debate about 
whether an elective caesarean section brings any added benefits in terms of a reduced 
risk of MTCT, particularly as there are risks associated with the procedure itself (Fiore et 
al. 2004).
When interventions are used in combination, MTCT rates can be reduced from between 
15-20% in the absence of any interventions (The Working Group on Mother-to-Child 
Transmission of HIV 1995) to less than 2% (European Collaborative Study 2005c, 
European Collaborative Study 2001, Mandelbrot et al. 1998, Kind et al. 1998). The 
success of interventions is evident in the reduction of reported paediatric HIV infections 
(Tookey 2005b, Hamers and Downs 2004).
1.6 Antiretroviral therapy exposure and potential adverse effects in 
children
Concern has been raised regarding the risk of adverse effects in children exposed to ART 
in utero and/or in the neonatal period (Mofenson and Munderi 2002). Long-term 
permanent toxicities have been reported in some epidemiological and animal studies 
(Blanche et al. 1999, Olivero et al. 2002). The need to assess adverse effects is 
particularly important in uninfected children due to their increasing numbers (Tookey 
2005b), and the fact that they are likely to be discharged from paediatric care when they 
are confirmed uninfected (usually around 18 months of age) (Newell et al. 2002). HIV
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infected women are taking increasing numbers of drugs and drug combinations during 
pregnancy (European Collaborative Study 2005c, Townsend et al. 2006). HAART is 
often started before HIV symptoms develop, therefore women may be already on therapy 
when they conceive; and HIV infected pregnant women are recommended to use ART 
for their own health if appropriate (Hawkins et al. 2005, Public Health Service Task 
Force 2005a).
Information about the safety of ART exposure in children bom to HIV infected women 
comes mainly from multi-centre cohort studies such as the European Collaborative Study 
(ECS) (European Collaborative Study 2004b), the French Perinatal Cohort Study (Le 
Chenadec et al. 2003) and the Women and Infants Transmission Study (WITS) (Cooper 
et al. 2002); and MTCT trials such as the PACTG trials (Sperling et al. 1998) and the 
Thai trials (Chotpitayasunondh et al. 2001). Animal studies also provide information on 
potential adverse effects (Olivero et al. 1997).
1.6.1 Congenital abnormalities
Teratogenicity studies have been carried out on individual antiretroviral drugs. Fetal 
malformations have been reported in rats given near lethal doses of ZDV; and significant 
central nervous system malformations were observed in 3 out of 20 monkeys exposed to 
efavirenz in utero. Abacavir and zalcitabine have also been associated with an increased 
risk of malformations in rats (Public Health Service Task Force 2005b, Thome and 
Newell 2005).
There have been case reports of congenital abnormalities in humans exposed to efavirenz 
in utero. These include neural tube defects and spinal malformations (Fundaro et al.
2002, De Santis et al. 2004). Due to these reports and the teratogenic findings in
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primates, it is recommended that efavirenz is not taken in the first trimester of 
pregnancy, the primary period of fetal organogenesis (Public Health Service Task Force 
2005b).
The possibility of a synergistic effect of combination therapy and folate antagonists 
prescribed for Pneumocystis carinii pneumonia (PCP) prophylaxis has been raised. 
Severe spinal malformations have been reported in the fetuses of two women in the UK 
(Richardson et al 2000). In a retrospective case note review, Jungmann et al. found 
exposure to both combination therapy and folate antagonists in the first trimester was 
associated with an increased risk of congenital abnormalities (Jungmann et al. 2001). 
However the study was relatively small with 195 mother-child pairs and this association 
has not been reported elsewhere.
In the PACTG 076 trial, no differences in structural abnormalities between infants in the 
study drug arm and those in the placebo arm were observed (Table 1.3) (Sperling et al. 
1998). An analysis on over 3500 mother-child pairs from the ECS found no evidence to 
suggest that exposure to first trimester ART, including HAART, increased the risk of 
congenital abnormalities (European Collaborative Study 2005a). Furthermore, recent 
data from obstetric and paediatric HIV surveillance in the UK and Ireland on over 3000 
infants bom to HIV infected women, showed no statistically significant association 
between the prevalence of congenital abnormalities and exposure to ART. Prevalence 
was similar regardless of whether exposure occurred in the first trimester (Townsend et 
al. 2006).
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Table 1.3 Antiretroviral therapy exposure and potential adverse effects in children: follow-up data from mother-to-child transmission
clinical trials
Study
(Reference)
Setting Number of
HIV-exposed
children
Follow- up ART exposure 
(n)
Main adverse effects 
addressed
Findings
PACTG 076 
(1)
USA & 
France
417 342 (82%) followed 
up to 18 months of 
age
PACTG 076 
protocol* (209) 
Placebo group 
(208)
Anaemia More common in 
ZDV group
Structural abnormalities No difference
Growth No difference
Immunologic function No difference
PACTG
076/219
(2)
USA 234 (uninfected 
children)
Median age at last 
follow-up 4.2 years 
(range 3.2-5.6)
PACTG 076 
protocol* (122) 
Placebo group 
(112)
Deaths & malignancies None
Growth No difference
Immunologic function No difference
BCPHTSG
(3)
Thailand 395 319 (81%) followed 
up to 18 months of 
age
Bangkok 
protocol# (196) 
Placebo group 
(199)
Growth No difference
Immunologic function No difference
Malignancies None
PACTG, Pediatric AIDS Clinical Trials Group; BCPHTSG, Bangkok Collaborative Perinatal HIV Transmission Study Group; ZDV, zidovudine 
*PACTG 076 protocol: antepartum oral ZDV initiated at 14-34 weeks gestation and continued for duration of pregnancy, intrapartum intravenous 
ZDV at the onset and during labour, postpartum oral ZDV administered to the infant for 6 weeks (Connor et al. 1994)
#Bangkok protocol: antepartum oral ZDV initiated at 36 weeks gestation until delivery (Shaffer et al. 1999)
References:
1) (Sperling et al. 1998)
2) (Culnane et al. 1999)
3) (Chotpitayasunondh et al. 2001)
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The Antiretroviral Pregnancy Registry (APR) in the USA is designed to monitor prenatal 
exposure to antiretroviral therapy and to assess the risk of birth defects. In 2004 the APR 
published their findings on over 3500 infants exposed to ART. Among 1391 first 
trimester exposures, the rate of birth defects was 2.7%, not significantly higher than the 
USA population surveillance rate (Watts et al. 2004).
1.6.2 Prematurity
The possibility of an association between in utero ART exposure and prematurity was 
first highlighted in a report from Switzerland in 1998. Of 30 infants exposed to Pis 
combined with other antiretroviral drugs, 10 were bom prematurely (before 37 weeks 
gestation) (Lorenzi et al. 1998). Although the numbers were small in this study, the 
findings prompted a joint analysis between the ECS and the Swiss Mother + Child HIV 
Cohort. In nearly 4000 mother-child pairs, use of combination therapy in pregnancy was 
associated with a 2.5 times increased risk of prematurity compared with no therapy, 
adjusting for maternal HIV disease and drug use (European Collaborative Study and the 
Swiss Mother + Child HIV Cohort Study 2000). HAART use in pregnancy has been 
observed to be significantly associated with premature delivery in over 4000 infants bom 
to HIV infected women in the UK and Ireland (Personal communication, P Tookey, 
2006).
While European cohorts have reported an association between combination therapy, 
particularly HAART, and prematurity, this has not been observed in the USA. A meta­
analysis including over 3000 mother-child pairs from seven cohorts did not find a 
statistically significant association between combination therapy and prematurity 
(Tuomala et al. 2002), and a more recent analysis from the WITS confirmed this 
(Tuomala et al. 2005). The disparity observed between cohorts in Europe and those in
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the USA could be due to differences in the underlying population characteristics or 
methods used in data collection (Thome et al 2003).
1.6.3 Growth
Whether ART exposure has an adverse effect on growth has only been investigated in a 
small number of studies. Although findings to date have been reassuring, the analyses 
were only based on ZDV exposure (Sperling et al 1998, Chotpitayasunondh et al. 2001) 
(Table 1.3).
1.6.4 Haematological parameters
Exposure to ZDV according to the PACTG 076 protocol has been associated with 
reversible anaemia in early life (Connor et al 1994). Subsequent analyses of data on 
children enrolled in the PACTG 076 trial showed no differences between haematological 
parameters such as CD4 and CD8 lymphocytes at 18 months and three years of age 
(Sperling et a l 1998, Culnane et al 1999) (Table 1.3). However, several more recent 
reports have suggested an association between ART exposure and haematological 
parameters in uninfected children. In the French Perinatal Cohort Study, over 4000 
uninfected infants were followed up until 18 months of age and haematological variables 
were measured. As seen elsewhere, haemoglobin levels were transiently reduced in 
infants exposed to ZDV. In addition, platelets, neutrophils and lymphocytes were slightly 
lower in the ART-exposed infants than the unexposed; and combination therapy was 
associated with a larger decrease than monotherapy exposure, after adjusting for age, 
prematurity and maternal factors (Le Chenadec et al 2003).
In the ECS, analyses of neutrophil counts up to eight years of age in just over 1500 
uninfected children revealed that ART exposure {in utero, intrapartum or neonatal) was
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significantly associated with a reduced count, after adjustment for year of birth, age and 
maternal factors (European Collaborative Study 2004b). A subsequent ECS analysis of 
over 1600 uninfected children, again up to eight years of age, showed that both duration 
and intensity of ART was associated with a reduced total lymphocyte count (European 
Collaborative Study 2005b). Lymphocytes and neutrophils are important components of 
the immune system. Whether the observed reduction associated with ART exposure has 
any clinical implications, such as increased susceptibility to viral and bacterial infections, 
is unknown.
1.6.5 Mitochondrial disorders and febrile seizures
As well as NRTIs having an affinity for reverse transcriptase, they are also substrates for 
DNA polymerase, the enzyme required for replication of mitochondrial DNA. In HIV 
infected adults, recognised adverse effects of NRTIs include myopathy, neuropathy and 
lactic acidaemia, complications associated with toxic effects on mitochondria (Morris 
and Carr 1999, Brinkman et al. 1998). Damage to the mitochondria of monkey fetuses 
has been observed after the maternal infusion of ZDV (Ewings et al. 2000); and damage 
in fetuses exposed to ZDV plus lamivudine has been found to be greater than when 
exposed to ZDV alone (Olivero et al. 2002).
In a report from France in 1999, Blanche et al. identified eight uninfected children with 
persistent mitochondrial dysfunction who had been exposed in utero and/or neonatally to 
ZDV or ZDV plus lamivudine, out of a total of 1754 ART-exposed children (Blanche et 
al. 1999). Two of the children presented with clinical symptoms and subsequently died 
aged 11 and 13 months of age. The other six children were identified through 
retrospective screening for mitochondrial symptoms. Five children in total, including the 
two who died, had neurological symptoms. Three children were symptom-free but were
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identified due to abnormal biochemical test results. In a subsequent analysis from the 
French group, a predetermined algorithm was used for classifying unexplained 
symptoms compatible with mitochondrial dysfunction. The analysis included 4426 
uninfected and indeterminate children, 2644 of whom had been exposed to ART (in 
utero, intrapartum or neonatal). Subsequent investigations were then carried out as 
appropriate. Further to the eight children identified in the previous review, four other 
children were found to have mitochondrial dysfunction. The 18-month incidence was 
0.26% in ART-exposed children, compared with 0.01% in the general population (Barret 
et a l 2003). The French Perinatal Cohort Study also found exposure to ART was 
associated with febrile seizures in children younger than 18 months (Landreau-Mascaro 
et al. 2002), but this has not been observed elsewhere.
In response to the first French report, reviews of deaths of uninfected and indeterminate 
children bom to HIV infected women in five cohorts in the USA were carried out. Of 
over 20 000 children in the cohorts, more than half had been exposed to NRTIs. A total 
of 223 children died. According to the classification system used, the cause of death for 
three indeterminate children was considered as being possibly related to a mitochondrial 
disorder. Two of these children had never been exposed to ART and the third child had 
not been exposed after birth. The rate of death due to sudden infant death syndrome 
(SIDS) (1.8/1000 live births) found in the five cohorts was not out of the normal range 
(The Perinatal Safety Review Working Group 2000, Dominguez et al 2000, Bulterys et 
al 2000).
Findings on the association between ART exposure and mitochondrial dysfunction are 
conflicting. The prevalence of mitochondrial dysfunction is rare in the general 
population, and probably linked to genetic factors (Thome and Newell 2005). As
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mitochondrial dysfunction is likely to be associated with a broad spectrum of clinical 
symptoms, its identification is particularly difficult. Neurological symptoms observed in 
cohorts of uninfected children bom to HIV infected women may be due to other factors 
that affect this population, such as illicit drug exposure or prematurity.
1.6.6 Malignancies
As NRTIs become incorporated into host DNA, there is potential for long-term 
carcinogenic effects. In adult mice, ZDV is a weak carcinogen: Ayres et al. reported an 
increase in vaginal tumours after a lifetime exposure to the drug (Ayers et al. 1996). 
Findings from animal studies have also raised concerns over the potential for 
transplacental carcinogenic effects of ART. In adult mice exposed to high doses of ZDV, 
dose-dependent and significant increases in the incidence of lung, liver, skin and female 
reproductive organ tumours were observed in the offspring at one year of age (Olivero et 
al. 1997).
The relevance of animal data to humans is uncertain; however these studies show a 
theoretical risk of carcinogenicity. In an analysis of 234 uninfected children initially 
enrolled in the PACTG 076 trial (Connor et al. 1994) and who were subsequently 
followed up in the PACTG 219 study, no deaths or malignancies were observed in either 
the ZDV or placebo group after a median follow-up of four years (Culnane et al. 1999) 
(Table 1.3). Hanson et al. evaluated the short-term risk for tumours in 727 infants with in 
utero and/or neonatal ZDV exposure (Hanson et al. 1999). The infants were enrolled in 
the WITS and the PACTG 076/219 study, with mean length of follow-up of 14.5 months 
(743.7 person-years) and 38.3 months (366.9 person-years) respectively. No tumours 
were reported. Overall mortality was 2.3% (17/727), though no child had evidence of 
malignancy by autopsy or death certificate review.
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Although reports from epidemiological studies have been reassuring to date, they have 
been limited in number and have only focused on ZDV exposure. Moreover, follow-up 
has only covered the first few years of childhood, and the findings do not preclude the 
possibility of malignancies occurring at later ages.
1.7 Conclusion
Many of the studies which have addressed ART exposure and the risk of adverse effects 
so far have been limited in scope; for example, most have only considered ZDV 
exposure. In addition, there has been limited work on the long-term effects of ART 
exposure, with most studies concentrating on the first few years of life (Sperling et al. 
1998, Chotpitayasunondh et al 2001, Culnane et al. 1999).
While national guidelines on treatment of HIV infected pregnant women recommend the 
long-term monitoring of uninfected children exposed to ART, practical ways of doing 
this are not laid out (Public Health Service Task Force 2005a). The benefits of ART in 
reducing rates of MTCT of HIV are great. However as concerns over safety have been 
raised, it is important to investigate further whether there is an association between ART 
exposure and adverse events in children; and what sort of mechanisms could be used to 
monitor any potential adverse side effects.
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1.8 Aim and objectives of thesis
Aim
To explore the association between antiretroviral therapy (ART) exposure in fetal and/or
early life and clinical outcomes in uninfected children bom to HIV infected women in
Europe.
Objectives
1) To describe the early social environment of uninfected children bom to HIV
infected women in a European cohort study.
2) To investigate the association between ART exposure, perinatal problems and
subsequent adverse health outcomes in uninfected children.
3) To investigate the effect of ART exposure on growth in the first 18 months of life
in uninfected children.
4) To explore the feasibility of monitoring death and cancer registration in children
bom to HIV infected women in England and Wales by matching perinatal data 
with national data on death and cancer held by the Office for National Statistics.
5) To assess the feasibility of a national clinic-based follow-up of uninfected
children bom to HIV infected women in the UK in order to monitor adverse 
health events that could be related to ART exposure in fetal and/or early life.
6) To assess parental and health professional perceptions of the acceptability of
maintaining long-term contact with uninfected children.
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Chapter 2 Data sources and methods
2.1 The European Collaborative Study
The European Collaborative Study (ECS) is an ongoing multi-centre cohort study. HIV 
infected women are enrolled in the ECS during pregnancy and their children are 
prospectively followed up according to standard protocols (European Collaborative 
Study 2001, European Collaborative Study 2003a) (Appendices 1 and 2). Aims of the 
ECS are to estimate the rate of and risk factors for mother-to-child transmission (MTCT) 
of HIV infection, to evaluate the benefits and potential risks of interventions to reduce 
MTCT and to assess the health of HIV infected pregnant women and their children. The 
ECS was established in 1985 and by the end of 2005 included 25 centres in 10 European 
countries. The ECS coordinating centre is based at the Institute of Child Health in 
London. Local ethics approval has been granted in all centres.
Informed consent is obtained before enrolment. Information collected at enrolment and 
during pregnancy includes maternal socio-demographic characteristics, antiretroviral 
therapy (ART) use, HIV-related laboratory tests, obstetric history, most likely mode of 
acquisition of HIV infection, and drug use on the basis of self-report and examination 
(European Collaborative Study 2004b).
Delivery and neonatal characteristics including gestational age, birth weight and the
presence of congenital abnormalities are recorded (European Collaborative Study and the
Swiss Mother + Child HIV Cohort Study 2000). At child follow-up assessments,
information on laboratory tests, clinical findings and social care is collected according to
standard laboratory and clinical protocols (European Collaborative Study 2003b,
European Collaborative Study 2005c). In 13 paediatric centres, assessments are
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scheduled at birth, at 3 and 6 weeks, at 3, 4.5, 6, 9, 12, 18 and 24 months, and then six- 
monthly for infected children and annually for uninfected children. In the remaining 
obstetric centres, follow-up is less intensive and usually only continues until the child’s 
HIV status is determined.
Data collection forms (Appendix 2) are completed by clinicians in all centres. Forms are 
sent to the ECS coordinating centre by post or electronically. After verification and 
coding, data are entered onto the ECS database (Microsoft Access 2002). Routine data 
checking programmes are carried out.
Analyses
Analyses that were conducted for the purposes of this thesis, using ECS data on 
uninfected children and their mothers, are outlined in Table 2.1. Analyses of outcomes 
after three weeks of age were based on mother-child pairs from paediatric centres only. 
The description of ART exposure (Section 4.4) and the analysis of exposure to ART and 
early health outcomes (Section 4.5) were based on mother-child pairs from all centres.
Table 2.1 Analyses conducted using European Collaborative Study data
Analysis (year conducted) ECS 
centres 
included in 
analysis
Mother
-child
pairs
(n)
Age criteria of 
child
Chapter 
/ section 
of thesis
1) Social environment (2002) Paediatric 1667 Up to one year 3
2a) ART exposure (2001) Obstetric & paediatric 2414 - 4.4
2b) Exposure to ART & early 
health outcomes (2001)
Obstetric & 
paediatric 2414
Up to three 
weeks 4.5
2c) Exposure to ART & longer- 
term health outcomes (2001) Paediatric 1511
Up to age of 
last follow-up 4.6
3) Exposure to ART & growth 
(2003) Paediatric 1912
Up to 18 
months 5
ART, antiretroviral therapy
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Data for the analyses were extracted from the ECS database. Inconsistencies in the data 
were identified through data checking processes and were investigated by consulting the 
original data collection forms or contacting the clinicians as appropriate.
Definitions 
Infection status
A child was classed as uninfected if they were HIV antibody-negative at or after 18 
months of age and no virus or antigen had ever been detected. If a child was aged less 
than 18 months and virological tests were negative on at least two occasions, the child 
was presumed uninfected (European Collaborative Study 2003a).
Gestational age
Gestational age was assessed by ultrasound and reported in completed weeks. A child 
was considered premature if gestational age was less than 37 weeks.
Maternal illicit drug use
Details on maternal illicit drug use (IDU) before and during pregnancy were based on 
self-report, recorded clinical presentation and presence of drug withdrawal symptoms in 
the neonate. Maternal IDU was categorised into “never”, “past/timing unknown” and 
“current” to describe drug use in relation to the index pregnancy.
CD4 cell count
Maternal CD4 cell count, determined locally, has been routinely collected in the ECS 
since 1992. Where there were multiple measurements available for a pregnancy, the one 
closest to delivery was used in analyses. CD4 cell count in pregnancy was categorised 
into: <200, 200-499 and >500 cells/mm3.
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Antenatal ART exposure
Antenatal ART exposure was categorised into “none”, “monotherapy” and “combination 
therapy” (double therapy and highly active antiretroviral therapy (HAART)). The most 
intensive drug therapy (in terms of number of drugs) that the mother was on during 
pregnancy was used in analyses.
2.2 The National Study of HIV in Pregnancy and Childhood
Surveillance of obstetric and paediatric HIV in the UK and Ireland is carried out through 
the National Study of HIV in Pregnancy and Childhood (NSHPC) also based at the 
Institute of Child Health (Ades et al 1993, Tookey 2005b). The aims of the NSHPC are 
to monitor HIV infection in pregnant women and children, to monitor uptake of 
interventions to reduce MTCT and to explore progression of paediatric HIV infection 
(Nicoll et al 1998, Gibb et al 2003). Obstetric data are used for alignment with results 
from the unlinked anonymous (UA) surveys to estimate detection rates for HIV in 
pregnancy (The UK Collaborative Group for HIV and STI Surveillance 2005). Paediatric 
data are included in national quarterly surveillance reports, and in the Survey of 
Prevalent HIV Infections Diagnosed (SOPHID) which is used for service planning and 
resource allocation (The UK Collaborative Group for HIV and STI Surveillance 2005).
The core surveillance mechanisms are two parallel reporting schemes, both of which are 
anonymous, active, confidential and voluntary (Ades et al 1993). Children with HIV 
infection and children bom to HIV infected women are reported to the NSHPC either 
through the British Paediatric Surveillance Unit (BPSU) of the Royal College of 
Paediatrics and Child Health (RCPCH) (British Paediatric Surveillance Unit 2005) or 
directly (Figure 2.1). Respondents provide information on HIV-related laboratory 
investigations, perinatal details, vital status, ART exposure, maternal risk group and
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maternal demographic characteristics (Appendix 3.3). Reports are followed up to 
establish infection status (Appendices 3.3 and 3.4). Once reported children are confirmed 
uninfected, no further information is requested for surveillance purposes. Definitions of 
infection status used in the NSHPC are outlined in Appendix 3.3.
In the second reporting scheme, pregnancies in HIV infected women are reported 
through a system run by the NSHPC under the auspices of the Royal College of 
Obstetricians and Gynaecologists (RCOG) (Figure 2.1). Respondents provide 
information on maternal demographic characteristics, risk group, ART use and 
pregnancy outcome (Appendices 3.1 and 3.2).
Live births reported through the obstetric scheme are linked with paediatric reports using 
demographic information, in order to combine data on the mother and child, and to avoid 
double counting of a birth (Ades et a l 1993). Laboratory reports are also made to the 
NSHPC and are linked with paediatric and obstetric reports. The paediatric and obstetric 
reporting schemes were established in 1986 and 1989 respectively. The majority of 
infants are reported through both schemes.
Data collection forms are processed, and inconsistencies in the data are clarified with 
respondents. Data are entered onto the NSHPC database (Microsoft Access 2002) and 
routine data checking programmes are carried out. The NSHPC is national anonymised 
surveillance and there is no enrolment; consent for notification of reports is not 
requested. Case identifiers include date and place of birth, hospital number, initials, 
truncated postcode of residence (postcode with the last letter deleted e.g. A12 3BC 
truncated to A12 3B) and National Health Service (NHS) number where available (see 
Appendix 3). The NSHPC was most recently reviewed and approved by the London
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Multi-centre Research Ethics Committee in 2004 (ref 04/2/009). Overlap between the 
ECS and NSHPC is very limited and does not affect the analyses presented in this thesis.
Figure 2.1 The National Study of HIV in Pregnancy and Childhood: obstetric 
and paediatric surveillance
RCOG
reports
NSHPC 
at ICH
BPSU or 
direct reports
HIV infected 
pregnant 
women
Infants bom to 
HIV infected 
women
HIV infected 
children
Infants bom to 
HIV infected 
women
RCOG, Royal College of Obstetricians and Gynaecologists; BPSU, British Paediatric 
Surveillance Unit; NSHPC, National Study of HIV in Pregnancy and Childhood; ICH, Institute 
of Child Health
2.3 Follow up of uninfected children born to HIV infected women: the 
CHART study
The CHART study, carried out between 2002 and 2005, was a consented annual clinic- 
based follow-up of uninfected children bom to HIV infected women in the UK and 
reported to the NSHPC. The aims of the CHART study were to explore the feasibility of 
clinic-based follow-up of uninfected children on a national basis to monitor adverse 
health events that could be related to ART exposure in fetal and/or early life; and to 
investigate adverse health events reported for children enrolled in the study, with respect 
to ART exposure.
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Study protocol
The CHART study was dependent on the NSHPC for the identification of uninfected 
children, as well as for prospectively collected perinatal, demographic and ART 
exposure information. As reports to the NSHPC do not include names or contact details 
of cases, enrolment and data collection in the CHART study was reliant on a network of 
health professionals. After the initial report of a child’s uninfected status was made to the 
NSHPC, the paediatric respondent was asked to approach the parent or carer regarding 
enrolment of the child, either at the next clinic appointment or over the telephone ([1] on 
Figure 2.2). If it was more appropriate, the paediatric respondent could specify an 
alternative health professional in contact with the family and aware of the mother’s HIV 
infection status (e.g. general practitioner (GP), genitourinary (GU) physician) ([2] on 
Figure 2.2). They were then contacted regarding enrolment of the child ([3] on Figure 
2 .2).
Consent was sought from the parent or carer, and a questionnaire was completed by the 
health professional in consultation with them (Appendix 6.2). The consent form 
(Appendix 6.3) and a copy of the questionnaire were kept in the clinic; confirmation of 
consent (Appendix 6.1) and a copy of the questionnaire were returned to the researcher at 
the Institute of Child Health. Subsequent questionnaires were then sent to appropriate 
health professionals a year after the previous one had been completed. If the child could 
not be enrolled for any reason (e.g. they had left the UK, were lost to follow-up, parent 
or carer had declined), this was recorded on the follow-up status form (Appendix 6.1).
The study protocol was flexible so that every attempt was made to ensure that enrolment 
and data collection was done in the most convenient way for both the health professional
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and the parent or carer. Additional clinic appointments were not requested. The 
eligibility criteria for the CHART study are outlined in Chapter 7.
Figure 2.2 The CHART study protocol
Details o f  children 
eligible* for the 
CHART study obtained 
from NSHPC database
Completed 
questionnaire or 
other response^
Researcher at 
the Institute o f  
Child Health
CHART
May specify 
alternative
CHART HP [2]
Completed 
questionnaire or 
other response^
Secondary
forms# sent forms# sent
, PI [1] . Primary
CHART contact /  \ CHART contact
Alternative health * Communication * NSHPC paediatric
professional e.g. GP, *  regarding * respondent
GU physician, HV identification o f
child/parent
No response
Notes
HP, health professional; GP, general practitioner; GU, genitourinary; HV, health visitor; 
NSHPC, National Study of HIV in Pregnancy and Childhood.
* eligibility criteria are outlined in Chapter 7
\|/ other responses: parent/carer declined, not possible to enrol child (e.g. lost to follow- 
up, left UK, inappropriate to contact family).
# CHART forms: information sheets, questionnaire, follow-up status form.
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Information sheets
Information sheets were provided for both the health professional and the parent or carer. 
They included details on what was involved in the study, guidance on completing the 
questionnaire and contact details of the researcher (Appendices 6.3 and 6.4).
Questionnaire
A standard summary of routinely available information on the child’s general health and 
development was collected on the CHART study questionnaire (see Appendix 6.2). No 
investigations additional to routine clinical care were requested. The questionnaire, 
though completed by the health professional, was directed to the parent or carer of the 
child. It was designed to cause minimal inconvenience to the health professional and 
family, and to act as a filter to identify children with any major health problems. Ideally 
the questionnaire was completed in the presence of the child and their parent or carer, but 
if necessary the health professional could complete the questionnaire in the absence of 
the child, or over the telephone.
Data management
A Microsoft Access 2002 database was established which was used both for study 
management and data storage. This combined prospectively collected data from the 
NSHPC database, with the CHART study enrolment and questionnaire data (see Figure 
2.3).
Univariable comparisons for categorical variables were tested with x2 tests or x2 tests for 
linear trend. Data analysis was carried out using SAS statistical software (version 9.1, 
SAS Institute, Cary, North Carolina, USA).
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Ethics approval
The CHART study was reviewed and approved by the Great Ormond Street Hospital for 
Children NHS Trust / Institute of Child Health Local Research Ethics Committee in 2001 
for the period 2001-2006. Due to changing requirements regarding ethics approval, the 
CHART study was reviewed and approved by the London Multi-centre Research Ethics 
Committee in 2004 for the period 2004-2006 (ref 04/MRE02/47).
Figure 2.3 Data management in the CHART study
NSHPC database
CHART study 
questionnaire data
CHART study 
enrolment data
*Follow-up status 
* Consent status 
*Correspondence with HPs
Information on uninfected children
♦Case identifiers: hospital, hospital number, NHS number 
♦Child details: DOB, sex, BW , GA, vital status 
♦Maternal details: HIV risk factor, COB, DOB 
♦Confirmation o f  infection status 
♦ART exposure
HP, health professional; NSHPC, National Study of HIV in Pregnancy and Childhood; 
DOB, date of birth; COB, country of birth; BW, birth weight; GA, gestational age; NHS, 
National Health Service
2.4 The Office for National Statistics flagging study
National Health Service Central Register
The National Health Service Central Register (NHSCR) is the central record of National 
Health Service (NHS) patients registered in England and Wales, and is administered by 
the Office for National Statistics (ONS). The NHSCR database, developed in 1991, holds
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a unique record for every patient who was alive and registered in 1991, plus anyone who 
has registered since; and all births in England and Wales since 1991 (Botting et al.
1995). Recorded data include:
• NHS number, name, sex, date of birth
• health authority where the patient is registered with a GP
• if applicable: death registration, cancer registration, entry or exit from the NHS (e.g. 
known to have left the UK, or gone into prison, a psychiatric hospital or the care of 
the armed forces)
Flagging studies
With appropriate approval and safeguards on confidentiality, medical researchers can use 
the NHSCR to monitor death and cancer registration in individual subjects in their study. 
Once subjects have been identified on the NHSCR, their records are marked with a study 
number, i.e. “flagged”. For as long as subjects are flagged on the NHSCR, if any of them 
die, have a diagnosis of cancer registered, or enter or exit the NHS (have an “event”), 
then a designated researcher from the study receives a notification from ONS (Botting et 
al. 1995). Details provided include: date and cause of death; year of diagnosis, site and 
type of cancer (Greenberg and Coleman 2000). Retrospective events are notified. Events 
are reported to the NHSCR from various sources (see Figure 2.4):
• Death registration is mandatory and is reported from the General Register Office 
(GRO) at ONS.
• Details of cancer diagnoses are reported from regional cancer registries via the 
National Cancer Intelligence Centre (NCIC) at ONS. Reporting has been mandatory 
since 1993 (Office for National Statistics 2005).
• Entry or exit from the NHS can be reported from sources such as Immigration, the 
Home Office and health authorities.
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Figure 2.4 The National Health Service Central Register and event reporting
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Notes: NCIC, National Cancer Intelligence Centre; GRO, General Register Office; HA, health authority; 
NHSCR, National Health Service Central Register; GP, general practitioner; NHS, National Health Service
Identification of subjects on the NHSCR is determined by whether date of birth, NHS 
number (see below) and name are available to the researchers. If subjects cannot be 
traced directly on the NHSCR, but appropriate information on them is available, e.g. date 
of birth, sex and mother’s date of birth, the Births/Deaths Registration Database (BDRD) 
at the GRO can be searched to identity the birth registration records of the subjects. 
Details obtained from these can then be used to identify the records on the NHSCR, 
which can then be flagged. Fees for flagging work charged by ONS are based on the 
number of subjects attempted to flag and how they are identified; and a fee is charged 
each time an event is notified.
National Health Service number
The NHS number is a unique identifier given to babies bom in England and Wales, and 
to patients registered with the NHS. Up until 2002, NHS number was allocated to a baby
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at the time of civil registration, which could have been up to six weeks after birth. The 
NHS “Numbers for Babies” (NN4B) initiative, whereby NHS number is issued at birth 
by the midwife, was launched in October 2002 (Connecting for Health 2006b). As a 
result, NHS number has become available on newborn babies’ hospital records; and with 
improvements in information technology, has become more widely used throughout the 
NHS.
National Study of HIV in Pregnancy and Childhood: flagging
In the late 1990s, children reported to the NSHPC (see Section 2.2) were flagged on the 
NHSCR for notifications of death and cancer registration, in order to monitor possible 
long-term adverse outcomes in children exposed to ART. The BDRD was manually 
searched to identify the birth registration records of the children. A total of 329 children 
bom in England and Wales between 1996 and 1999 were flagged in this way. However, 
progress was slow because of the manual approach to identifying birth registration 
records and because of the then limited availability of NHS number in the NSHPC. After 
the implementation of the NN4B initiative however, the proportion of reports to the 
NSHPC for which NHS number was provided increased.
In 2005 a revised protocol was developed for flagging children reported to the NSHPC 
on the NHSCR, through an automatic matching procedure. Details on the protocol are 
provided in Chapter 6.
Flagging studies which were underway in 2002 have support under Section 60 of the 
Health and Social Care Act 2001 from the Patient Information Advisory Group (PIAG) 
(ref PIAG 4-07(h)/2002). The ONS flagging study was most recently reviewed and
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approved by the Great Ormond Street Hospital for Children NHS Trust / Institute of 
Child Health Local Research Ethics Committee in 2001 for the period 2001-2006.
2.5 Parent and carer survey
To obtain views of parents and carers on the importance and acceptability of the long­
term follow-up of uninfected children, a cross-sectional survey was carried out in 
2004/5. Parents and carers were invited to participate if they cared for at least one 
uninfected child bom in the UK to an HIV infected woman who took ART during 
pregnancy. The survey method used was a self-completed anonymous questionnaire 
(Appendix 11).
The survey was conducted in 12 paediatric and two GU clinics in 12 hospitals in 
England, Scotland and Wales (Appendix 9). Hospitals were selected on the basis of the 
number of reports of uninfected children made to the NSHPC, and also to give a 
geographically representative sample (Table 2.2). The survey was reviewed and 
approved by the London Multi-centre Research Ethics Committee (ref 04/MRE02/48).
Researcher clinics
The researcher visited five paediatric clinics and one GU clinic in London on 33 
occasions to invite potential respondents to participate in the survey (see Table 8.1). 
Children booked for the paediatric clinics were generally attending for their 3, 12 or 18 
month blood tests. The researcher liaised with clinic staff so only parents and carers who 
met the inclusion criteria were approached. Discussion between the researcher and the 
parent or carer took place in a private consultation room; and generally questionnaires 
were completed there, though they could be completed at home and returned by post. 
The researcher consulted with clinic staff to ensure that potential respondents were only
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approached once. The number of children booked for the clinic and number attended 
were also recorded each time the researcher visited a paediatric clinic. Data collection 
took place between October 2004 and June 2005.
Table 2.2 Uninfected children born to HIV infected women in the UK
reported to the NSHPC and the number of hospitals included in
the parent and carer survey
Geographical region Uninfected 
children reported 
to the NSHPC* 
n (%)
Hospitals 
in the 
survey (n)
Uninfected children 
reported to the 
NSHPC* from 
hospitals in the 
survey 
n (%)
England#
London 672 (62) 6 351 (88)
South 118(11) 2 25 (6)
North 82 (8) 1 3(1)
Midlands & the East 158(15) 1 7(2)
Wales 8(1) 1 4(1)
Scotland 40 (4) 1 8(2)
Northern Ireland 1 (<1) - -
Total 1079 12 398
NSHPC, National Study of HIV in Pregnancy and Childhood 
*bom since 2001 and reported to the NSHPC by April 2004 
#by Strategic Health Authority region
Non-researcher clinics
The clinic caseload was smaller in the survey hospitals outside London (Table 2.2) and 
clinic staff agreed they could coordinate recruitment. Potential respondents were invited 
in clinic to participate, or if the health professional thought it appropriate, they were sent 
the survey material (see Table 8.2). Questionnaires were returned directly to the 
researcher in a prepaid envelope. Staff in one paediatric clinic and one GU clinic in 
London were able to manage recruitment.
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Other respondents
Potential respondents were also invited to participate by a member of staff at Positively 
Women, a support group for HIV-affected women (www.positivelywomen.org.uk), and 
through an advert in Positive Nation, a magazine published by the UK Coalition of 
People Living with HIV and AIDS (www.positivenation.co.uk). These questionnaires 
were returned directly to the researcher.
Survey information sheet and questionnaire
An information sheet was provided for all potential respondents to explain why the 
survey was being conducted and to provide assurance that it was anonymous and 
voluntary (Appendix 10). The questionnaire was piloted with the assistance of Positively 
Women, and comments on drafts of the information sheet and questionnaire were 
obtained from colleagues at the Institute of Child Health. The questionnaire included 
general questions about the respondent’s family and their contact with health services. 
Several possible long-term follow-up options were described, and respondents’ views on 
them were sought. Further details are provided in Section 8.5. Only limited personal and 
demographic information was requested on the questionnaire, and at the end there was a 
section for comments (Appendix 11). The survey material was translated into French, a 
common alternative language for HIV-affected families in the UK.
Statistical analysis
A database for survey management and data entry was designed in Microsoft Access 
2002. Data analysis was conducted using SAS statistical software (version 9.1, SAS 
Institute, Cary, North Carolina, USA). Univariable comparisons of categorical variables 
were tested with x2 tests, and comparisons of means were tested with t tests.
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2.6 Health professional survey
A questionnaire survey was conducted with health professionals to obtain information on 
their experiences with the CHART study, and their views on approaches to long-term 
follow-up of ART-exposed uninfected children. Health professionals were asked to take 
part in the survey if they were the main NSHPC paediatric respondent in a hospital 
where:
• 10 or more uninfected children bom 2001 - April 2004 had been reported to the 
NSHPC by April 2005, regardless of enrolment in the CHART study (35 hospitals)
• less than 10 uninfected children bom 2001-April 2004 had been reported to the 
NSHPC by April 2005, and at least two children had been enrolled in the CHART 
study (11 hospitals)
A distinction was made between hospitals with 10 or more reported children and those 
with less than 10 reported children, as the majority of uninfected children reported in the 
specified time period were from the former (1340/1760, 76%) and the latter consisted of 
125 hospitals.
The questionnaire consisted of structured questions and there was space at the end for 
additional comments (Appendix 7). Respondents were asked about clinic practice in their 
hospital regarding uninfected children, their involvement in the CHART study and issues 
they felt could have affected study enrolment. Four long-term follow-up scenarios for 
uninfected children were outlined in the questionnaire, and respondents were asked 
which they found acceptable and if there were any they strongly objected to. The 
scenarios and questions corresponded to the parent and carer survey questionnaire (see 
Sections 2.5 and 8.5).
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The questionnaire and a covering letter explaining the aims of survey were sent to 46 
NSHPC paediatric respondents in June 2005 to coincide with the end of the data 
collection for the CHART study. Those who had not responded after one month were 
sent a reminder email with another copy of the questionnaire. Data collection ceased in 
August 2005. A database for survey management and data entry was designed in 
Microsoft Access 2002. Data analysis was conducted using SAS statistical software 
(version 9.1, SAS Institute, Cary, North Carolina, USA). Univariable comparisons of 
categorical variables were tested with x2 tests.
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Chapter 3 Social environment of uninfected children
“....Ifind it crucial to keep our family health care as ‘normal’ as possible - less 
explaining, and I  think less stigmatised. ”
[Mother of one child (aged 6 years)]
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3.1 Introduction
Morbidity and mortality within HIV-affected families could result in children requiring 
social care from non-parental sources (Blanche et al. 1996, Paul et al. 2005). Families 
may also have immigration, drug or financial problems (Rajamanoharan et al. 2004, Mok 
et al. 1996, Schrooten et al. 2002). These issues, together with concerns over 
confidentiality and the stigma of HIV, may affect families’ access to health and social 
services. In order to provide a general background against which to assess possible 
adverse effects of antiretroviral therapy (ART) exposure and mechanisms to monitor 
them, the early social environment and morbidity of uninfected children in the European 
Collaborative Study (ECS) are described is this chapter.
3.2 Methods
The methods of the ECS are described in Section 2.1. Univariable comparisons for 
categorical variables were tested with x2 tests or x2 tests for linear trend. Univariable and 
multivariable logistic regression was used to obtain odds ratios (OR), adjusted odds 
ratios (AOR) and 95% confidence intervals (Cl) (SAS statistical software, version 8.02, 
SAS Institute, Cary, North Carolina, USA). General definitions are provided in Section
2.1, but those specific to this chapter are described here.
Mode o f acquisition o f maternal HIV infection
Reported mode of acquisition of maternal HIV infection was categorised to capture the 
broad social circumstances of the woman around the time of enrolment in the ECS, and 
therefore the child’s early environment (Mok et al. 1996, Nostlinger et al. 2004, 
Anderson and Doyal 2004):
• Intravenous drug use-related: woman was a past or current intravenous drug user
and/or woman had a sexual partner with a history of intravenous drug use
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• From an HIV high-prevalence country: woman was from a country with a high 
prevalence of HIV infection e.g. sub-Saharan African countries, Thailand 
(UNAIDS/WHO 2005) (most likely heterosexual contact)
• Other heterosexual contact: woman acquired HIV infection heterosexually but 
was not reported to be from an HIV high-prevalence country or to have had a 
sexual partner with a history of intravenous drug use
• Blood transfusion recipient: woman acquired HIV infection through a blood 
transfusion
• Not stated: risk factor not stated by reporting clinician (most likely heterosexual 
contact)
Maternal HIV disease
Disease staging at enrolment was categorised into “AIDS” (CDC stages 4C1 and 4D) 
and “non-AIDS” (Centers for Disease Control and Prevention 1992).
Social care
The type of social care that a child had at the time of each follow-up assessment was 
categorised into “parental” if they were living with one or both of their natural parents 
and “alternative” if they were living with other relatives, a foster or adoptive parent, or in 
a hospital or institution (European Collaborative Study 1998).
Child morbidity
Reported morbidity information at each follow-up assessment, relating to infective
episodes requiring medical attention were categorised into “moderate/severe” (diarrhoea,
unexplained fever, sepsis, meningitis, urinary tract infection, pneumonia and other
serious bacterial infection) and “mild” (lymphadenopathy, hepatomegaly, splenomegaly,
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dermatitis, parotitis, upper respiratory infection, sinusitis, otitis media, oral Candida).
Mild episodes were grouped with no reported episodes in this analysis. A hospital 
admission was defined as a stay in hospital for at least one night after the delivery- 
associated routine postnatal stay.
3.3 Socio-demographic characteristics of mother-child pairs
By November 2002, 1667 uninfected children (51.5% male) bom to 1494 HIV infected 
women had been enrolled in ECS paediatric centres. Among these children were 157 sets 
of siblings, including 25 sets of twins and one set of triplets. Fourteen uninfected 
children had an HIV infected older sibling and three had an HIV infected twin also 
enrolled in the ECS. This analysis included 66 children bom less than one year before 
the time of analysis. Total length of follow-up in the first year of life for the 1667 
uninfected children was 1475 child-years.
Socio-demographic characteristics for the 1667 mother-child pairs are shown in Table
3.1. Overall median maternal age was 27.5 years (range 14.0-44.9) and this had increased 
from 23.2 years for children bom in 1985 to 28.4 years in 2002. For children bom to 
white women, median maternal age was slightly lower (26.9 years) than for black (28.9 
years) and other ethnicities (28.2 years).
The proportion of infants bom to black women (the majority from sub-Saharan Africa)
increased from 5% (10/215) in 1985-1987 to 46% (136/296) in 2000-2002 (x2trend,
208.86, p<0.001); the proportion bom to white women decreased from 93% (200/215) to
47% (140/296) (x^ rend, 235.54, p<0.001). Few infants were bom to women of other
ethnicities, though the proportion increased gradually over time from 2% (5/215) in
1985-1987 to 7% (20/296) in 2000-2002 (x^ rend, 10.91, p<0.001). These trends were
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observed both in southern European centres (Italy and Spain) and northern European 
centres (Germany, UK, The Netherlands, Sweden, Belgium and Denmark).
Table 3.1 Socio-demographic characteristics of mother-child pairs
n (%)
Child year of birth (n=1664)
1985-1990 580 (35)
1991-1996 460 (28)
1997-2002 624 (38)
Child country of birth (n=1667)
Belgium 291 (17)
Denmark 30(2)
Germany 229(14)
Italy 386(23)
Spain 366 (22)
Sweden 178(11)
The Netherlands 81(5)
UK 106(6)
Maternal ethnicity (n=1603)
White 1064 (66)
Black 449 (28)
Other 90 (6)
Maternal area of birth (n=1559)
Europe 1044(67)
Sub-Saharan Africa 431 (28)
The Americas 36(2)
Asia 28 (2)
North Africa & Middle East 20(1)
Maternal age (n=1525)
<25 years 476 (31)
25-29 years 552 (36)
>29 years 497 (33)
Maternal previous live births (n=1514)
0 776 (51)
1 432 (29)
2 169(11)
3 80 (5)
4 or more 57(4)
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Overall, of children bom in southern European centres, more had a mother who was 
white (650/731, 89%) than black (50/731, 7%), whereas for those bom in northern 
European centres, there was little difference: 47% (414/872) and 46% (399/872) 
respectively.
A total of 568 (568/1559, 36%) children were bom to women who themselves had been 
bom abroad. Of those bom abroad, most were from sub-Saharan African countries 
(431/568, 76%), particularly Democratic Republic of the Congo (Zaire), Uganda, Ghana 
and Rwanda.
Mode of acquisition of maternal HIV infection
The most commonly reported mode of acquisition of maternal HIV infection was 
intravenous drug use-related (Table 3.2). A total of 728 children (728/1667, 44%) had 
mothers who were past or current intravenous drug users, and just over half of these 
(n=389) had mothers who had a sexual partner with a history of intravenous drug use. A 
further 160 children (160/1667, 10%) had mothers who had a sexual partner with a 
history of intravenous drug use, though they were not reported to have been users 
themselves. There was little overlap between intravenous drug use-related acquisition 
and other risk factors for HIV infection, though prostitution or many sexual partners had 
been reported for the mothers of 32 children; and another 33 children were bom to 
mothers who had high-risk sexual partners not known to be intravenous drug users: 
haemophiliac (2), bisexual (2), prisoner (1), known HIV infected (2), from an HIV high- 
prevalence country (1), unspecified (25).
A quarter of children (434/1667, 26%) were bom to women from an HIV high- 
prevalence country, who were most likely to have acquired their HIV infection
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heterosexually; and in 326 cases, a sexual partner from an HIV high-prevalence country 
was also reported as a risk factor. The majority of these 434 children were bom to 
mothers who were black and from sub-Saharan Africa (392/434, 90%).
Table 3.2 Maternal HIV-related characteristics of mother-child pairs
n (%)
Mode of acquisition of HIV infection (n=1667)
Intravenous drug use-related* 888 (53)
From an HIV high-prevalence country 434 (26)
Other heterosexual contact§ 188(11)
Blood transfusion recipient 23(1)
Not stated 134 (8)
Clinical status at enrolment (n=1667)
Non-AIDS 1603(96)
AIDS 64 (4)
Antenatal antiretroviral therapy (n=1667)
No 975 (58)
Yes 692 (42)
* Includes 5 whose mother was from an HIV high-prevalence country
§ Rape, prostitution/many sexual partners; or a sexual partner who was: haemophiliac, blood transfusion 
recipient, bisexual, prisoner, known HIV infected, from an HIV high-prevalence country, o f  an unspecified  
risk factor.
A total of 11% (188/1667) of children were bom to women who acquired HIV infection 
heterosexually but who were not reported to be either from an HIV high-prevalence 
country or to have had sexual contact with an intravenous drug user. In these cases, the 
reported mode of acquisition was rape (2), prostitution or many sexual partners (16); or a 
sexual partner who was haemophiliac (6), a blood transfusion recipient (1), bisexual (10), 
a prisoner (2), known HIV infected (37), from an HIV high-prevalence country (38) or 
with an unspecified risk factor (76). Eight percent (134/1667) of children were bom to 
women where a risk factor had not been stated, though it is likely that these women 
acquired their infection heterosexually (Table 3.2).
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Over the study period, intravenous drug use-related HIV infection decreased from 87% 
(409/470) in 1985-1989 to 27% (116/436) in 1999-2002, and HIV high-prevalence 
country acquired infection increased from 4% (20/470) to 45% (197/436) (Figure 3.1).
Figure 3.1 Trends in maternal ethnicity and mode of acquisition of HIV 
infection for mother-child pairs
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□  Black & WHPC
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IDUR, intravenous drug use-related; WHPC, woman from an HIV high-prevalence country 
Uninfected children enrolled in paediatric centres by year o f  birth: 1985-1987 n=215, 1988-1990 n=359, 
1991-1993 n=193, 1994-1996 n=243, 1997-1999 n=296, 2000-2002 n=296.
Maternal AIDS and antenatal ART use
Only 4% (n=64) of infants were bom to mothers who had progressed to AIDS by the 
time of enrolment in the ECS. Of children bom after 1994, 83% (656/788) were bom to 
mothers who had taken ART during pregnancy, which was in line with their increasing 
use either to delay HIV disease progression and/or to prevent mother-to-child 
transmission (Connor et al. 1994, Kirk et al. 1998, European Collaborative Study 2005c) 
(Table 3.2).
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Maternal illicit drug use (IDU)
Infants bom earlier in the study period were more likely to have been bom to women 
who used illicit drugs during pregnancy than those bom later: 36% (167/468) of infants 
bom before 1990 versus 10% (114/1121) of infants bom from 1990 onwards (x2, 147.65, 
p<0.001), and this was observed for infants both in northern and southern European 
centres.
Family size
Using number of previous live births as a proxy for current number of siblings, children 
bom to black women were more likely to have older siblings (278/441, 63%) than 
children bom to white women (400/967, 41%). Mean number of older siblings was 1.83 
for children bom to black women and 1.68 for those bom to white women. There was no 
significant association between maternal ethnicity and multiple enrolment of the mother: 
13% (50/397) of black women were enrolled in more than one pregnancy versus 10% 
(99/955) of white women (x2, 1.42, p=0.233).
3.4 Social care in the first year of life
Information on social care in the first year of life was available for 1652 (99%) of the 
1667 children enrolled in ECS paediatric centres. Of the remaining 15 children, all were 
bom to mothers not living with a partner at the time of enrolment.
By their last assessment in the first year of life, most children (1465/1652, 89%) had
lived with one or both of their parents since birth. A total of 122 (7%) children had been
in both parental and alternative care. Generally children were only cared for in one type
of alternative care (Table 3.3), though they may have been moved several times between
this care setting and their parents. At their last assessment, 73 of the 122 children (60%)
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were in parental care. Four percent of children (n=65) had always lived in alternative 
care (Table 3.3). Of the 187 children who had been in alternative care, half had lived 
with other relatives (94/187, 50%) and these were generally grandparents; 44% (82/187) 
had lived in a foster or adoptive family setting and 19% (35/187) in a hospital or 
institution.
Table 3.3 Type of alternative care that children had in their first year of life
Type of care
Children who 
spent some time in 
alternative care 
n (%)
Children who 
were always in 
alternative care 
n (%)
Non-parental relative only 55 (45) 19(29)
Fostered only 40 (33) 20 (31)
Adopted only 2(2) 3(5)
Hospital only 4(3) 8(12)
Institution only 9(7) 2(3)
More than one type of alternative care* 12(10) 13 (20)
Total 122 (100) 65 (100)
*non-parental relative, adoptive or foster parent, hospital or institution
The proportion of children who had been in alternative care in the first year of life 
decreased over the study period from 17% (37/217) in 1985-1987 to 5% (16/310) in 
2000-2002 (x2^ ,  33.07, p<0.001) (Figure 3.2).
Children bom to women who were reported to have used illicit drugs during pregnancy 
were more likely to have spent time in alternative care than children whose mothers had 
no reported drug use, after adjusting for maternal ethnicity, age and clinical status 
(AOR=14.54, 95% Cl: 7.72-27.40, p<0.001). Maternal ethnicity and clinical status were 
not associated with alternative care placement, after adjusting for maternal IDU, age and 
clinical status or ethnicity respectively.
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Figure 3.2 Type of social care by year of birth of child
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3.5 Morbidity and hospitalisation in the first year of life
Infectious disease morbidity
Sufficient information to enable categorisation of infectious disease morbidity in the first 
year of life was available for 1617 (97%) of the 1667 uninfected children. Of the 
remaining 50 children, 52% (26/50) were bom to women who had intravenous drug use- 
related HIV infection and nearly two thirds were bom to white women (n=32).
A total of 135 (135/1617, 8%) infants experienced at least one moderate/severe infective 
episode requiring medical attention in the first year of life. Of these, 92 infants had at 
least one episode of diarrhoea, 47 had at least one episode of a serious bacterial infection 
(most commonly sepsis (10), pneumonia (12), urinary tract infection (8), meningitis (6)); 
and 13 had an unexplained fever. There were 183 episodes in total and 36 children had 
more than one episode.
71
The proportion of children who had a moderate/severe infective episode decreased over 
the study period: from 11% (61/557) of children bom in 1985-1990 to 7% (44/614) in 
1997-2002 (x^2trend? 5.29, p=0.021). Although nearly half of the episodes of bacterial 
infection (24/53, 45%) occurred during the first three months of life, no specific pattern 
was observed for episodes of diarrhoea or fever. There were four episodes of bacterial 
infection, one of fever and eight of diarrhoea per 100 child-years of follow-up. There was 
little correlation between recorded socio-demographic and child characteristics, and risk 
of the infant having a moderate/severe infective episode requiring medical attention in 
the first year of life.
Hospitalisation
Hospitalisation for any reason in the first year of life in uninfected children remained 
relatively stable over the study period: 264 admissions per 1000 child-years of follow-up 
in 1985-1989, 243 in 1990-1994, 299 in 1995-1999 and 407 in 2000-2001. Median 
length of stay in hospital also remained constant (Table 3.4).
Table 3.4 Hospitalisation for any reason in uninfected children
Year of 
birth
Children
hospitalised
(n)
Hospital
admissions
(n)
Follow-
up
(child-
years)
Admissions 
per 1000 
child-years 
follow-up 
(95% Cl)
Median 
number of 
days in 
hospital 
(interquartile 
range)
1985-1989 89 118 447 264 (224-307) 8(13)
1990-1994 65 91 374 243 (201-290) 7(12)
1995-1999 92 129 431 299 (256-345) 8(12)
2000-2001 62 88 216 407 (341-476) 10(18)
72
3.6 Key points
• two thirds of children were bom to white women, though the proportion of children 
bom to black women (majority from sub-Saharan Africa) increased from 5% in 
1985-1987 to 46% in 2000-2002
• half the children had mothers with intravenous drug use-related HIV infection, 
though HIV high-prevalence country acquired infection (majority from sub-Saharan 
Africa) increased over the study period
• 4% of children were bom to women who had progressed to AIDS by the time of 
enrolment
• the majority of children (89%) had lived with one or both of their parents from birth 
up to their last assessment in the first year of life
• the most common type of alternative care was non-parental relatives
• the proportion of children who had been in alternative care decreased from 17% in 
1985-1987 to 5% in 2000-2002
• children bom to women who had used illicit drugs in pregnancy were more likely to 
have spent time in alternative care than children whose mothers had no reported drug 
use, after adjusting for maternal ethnicity, age and clinical status
• a total of 135 (8%) infants experienced at least one moderate/severe infective episode 
requiring medical attention in the first year of life; there was little correlation 
between recorded socio-demographic and child characteristics, and risk of the infant 
having a moderate/severe infective episode
• hospitalisation for any reason remained relatively stable over the study period
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Chapter 4 Exposure to antiretroviral therapy and the health of
uninfected children
“I  strongly feel that it's very important to follow up on our children since nobody knows 
what the long term effects o f these drugs can be. "
[Mother of two children (aged 3 and 7 years)]
“I f  they think there are problems then it [follow-up] is important. I f  there aren't side
effects then it is wasting time. ”
[Mother of four children (aged 2, 3, 11 and 14 years)]
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4.1 Introduction
The risk of mother-to-child transmission (MTCT) of HIV infection is significantly 
reduced by the use of prophylactic antiretroviral therapy (ART) in the antenatal, 
intrapartum and neonatal periods (Connor et al. 1994, Mandelbrot et al. 2001, Cooper et 
al. 2002, European Collaborative Study 2005c). HIV infected pregnant women may also 
require highly active antiretroviral therapy (HAART) for their own health. Concerns 
have been raised that exposure to ART could have adverse effects on the fetus and 
newborn, both in the short- and long-term (Blanche et al. 1999, Olivero et al. 1997, 
Mofenson and Munderi 2002). In this chapter, ART exposure in uninfected children 
enrolled in the European Collaborative Study (ECS) is described; and health outcomes in 
these children, with respect to ART exposure, are assessed.
4.2 Methods
The analyses presented here were based on data on uninfected children enrolled in all
ECS centres (obstetric and paediatric), apart from the analysis of longer-term health
outcomes (Section 4.6) which was restricted to those enrolled in paediatric centres. The
ECS methodology and general definitions used are given in Section 2.1. In addition,
neonatal anaemia was defined as grade 2 or 3 toxicity according to the Pediatric AIDS
Clinical Trials Group (PACTG) toxicity tables, which take into account age of the infant
at the time of haemoglobin quantification (Division of AIDS (DAIDS) 2005). Low birth
weight was defined as less than 2500g. Clinical symptoms in the child reported at each
assessment were categorised into four groups: “not symptomatic”, “mildly
symptomatic”, “moderately symptomatic” and “severely symptomatic”, modelled on the
Centers for Disease Control and Prevention (CDC) 1994 Revised Classification System
for HIV Infection in Children Less Than 13 Years of Age (Centers for Disease Control
and Prevention 1994) and designed to capture symptoms suggestive of mitochondrial
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dysfunction (including febrile seizures) (Landreau-Mascaro et al. 2002, Dominguez et al. 
2000), malignancies (Olivero et al. 1997) and other major infections (European 
Collaborative Study 2004b).
2 2Univariable comparisons for categorical variables were tested with % tests or % tests for 
linear trend. Univariable and multivariable logistic regression was used to obtain odds 
ratios (OR), adjusted odds ratios (AOR) and 95% confidence intervals (Cl). Analyses 
were performed using SAS statistical software (version 6.12, SAS Institute, Cary, North 
Carolina, USA).
4.3 Pregnancy and delivery characteristics of mother-child pairs
By December 2001, 2414 uninfected children bom to 2251 mothers had been enrolled in 
the ECS. Pregnancy and delivery characteristics are shown in Table 4.1. Of the 2414 
children, 1511 (63%) had been enrolled in paediatric centres and 903 (37%) in obstetric 
centres (Figure 4.1).
Table 4.1 Pregnancy and delivery characteristics of mother-child pairs
n (%)
Maternal age (years) (n=2174)
<25 649 (30)
25-29 841 (39)
>29 684 (31)
Maternal illicit drug use (IDU) (n=2226)
Never 1007(45)
Past user/user timing unknown 782 (35)
Current 437 (20)
Mode of delivery (n=2386)
Vaginal 1319(55)
Emergency caesarean section 245(10)
Elective caesarean section 822 (34)
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Figure 4.1 Enrolment of uninfected children in the European Collaborative 
Study by year of birth and type of centre (by the end of 2001)
^  Obstetric 
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■ Paediatric 
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Year of birth of child
Maternal CD4 cell counts during pregnancy were available for 976 mother-child pairs 
(976/2414, 40%). The majority (83%) of the tests taken nearest to delivery were carried 
out in the third trimester. Maternal CD4 cell count was <200 cells/mm3 in 14% (134/976) 
of mother-child pairs.
4.4 Antiretroviral therapy exposure
Of the 2414 children, 687 (28%) were exposed to ART during the antenatal, intrapartum 
and neonatal periods. A further 193 (8%) children were exposed to ART in two periods 
and 128 (5%) in one period. Of the 1008 exposed children, 906 (90%) were exposed 
antenatally, 840 (83%) neonatally and 829 (82%) in the intrapartum period (Figure 4.2). 
A total of 1406 (1406/2414, 58%) infants were not exposed to any ART, and of these,
113 were bom after 1994 and therefore after publication of the results of the PACTG 076 
trial (Connor et al. 1994). These 113 infants were not clustered in particular centres. A
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total of 89 (79%) of them were bom to white women, and median maternal age was 29.0 
years (range 18.7-39.5).
The proportion of infants exposed to any ART significantly increased, from 23% 
(49/210) in 1994 to 78% (102/131) in 1996, 97% (143/147) in 1998 and 100% (179/179) 
in 2000 (x^ irend) 23.82, pO.OOl).
Figure 4.2 Antiretroviral therapy exposed children: periods of exposure 
(n=1008)
Antenatal
Intrapartum Neonatal
Zidovudine (ZDV) for six weeks according to the PACTG 076 regimen (Connor et al. 
1994) was the most common neonatal ART; in one centre the neonatal regimen consisted 
of intravenous ZDV for 10 days (Grosch-Womer et al. 2000). Of the infants exposed to 
intrapartum ART, the majority were exposed to ZDV only (726/829, 88%), with 70 (8%) 
exposed to ZDV + nevirapine (NVP), 20 (2%) to ZDV + lamivudine (3TC) and the 
remaining 13 (2%) to 10 different drug combinations.
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Of the 906 infants exposed to antenatal ART, 52% (475/906) were exposed to ZDV 
monotherapy and 48% (431/906) to combination therapy. Exposure to combination 
therapy increased over the study period (Figure 4.3). Of the 123 infants exposed to 
double therapy, the majority (n=92, 75%) were exposed to ZDV + 3TC; 13 were exposed 
to 3TC + stavudine (d4T), 11 to ZDV + didanosine (ddl), and the remaining seven to six 
different drug combinations.
Figure 4.3 Antenatal antiretroviral therapy exposure by year of birth of child
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Exposure to three or more antiretroviral drugs occurred in 308 infants. Drugs used in 
regimens with nucleoside analogue reverse transcriptase inhibitor (NRTI) backbones 
were: ZDV, 3TC, d4T, ddl, zalcitabine (ddC) and abacavir (ABC). NVP was the most 
commonly used non-nucleoside reverse transcriptase inhibitor (NNRTI) (n=63). Three 
infants were exposed to efavirenz (EFV); in all cases the drug had been started pre­
conception, but was stopped early on in the pregnancy. A total of 194 infants were
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exposed to a protease inhibitor (PI). The most frequently used PI was nelfinavir (NFV) 
(n=127, 65%), followed by indinavir (IDV), saquinavir (SQV) and ritonavir (RTV).
Information on the timing of initiation of antenatal ART was available for the mothers of 
713 children (713/906, 79%). Of these, 139 (19%) infants were exposed to ART at 
conception: 31 to monotherapy and 108 to combination therapy. A total of 114 (16%) 
infants were bom to women who initiated ART in the first trimester, 231 (32%) in the 
second and 229 (32%) in the third. Furthermore, exposure to ART at conception was 
more likely later in the study period (1998-2001) (108/471, 23%) than earlier (1994- 
1997) (30/241, 12%) (x2, 11.21, p<0.001). Of the 193 children where information on the 
timing of antenatal ART exposure was not available, 143 (74%) were exposed to 
monotherapy and 50 (26%) to combination therapy.
The proportion of children exposed to antenatal ART did not significantly differ between 
paediatric (559/1511, 37%) and obstetric (347/903, 38%) centres (x2, 0.49, p=0.482).
4.5 Early health outcomes
4.5.1 Congenital abnormalities
Congenital abnormalities were recorded in 37 (1.5%) out of the 2414 children, 13 of
whom had been exposed to ART antenatally (Table 4.2). Of the exposed children, seven
had been exposed in the first trimester: a child with Down’s syndrome (ZDV + 3TC),
two with a ventricular septal defect (AZT + 3TC, ZDV + 3TC + D4T + NVP), and one
with hydronephrosis (ZDV + 3TC + NVP). The remaining three children exposed in the
first trimester had unspecified anomalies at birth, but in follow-up assessments one was
reported to have ileostoma and enteritis (ZDV + 3TC + NVP) and one an atrial septal
defect (ZDV + 3TC + RTV); no further clinical information was available for the third
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child (ZDV + 3TC). The pattern and prevalence of abnormalities in infants exposed to 
antenatal ART (13/906, 1.4%) was similar to those not exposed (24/1508, 1.6%) (x2, 
0.09, p=0.762) (Table 4.2). The prevalence of congenital abnormalities in children 
exposed to ART in the first trimester (7/253, 2.8%) was similar to that in those exposed 
in the second or third trimester (6/460, 1.3%) (Fisher exact test, p=0.163).
Table 4.2 Children with a congenital abnormality by antenatal antiretroviral
therapy exposure (n=37)
Congenital abnormality
Not exposed to 
antenatal ART 
(n)
Exposed to 
antenatal ART 
in the first 
trimester (n)
Exposed to 
antenatal ART 
in the second or 
third trimester 
(n)
Polycystic kidney 2 1
Ventricular septal defect 
Multiple intracardiac tumours 
Situs inversus 
Cleft palate 
Hydrocephalus
4
1
1
1
1
2 1
Down’s syndrome 
Cateract 1
1 2
Hydronephrosis 
Microcephaly 
Fallot tetrology 
Oesophageal atresia
1
1
1
2
1
Polydactyly 3 1
Unspecified abnormalities 5 3 1
Total 24 7 6
ART, antiretroviral therapy
4.5.2 Low birth weight
Birth weight was available for 97% of enrolled children (2339/2414): mean 2927g (SD 
561) and median 2950g (range 735-5300). Nineteen percent (449/2339) of infants had 
low birth weight (LBW) (<2500g) and of these, 33 had very low birth weight (VLBW) 
(<1500g). There was no association between antenatal ART exposure and LBW: 18%
(160/874) of those exposed were of LBW compared with 20% (289/1465) of those not 
exposed (x2, 0.71, p=0.399). Of the 33 infants with VLBW, 14 had been exposed to 
antenatal ART and 19 were not exposed.
4.5.3 Requirement for a blood transfusion
Thirty-two infants required a blood transfusion in the immediate postpartum period:
1.2% (11/906) of the antenatally exposed infants and 1.4% (21/1508) of those not 
exposed. There was no association between antenatal ART exposure and the need for a 
blood transfusion (x2, 0.14, p=0.710). One infant required a transfusion following 
surgery, five had anaemia, one had thrombocytopenic purpura, 20 were premature, and 
for five the reason was not recorded.
4.5.4 Prematurity
Gestational age information was available for 2326 children (2326/2414, 96%). Of the 
88 children with no information, 22 (25%) had been exposed to antenatal ART and 66 
(75%) had not been exposed.
The overall crude prematurity (gestational age <37 weeks) rate was 17% (396/2326), and 
this increased from 16% (73/460) in 1985-1989 to 25% (178/710) in 1997-2001. For 
infants not exposed to antenatal ART, the crude prematurity rate was 15% (221/1442); 
for infants exposed to monotherapy it was 16% (75/465) and for those exposed to 
combination therapy it was 24% (100/419) (x2, 17.09, p<0.001).
Antenatal ART exposure was significantly associated with prematurity in multivariable 
logistic regression analysis (Table 4.3).
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Table 4.3 Risk factors for prematurity (gestational age <37 weeks) in children enrolled in obstetric and paediatric centres
Prematurity
No (%) Yes (%) Unadjusted odds ratio Adjusted odds ratio*
(95% Cl) p value (95% Cl) p value
Antenatal ART exposure
None 1221 (85) 221 (15) 1.00 1.00
Monotherapy 390 (84) 75 (16) 0.73 (0.43-1.24) p=0.242 0.90 (0.51-1.58) p=0.704
Combination therapy without PI 182 (79) 49 (21) 2.00(1.20-3.31) p=0.008 2.66(1.52-4.67) p=0.001
Combination therapy with PI 137(73) 51 (27) 3.45 (2.08-5.72) p<0.001 4.14(2.36-7.23) p<0.001
X2=19.66, p<0.001
Maternal illicit drug use
Never 841 (86) 138(14) 1.00 1.00
Past user/user timing unknown 622 (82) 137(18) 1.12(0.74-1.71) p=0.596 1.37(0.87-2.14) p=0.175
Current user 324 (77) 96 (23) 1.72(1.05-2.81) p=0.031 2.76(1.56-4.86) p<0.001
X2=16.45,p<0.001
Maternal CD4 cell count
(cells/mm3)
>500 316(87) 49(13) 1.00 1.00
200-499 396 (83) 81 (17) 1.14(0.76-1.71) p=0.536 1.04 (0.68-1.59) p=0.849
<200 109 (81) 25 (19) 1.32(0.76-2.29) p=0.324 1.22 (0.69-2.17) p=0.500
X2=2.85, p=0.240
Maternal age (years)
<25 527(84) 99(16) 1.00 1.00
25-29 694 (85) 126(15) 0.79 (0.48-1.30) p=0.355 0.75 (0.44-1.26) p=0.276
>29 531(80) 133 (20) 1.26 (0.78-2.03) p=0.342 1.10(0.66-1.84) p=0.724
X2=6.50, p=0.039
The univariable and multivariable odds ratio included 864 mother-child pairs with complete information on antenatal ART exposure, maternal illicit drug use, CD4 
cell count and age. *Adjusted for all other variables in model. Cl, confidence interval; ART, antiretroviral therapy; PI, protease inhibitor.
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Adjusting for maternal CD4 cell count, illicit drug use (IDU) and age, children exposed 
to combination therapy without a PI were more likely to be bom prematurely than 
children not exposed to antenatal ART (AOR 2.66, 95% Cl 1.52-4.67); and the 
association was more pronounced in children exposed to combination therapy with a PI 
(AOR 4.14, 95% Cl 2.36-7.23).
Elective caesarean section is recommended for HIV infected pregnant women to reduce 
the risk of MTCT, and here median gestational age for infants delivered by elective 
caesarean section was 38 weeks. The logistic regression analysis was repeated with mode 
of delivery included (categorised into elective caesarean section, emergency caesarean 
section, vaginal delivery): the AORs reduced a little to 2.05 (95% Cl 1.10-3.84) 
following exposure to combination therapy without a PI, and to 3.15 (95% Cl 1.68-5.92) 
following exposure to combination with a PI.
4.6 Longer-term health outcomes reported in follow-up assessments
The 1511 uninfected children enrolled in paediatric centres (see Section 4.3) had a 
median length of clinical follow-up of 2.2 years (range 0-15.9) and a combined length of 
follow-up of 4840 child-years (Figure 4.4).
4.6.1 Anaemia
Information on haemoglobin levels in the first six weeks of life was available for 763 of 
the 1511 infants (50%). Allowing for age at assessment, ART exposure during the 
antenatal, intrapartum or neonatal period was strongly associated with a diagnosis of 
anaemia (see Section 4.2): 33% (153/458) in exposed infants compared with 12% 
(38/305) in unexposed infants (x2, 42.81 p<0.001).
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Figure 4.4 Age at which children enrolled in paediatric centres were last seen for 
a follow-up assessment (by the end of 2001)
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4.6.2 Clinical symptoms
Clinical follow-up information, from which symptoms were categorised in terms of 
possible ART-associated toxicity (Section 4.2), was available for 1497 (99%) of the 
1511 children enrolled in paediatric centres. Total length of follow-up in the first 18 
months of life for the 1497 children was 1909 child-years. Of the 14 children with no 
clinical follow-up information, three were bom to mothers who had taken ART during 
pregnancy and the remainder were not exposed to any ART.
Follow-up assessments in the first 18 months of life 
Severe clinical symptoms
Six children (6/1497, 0.4%), none of whom had been exposed to any ART, had severe 
clinical symptoms in the first 18 months of life. Of these, one child had epilepsy (Child 1
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in Table 4.4) and two had febrile seizures (Children 2 and 3). A fourth child had infantile 
spasms (West syndrome) at 34 weeks of age, which then persisted with severe mental 
retardation (Child 4); and a fifth child had perinatal encephalopathy attributed to 
asphyxia and fetal alcohol syndrome (Child 5). One infant had encephalopathy (paresis, 
pathologic reflexes, increased tone, leucomalacia) at five weeks of age and died of 
sudden infant death syndrome (SIDS) at 22 weeks of age (Child 6).
Moderate clinical symptoms
A total of 240 children (240/1497, 16%) had moderate clinical symptoms (in terms of 
possible ART-associated toxicity) in the first 18 months of life. Most of these conditions 
consisted of one episode of an infection requiring medical attention such as: diarrhoea, 
candidiasis, bacterial meningitis, pneumonia or sepsis, unexplained fever. Of these 240 
children, 80 with 115 child-years of follow-up were exposed to ART (antenatal, 
intrapartum or neonatal) (incidence rate 0.696 cases per child-year) and 160 with 223 
child-years of follow-up were not exposed (incidence rate 0.717 cases per child-year) 
(rate ratio 0.970, p=0.827).
Factors associated with moderate/severe clinical symptoms or death in the first 18 
months o f life
In multivariable logistic regression analysis, children with severe/moderate symptoms 
and/or who had died (three children died, see Section 4.6.3) were compared with 
children with mild/no symptoms. A child’s most severe clinical category reached during 
follow-up in the first 18 months of life was considered in analysis. In order to maximise 
the follow-up data available for analysis, children were included regardless of whether 
they had reached 18 months of age at the time of analysis. There were 117 (7.7%, 
117/1511) children bom less than 18 months before the time of analysis. Children
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exposed to ART during the antenatal, intrapartum or neonatal period were no more likely 
to experience moderate/severe symptoms or die in the first 18 months of life than 
children who were not exposed to any ART (AOR 1.42, 95% Cl 0.71-2.84, p=0.320), 
after adjusting for year of birth of the child and maternal IDU, ethnicity and age (Table 
4.5). Children bom 1999-2001 were less likely to have moderate/severe symptoms or die 
than those bom early in the study period (AOR 0.37, 95% Cl 0.16-0.87, p=0.022). This 
finding could reflect the fact that not all children within this category reached 18 months 
of age and therefore may yet have developed clinical symptoms.
Follow-up assessments after the first 18 months of life
In addition to the six children who had severe clinical symptoms in the first 18 months of 
life, five other children had severe clinical symptoms at later ages. One unexposed child 
had febrile seizures at 3.3 years (Child 7 in Table 4.4) and one had tuberculosis at 1.7 
years of age (Child 8). Two unexposed children had malignancies during follow-up: one 
had Hodgkin’s lymphoma at three years and another had a brain tumour (giant cell 
astrocytoma) at 11 years of age; no later assessments were conducted for either child 
(Children 9 and 10 respectively). The fifth child had static encephalopathy at 6.8 years of 
age; though no later assessments were conducted. The child’s mother had taken ZDV 
from 16 weeks gestation, but the child had not been exposed to ART in the intrapartum 
or neonatal periods (Child 11).
Forty-two children had moderate clinical symptoms after 18 months of age, of whom 13 
had been exposed to ART in the antenatal, intrapartum or neonatal period.
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Table 4.4 Details of children who had severe clinical symptoms or who died
Child Clinical symptoms and age at assessment Vital status at last assessment
Antiretroviral
therapy
exposure
Maternal illicit drug 
use in relation to the 
pregnancy
Age at last 
assessment
1 Epilepsy at 27 weeks Alive None IDU in pregnancy 5.6 years
2 Febrile seizures at 1.3 years Alive None Ex-IDU 6.1 years
3 Febrile seizures at 40 weeks Alive None None 2.6 years
4 Infantile spasms (West syndrome) at 34 weeks Alive None IDU in pregnancy 5.1 years
5
Perinatal encephalopathy (attributed to 
asphyxia and fetal alcohol syndrome) at 15 
weeks
Alive None Ex-IDU 2.8 years
6
Encephalopathy (paresis, pathologic 
reflexes, increased tone, leucomalacia) at 5 
weeks
Died of sudden infant death syndrome 
(SIDS) at 22 weeks None None 22 weeks
7 Febrile seizures at 3.3 years Alive None Ex-IDU 15.9 years
8 Tuberculosis at 1.7 years Alive None None 5.0 years
9 Hodgkin’s lymphoma at 3.1 years Alive None IDU in pregnancy 3.1 years
10 Malignancy of the brain at 11.1 years Alive None IDU in pregnancy 11.1 years
11 Static encephalopathy at 6.8 years Alive ZDV during pregnancy None 6.8 years
IDU, illicit drug user 
ZDV, zidovudine
Table 4.4 continued
Child Clinical symptoms Vital status at last assessment
Antiretroviral
therapy
exposure
Maternal illicit drug 
use in relation to the 
pregnancy
Age at last 
assessment
12 No symptoms. Gestational age 39 weeks and birth weight 331 Og
Died at 25 weeks. Cause of death not 
reported None IDU in pregnancy 25 weeks
13 No symptoms. Gestational age 37 weeks and birth weight 2900g
Died of group A beta haemolytic 
streptococcal septicaemia at 2.6 years None Ex-IDU 2.6 years
14 No symptoms. Gestational age 34 weeks and birth weight 251 Og
Died at 17 weeks. Cause of death not 
reported
ZDV + 3TC in 
pregnancy; 
and ZDV for 
neonate
Ex-IDU 17 weeks
IDU, il icit drug user
ZDV, zidovudine 
3TC, lamivudine
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Table 4.5 Factors associated with moderate/severe clinical symptoms or death in the first 18 months of life
Clinical sym ptom s
Mild/no symptoms (%) Moderate/severe symptoms Unadjusted odds ratio (OR) Adjusted odds ratio (AO R)*
or death (%) (95% Cl) p value (95% Cl) p value
ART exposure
No 701 (81) 166(19) 1.00 1.00
Yes 549 (87)
X2= 10.48, p=0.001
81 (13) 0.65 (0.48-0.87) p=0.005 1.42 (0.71-2.84) p=0.320
Maternal illicit drug use
Never 620 (86) 104(14) 1.00 1.00
Past user/user timing unknown 348 (80) 85 (20) 1.58(1.14-2.19) p=0.006 1.21 (0.81-1.82) p=0.355
Current user 222 (81) 
5C2=6.47, p=0.039
52(19) 1.44 (0.99-2.11) p=0.058 0.97 (0.61-1.54) p=0.891
Maternal ethnicity
White 820 (82) 180(18) 1.00 1.00
Black 314(87) 48(13) 0.62 (0.43-0.88) p=0.008 0.85 (0.55-1.33) p=0.477
Other 68(88)
X2=5.69, p=0.058
9(12) 0.66 (0.32-1.36) p=0.264 0.83 (0.39-1.76) p=0.626
Maternal age (years)
<25 347 (78) 98 (22) 1.00 1.00
25-29 424 (86) 71 (14) 0.55 (0.39-0.78) pO.OOl 0.60 (0.42-0.85) p=0.004
>29 360 (86) 
X2=13.05,p=0.001
59(14) 0.57 (0.40-0.82) p=0.002 0.72 (0.49-1.07) p=0.101
Year of birth
1985-1989 356 (76) 112(24) 1.00 1.00
1990-1993 259 (84) 48(16) 0.62 (0.42-0.92) p=0.017 0.70 (0.46-1.06) p=0.094
1994-1998 384 (88) 54(12) 0.55 (0.38-0.79) p=0.001 0.51 (0.25-1.03) p=0.059
1999-2001 249 (89) 
X2=29.84, pO.OOl
32(11) 0.44 (0.28-0.69) pO.OOl 0.37(0.16-0.87) p=0.022
The univariable and multivariable odds ratio included 1320 mother-child pairs with complete information on ART exposure, year o f  birth; and maternal illicit drug use, ethnicity and 
age. * Adjusted for all other variables in model. Cl, confidence interval; ART, antiretroviral therapy.
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4.6.3 Deaths
Four children died during follow-up. One child not exposed to any ART died at 25 
weeks of age though the cause of death was not reported (Child 12 in Table 4.4), and 
another unexposed child died of group A beta haemolytic streptococcal septicaemia at
2.6 years of age (Child 13). The only exposed child that died during follow-up had been 
exposed to ZDV + 3TC antenatally and ZDV neonatally, however the cause of death was 
not reported (Child 14). The fourth child died of SIDS at 22 weeks and was described in 
Section 4.6.2 (Child 6).
4.7 Key points
• just under a third of infants were exposed to ART during the antenatal, intrapartum 
and neonatal periods; 8% were exposed in two periods and 5% in only one
• the proportion of children exposed to any ART increased from 23% in 1994 to 100%
in 2000
• of the 906 infants exposed to antenatal ART, half were exposed to ZDV monotherapy 
and half to combination therapy; and exposure to combination therapy increased over 
the study period
• exposure to ART at conception was more likely later in the study period than earlier
• 37 (1.5%) infants had congenital abnormalities; the pattern and prevalence of 
abnormalities in infants exposed to antenatal ART was similar to those not exposed
• there was no association between antenatal ART exposure and low birth weight, or 
requirement for a blood transfusion in the immediate postpartum period
• adjusting for maternal CD4 cell count, IDU and age, children exposed to combination 
therapy with or without a PI were more likely to be bom prematurely than children 
not exposed to antenatal ART
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• allowing for age at assessment, ART exposure during the antenatal, intrapartum or 
neonatal period was associated with anaemia in the first six weeks of life
• in the first 18 months of life, six children, none of whom had been exposed to any 
ART, had severe clinical symptoms; and 240 children had moderate clinical 
symptoms, of whom 80 with 115 child-years of follow-up were exposed to ART and 
160 with 223 child-years of follow-up were not exposed (rate ratio 0.970, p=0.827)
• children exposed to ART during the antenatal, intrapartum or neonatal period were 
no more likely to experience moderate/severe symptoms or die in the first 18 months 
of life than children who were not exposed to any ART, after adjusting for year of 
birth of the child and maternal IDU, ethnicity and age
• two children had malignancies diagnosed after 18 months of age, neither were 
exposed to any ART
• four children died during follow-up, one of whom had been exposed to ZDV + 3TC 
antenatally and ZDV neonatally
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Chapter 5 Exposure to antiretroviral therapy and growth in
uninfected children
“I  sometimes think she's too skinny and wonder if  it’s the drugs. My other babies are
chubby. ”
[Mother of three children (aged 1, 3 and 12 years)]
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5.1 Introduction
There is only limited information on whether antiretroviral therapy (ART) exposure has 
an adverse effect on growth in uninfected children bom to HIV infected women in 
resource-rich settings. Initial reports addressing growth after zidovudine exposure were 
reassuring (Sperling et al. 1998, Culnane et al. 1999, Chotpitayasunondh et al. 2001), but 
uninfected children are increasingly exposed antenatally to highly active antiretroviral 
therapy (HAART), often throughout the whole gestational period (European 
Collaborative Study 2004a). Although antenatal ART exposure has not been observed to 
be associated with fetal growth (Fiore 2005), combination therapy, particularly HAART, 
has consistently been associated with prematurity in European cohorts (see Chapter 4) 
(Lorenzi et al. 1998, European Collaborative Study 2004a). In this chapter, weight, 
length/height and head circumference (occipitofrontal circumference, OFC) 
measurements in the first 18 months of life in uninfected children enrolled in the 
European Collaborative Study (ECS) paediatric centres are assessed, while allowing for 
maternal characteristics and antenatal ART exposure.
5.2 Methods
The general ECS methodology and definitions are outlined in Section 2.1. Weight and
OFC were recorded at birth, and weight, length/height and OFC were recorded at each
subsequent follow-up assessment (European Collaborative Study 1995). A z-score
(standard deviation from the mean of a population) for each measurement of weight,
length/height and OFC was calculated according to age and gender using the LMS
method. The LMS method summarises the changing distribution of a variable over age,
by curves that represent the median, coefficient of variation and skewness (Cole and
Green 1992). The use of z-scores means that measurements are no longer age-dependent
and therefore maximises the data available for analysis. As all children in this analysis
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were bom to HIV infected women, z-scores were calculated from within this population. 
In the calculation of z-scores, no adjustment was made for gestational age as this was a 
variable of particular interest given its association with HAART (European Collaborative 
Study 2004a).
Twins and triplets (n=75) were excluded for this analysis because of their different 
growth patterns and propensity for premature delivery compared with singletons. For the 
75 twins and triplets, mean birth weight was 2065g (SD 456g) and 77% (58/75) of them 
had a gestational age of less than 37 weeks.
An unpaired t-test was used to compare mean z-scores at birth. The Kaplan-Meier 
method (Kaplan and Meier 1958) was used to calculate survival estimates for the age at 
the first assessment where the child’s z-score exceeded the 25th centile within this 
population (i.e. z-score of >-0.6745), for weight and OFC. The log rank test was used to 
test statistical significance between strata. Children were censored at the age they were 
last measured within the first 18 months of life. Linear mixed effects regression models 
which allowed for repeated measures were used to investigate the effect of neonatal and 
maternal characteristics including antenatal ART exposure, on weight, length/height and 
OFC. The likelihood ratio test was used to assess the fit of models. The Akaike’s 
information criterion (AIC) was used to assess the improvement of models with 
inclusion of additional random effects on centre level.
Z-scores were calculated using LMS program (version 1.16, Institute of Child Health, 
London, UK). Analyses were conducted using SAS statistical software (version 8.02,
SAS Institute, Cary, North Carolina, USA), STATA (version 8.2, Statacorp, College
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Station, Texas, USA) and R statistical software (version 1.91, R Foundation for 
Statistical Computing, Vienna, Austria).
5.3 Results
By December 2003, 1912 uninfected singleton children (51%, n=972 male) bom to 1728 
mothers had been enrolled in ECS paediatric centres (Table 5.1). Of the 78 children with 
a gestational age of less than 34 weeks, 51 were bom at 33 or 32 weeks, 20 at 31 or 30 
weeks, three at 29 weeks, two at 28 weeks and two at 27 weeks. ART was initiated 
before pregnancy in 8% (26/317) of the 317 infants with monotherapy exposure, in 18% 
(23/125) of the 125 with double therapy exposure, and in 41% (200/483) of the 483 with 
HAART exposure.
5.3.1 Weight, length/height and head circumference
From birth to 18 months of age there were 11050 weight measurements for 1899 
children (mean, 5.8 per child), 8523 length/height measurements for 1776 children 
(mean, 4.8 per child) and 8928 OFC measurements for 1852 children (mean, 4.8 per 
child).
Cumulative length of follow-up to 18 months of age for 1513 term children (gestational 
age >37 weeks) was 1231 child-years for those with none/monotherapy antenatal ART 
exposure, and 418 child-years for those exposed to combination therapy; for the 344 
premature children (gestational age <37 weeks) it was 216 child-years for those with 
none/monotherapy antenatal ART exposure, and 150 child-years for those exposed to 
combination therapy. Overall median length of follow-up was 1.2 years.
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Table 5.1 Neonatal and maternal characteristics of mother-child pairs (n=1912)
n (%)
Gestational age (weeks) (n=1857)
<34 78 (4)
34-36 266 (14)
>37 1513 (81)
Birth weight (g) (n=1856)
<1500 22(1)
1500-2499 299(16)
>2500 1535 (83)
Exposure to antenatal antiretroviral 
therapy (n=1912)
None 987 (52)
Monotherapy 317(17)
Double therapy 125 (7)
HAART 483 (25)
Maternal CD4 count nearest delivery 
(cells/mm3) (n=744)
>500 212 (28)
200-499 407 (55)
<200 125(17)
Maternal ethnicity (n=1849)
White 1180 (64)
Black 561 (30)
Other 108(6)
Maternal illicit drug use (IDU) (n=1812)
Never 1048 (58)
Past user/user timing unknown 469 (26)
Current 295 (16)
To describe the patterns of the three growth measurements, z-scores for weight, 
length/height and OFC over age were plotted; and mean values of the z-scores by 
gestational age were calculated (Figures 5.1-5.3).
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Figure 5.1 Z-scores for weight with running-mean smoothing by gestational age
category
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Figure 5.2 Z-scores for length/height with running-mean smoothing by 
gestational age category
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Figure 5.3 Z-scores for head circumference with running-mean smoothing by
gestational age category
Age (years)
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-----------  < 3 4  wks (bottom line)
The analysis was further separated on two groups of antenatal ART exposure 
(none/monotherapy and combination therapy). Mean and standard deviation of z-scores 
at different age periods, stratified by gestational age and antenatal ART exposure are 
shown in Table 5.2.
Weight and OFC at birth
For term infants (gestational age >37 weeks), there was no significant difference in birth 
weight between infants with no or monotherapy exposure (mean z-score 0.26) and those 
with combination therapy exposure (mean z-score 0.23) (p=0.524); and there was no 
significant difference in OFC at birth between exposure groups: mean z-scores 0.15 and 
0.25 respectively (p=0.121) (Table 5.2).
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Table 5.2 Mean and standard deviation of z-score for weight, length/height and head circumference (OFC), at different age 
periods stratified by gestational age category and antenatal antiretroviral therapy exposure
<34 weeks (mean (SD) n) 34-36 weeks (mean (SD) n) >37 weeks (mean (SD) n)
None or Combination None or Combination None or Combination
monotherapy therapy monotherapy therapy monotherapy therapy
Weight
Birth -1.91 (0.76) -2.06 (0.64) -0.95 (0.68) -0.71 (0.72) 0.26 (0.92) 0.23 (0.80)
n=49 n=26 n=142 n=121 n=1039 n-439
<3 months -1.62 (0.79) -1.81 (0.68) -0.77 (0.72) -0.55 (0.76) 0.22 (0.83) 0.22 (0.70)
#i=57 n=26 n=144 #i=727 n=1053 n-448
15-18 months -0.78(1.24) -0.40(1.08) -0.46 (0.99) -0.33 (1.05) 0.03 (0.97) 0.31 (1.05)
n=34 n=14 n=64 n=42 n=567 n=120
Length*/
Height
<3 months -1.46(1.03) -1.84 (0.73) -0.63 (0.83) -0.61 (0.78) 0.24 (0.91) 0.15(0.78)
n=37 n=24 n=105 #i=775 n=760 n=408
15-18 months -0.65(1.22) -0.75(1.26) -0.41 (0.93) -0.15(0.99) 0.03 (1.00) 0.29(1.14)
n=33 n—13 n=61 n=40 n=525 #i=772
OFC
Birth -1.95 (0.93) -1.93 (0.60) -0.76 (0.93) -0.51 (0.78) 0.15(0.91) 0.25 (0.92)
n=37 n=18 n=117 n=106 n=844 n=321
<3 months -1.58 (0.92) -1.95 (0.63) -0.67 (0.86) -0.46 (0.71) 0.21 (0.84) 0.18(0.81)
n=46 n-24 n=134 #i=775 n=982 n=432
15-18 months -0.31 (1.22) -0.68 (0.77) -0.30 (0.84) 0.05(1.00) 0.03 (0.97) 0.04(1.17)
n=28 n=10 n=53 n-30 n=457 n=87
* Length was not recorded at birth; SD, standard deviation
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Infants bom at 34-36 weeks and exposed to combination therapy were significantly 
heavier at birth (mean z-score -0.71) than those with no or monotherapy exposure (mean 
z-score -0.95) (p<0.001). Infants bom at 34-36 weeks and exposed to combination 
therapy had a larger OFC at birth (mean z-score -0.51) than those with no or 
monotherapy exposure (mean z-score -0.76) (p=0.036) (Table 5.2).
For children bom before 34 weeks, there was no significant difference in birth weight 
between infants with no or monotherapy exposure (mean z-score -1.91) and those with 
combination therapy exposure (mean z-score -2.06) (p=0.403); and there was no 
significant difference in OFC at birth between exposure groups: mean z-scores -1.95 and 
-1.93 respectively (p=0.939) (Table 5.2).
Cumulative probability o f reaching a given centile for weight and OFC 
Cumulative probability of reaching the 25th centile for weight, stratified by gestational 
age category and antenatal ART exposure, is shown in Figure 5.4. An estimated 85% of 
all term children irrespective of ART exposure had already reached the 25th centile at 
birth (log rank test: p<0.001). An estimated 50% of those bom at 34-36 weeks with 
combination therapy exposure had already reached the 25th centile at birth; and for 
children bom at 34-36 weeks with no or monotherapy exposure, the estimated median 
age at reaching the 25th centile was just over three months of age (log rank test: 
p=0.003). For all children bom before 34 weeks, the estimated median age at reaching 
the 25th centile was over a year regardless of exposure (log rank test: p=0.944).
A similar pattern occurred for OFC (Figure 5.5) for term children and those bom at 34- 
36 weeks (log rank tests: p=0.008 and p=0.004 respectively); but for children bom before 
34 weeks, the estimated median age at reaching the 25th centile was fifteen months for
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children with combination therapy exposure and just over seven months for those with 
no or monotherapy exposure (log rank test: p=0.004).
Figure 5.4 Probability of reaching the 25th centile for weight stratified by 
gestational age category and antenatal ART exposure
1.510 5
A ge (years)
------------- >=37 w ks & none/m on o ------------- >=37 w ks & com b
................. 34 -36  w ks & none/m on o -------------  34 -36  w ks & com b
-------------<34 w ks & none/m ono ------------- < 3 4  w kS & com b
Figure 5.5 Probability of reaching the 25th centile for head circumference
stratified by gestational age category and antenatal ART exposure
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5.3.2 Factors associated with weight, length/height and head circumference in the 
first 18 months of life
To investigate factors associated with growth up to 18 months of age, regression models 
were fitted for weight, length/height and OFC (Tables 5.3-5.5). Prematurity (gestational 
age <37 weeks) had a negative effect on weight, length/height, and OFC. Maternal illicit 
drug use (IDU) also had a negative effect on growth, especially when used in pregnancy. 
Although there was a significant independent negative effect of combination therapy 
exposure on growth when compared with no or monotherapy exposure (adjusted 
coefficients: -0.10 for weight, -0.12 for length/height and -0.14 for OFC), the magnitude 
of this effect in actual measurements was small.
Although maternal IDU and ART exposure are both known determinants of prematurity, 
inclusion of two interaction terms (gestational age and IDU, gestational age and ART) in 
the models did not improve the fit of each model. The interaction between gestational 
age <34 weeks and ART in the OFC model was negative (coefficient -0.39, p=0.043, 
95% Cl: -0.77 to -0.01), in contrast to that of gestational age 34-36 weeks and ART 
(coefficient 0.26, p=0.012, 95% Cl: 0.06 to 0.47). This reflects the finding that children 
bom before 34 weeks and exposed to combination therapy reached a given centile later 
than those with no or monotherapy exposure; the opposite to that seen in the less 
premature children (Figure 5.5). The overall negative effect of combination therapy on 
OFC in Table 5.5 (adjusted coefficient -0.14, p=0.001, 95% Cl: -0.23 to -0.06) could be 
an underestimation of the effect in infants bom before 34 weeks.
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Table 5.3 Weight (z-score) and maternal and infant factors in the first 18
months of life
Unadjusted 
coefficient 
(95% Cl)
p value
Adjusted 
coefficient* 
(95% Cl)
p value
Antenatal ART
exposure
None/monotherapy 0.00 0.00
Combination therapy 0.07 p=0.133 -0.10 p=0.019
(-0.02, 0.15) (-0.18, -0.02)
Gestational age
(weeks)
>37 0.00 0.00
34-36 -0.70 p<0.001 -0.65 p<0.001
(-0.80, -0.59) (-0.75, -0.55)
<34 -1.56 p<0.001 -1.51 p<0.001
(-1.75,-1.38) (-1.68,-1.34)
Gender
Male 0.00 0.00
Female -0.01 p=0.790 -0.01 p=0.891
(-0.09, 0.07) (-0.07, 0.06)
Maternal ethnicity
White 0.00 0.00
Black 0.49 p<0.001 0.27 p<0.001
(0.41,0.58) (0.17, 0.36)
Other 0.15 p=0.077 0.04 p=0.607
(-0.02, 0.32) (-0.11,0.20)
Maternal illicit drug
use
Never 0.00 0.00
Past user/user timing -0.41 p<0.001 -0.29 p<0.001
unknown (-0.50, -0.32) (-0.39, -0.20)
Current -0.67 p<0.001 -0.51 p<0.001
(-0.77, -0.56) (-0.62, -0.40)
* Adjusted for all other variables in model.
The univariable and multivariable coefficient included 1745 mother-child pairs. 
Cl, confidence interval.
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Table 5.4 Length/height (z-score) and maternal and infant factors in the first 18
months of life
Unadjusted 
coefficient 
(95% Cl)
p value
Adjusted 
coefficient* 
(95% Cl)
p value
Antenatal ART
exposure
N one/monotherapy 0.00 0.00
Combination therapy 0.01 p=0.903 -0.12 p=0.008
(-0.08, 0.10) (-0.21,-0.03)
Gestational age
(weeks)
>37 0.00 0.00
34-36 -0.63 p<0.001 -0.58 p<0.001
(-0.74, -0.51) (-0.69, -0.47)
<34 -1.32 p<0.001 -1.26 p<0.001
(-1.52,-1.12) (-1.45,-1.07)
Gender
Male 0.00 0.00
Female -0.02 p=0.577 -0.02 p=0.690
(-0.11,0.06) (-0.09, 0.06)
Maternal ethnicity
White 0.00 0.00
Black 0.36 p<0.001 0.17 p=0.001
(0.27, 0.45) (0.07, 0.27)
Other 0.04 p=0.648 -0.03 p=0.756
(-0.14, 0.23) (-0.20, 0.15)
Maternal illicit drug
use
Never 0.00 0.00
Past user/user timing -0.30 p<0.001 -0.24 p <0.001
unknown (-0.39, -0.20) (-0.35, -0.13)
Current -0.56 p<0.001 -0.48 (-0.61, - p <0.001
(-0.68, -0.45) 0.36)
* Adjusted for all other variables in model.
The univariable and multivariable coefficient included 1638 mother-child pairs. 
Cl, confidence interval.
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Table 5.5 Head circumference (z-score) and maternal and infant factors in the
first 18 months of life
Unadjusted 
coefficient 
(95% Cl)
p value
Adjusted 
coefficient* 
(95% Cl)
p  value
Antenatal ART
exposure
None/monotherapy 0.00 0.00
Combination therapy 0.02 p=0.709 -0.14 p=0.001
(-0.07, 0.10) (-0.23, -0.06)
Gestational age
(weeks)
>37 0.00 0.00
34-36 -0.63 p<0.001 -0.57 p <0.001
(-0.73, -0.52) (-0.68, -0.47)
<34 -1.39 p<0,001 -1.33 p<0.001
(-1.58,-1.20) (-1.51,-1.15)
Gender
Male 0.00 0.00
Female -0.04 p=0.402 -0.04 p=0.340
(-0.12, 0.05) (-0.11,0.04)
Maternal ethnicity
White 0.00 0.00
Black 0.50 p<0.001 0.33 p <0.001
(0.41,0.58) (0.24, 0.43)
Other 0.16 p=0.078 0.09 (-0.07, p=0.266
(-0.02, 0.33) 0.26)
Maternal illicit drug
use
Never 0.00 0.00
Past user/user timing -0.38 p<0.001 -0.24 p <0.001
unknown (-0.48, -0.29) (-0.34, -0.14)
Current -0.57 p<0.001 -0.41 p<0.001
(-0.68, -0.46) (-0.52, -0.29)
* Adjusted for all other variables in model.
The univariable and multivariable coefficient included 1707 mother-child pairs. 
Cl, confidence interval.
Adjusting for unobserved variation between centres by inclusion of a random effects 
variable at centre level did improve the fit of the weight, length/height and OFC models, 
although the coefficients in Tables 5.3-5.5 remained of a similar magnitude.
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Adjusted coefficients for explanatory variables were broadly similar for all three growth 
measurements (Tables 5.3-5.5) suggesting they were internally consistent within child. 
To investigate this consistency further, sub-analyses were conducted where length/height 
categorised as z-score quartiles was added as an explanatory variable in the weight 
model, weight in the length/height model, and weight in the OFC model. This 
significantly improved the fit of each model (p<0.001). In the model for weight, children 
who were taller than the baseline were also heavier. This was also the case in the models 
for length/height and OFC.
In additional sub-analyses of mother-child pairs with available information, maternal 
CD4 cell count was not significantly associated with weight (705 mother-child pairs), 
length/height (669 mother-child pairs) or OFC (687 mother-child pairs) in univariable or 
multivariable models when adjusting for antenatal ART exposure, gestational age, 
gender, maternal ethnicity and IDU. Inclusion of CD4 cell count did not improve the fit 
of any of the models (weight p=0.712, length/height p=0.682 or OFC p=0.356) and the 
coefficients did not alter substantially.
5.4 Key points
• for term children or children bom before 34 weeks, weight and OFC at birth did not 
differ between those with no or monotherapy exposure and those with combination 
therapy exposure; children bom at 34-36 weeks with combination therapy exposure 
were heavier and had a larger OFC than children bom at 34-36 weeks with no or 
monotherapy exposure
• children bom at 34-36 weeks exposed to combination therapy reached the 25th 
centile for weight and OFC earlier than those bom at 34-36 weeks with no or
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monotherapy exposure (median age: birth versus three months for both weight and 
OFC)
• children bom before 34 weeks exposed to combination therapy reached the 25th 
centile for OFC later than those bom before 34 weeks with no or monotherapy 
exposure (median age: fifteen months versus seven months); for all children bom 
before 34 weeks, the estimated median age at reaching the 25th centile for weight 
was over a year regardless of exposure
• when adjusting for gestational age, gender, maternal ethnicity and maternal IDU, 
there was a marginal but significant negative effect of combination therapy exposure 
on growth up to 18 months of age when compared with no or monotherapy exposure 
(adjusted coefficients: -0.10 for weight (p=0.019), -0.12 for length/height (p=0.008) 
and -0.14 for OFC (p=0.001))
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Chapter 6 The Office for National Statistics flagging study
“When the baby is healthy and doesn't have any problems she doesn't need to be coming 
to the hospital. She's doing well but you never know if  she will get a problem. ” 
[Mother of one child (aged 3 months)]
“Personally Ifind it difficult to allocate outpatient slots as I  am seeing these patients in 
the context o f a busy neonatal follow up programme and as patient numbers increase 
this problem will escalate. A non clinic contact is therefore attractive. ”
[Paediatrician]
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6.1 Introduction
The carcinogenic potential of transplacental zidovudine (ZDV) exposure has been 
demonstrated in animal studies (Olivero et al. 1997, Olivero et al. 2002). Although ZDV 
exposure has not been reported to be associated with cancer in early childhood (Culnane 
et al. 1999, Hanson et al 1999), the possibility of development of cancer later on in life 
remains.
The UK Office for National Statistics (ONS) provides a resource whereby medical 
researchers are able to monitor death and cancer among subjects in their study. Subjects 
are identified on the National Health Service Central Register (NHSCR) and their 
records are marked with a study number (“flagged”). Details of death and cancer 
registration in the subjects are then supplied to the researchers (Greenberg and Coleman 
2000).
A protocol was established for flagging children reported to the National Study of HIV 
in Pregnancy and Childhood (NSHPC) to obtain notifications of death and cancer 
registration over the long term. This was done through an automatic matching procedure 
on the Births/Deaths Registration Database (BDRD) at the General Register Office 
(GRO). By the end of 2005, the majority of children reported to the NSHPC bom in 
England and Wales 2001-2004 had been flagged. Details on the methods of the NSHPC 
and flagging studies are provided in Sections 2.2 and 2.4 respectively.
6.2 Development of a protocol for flagging
6.2.1 Matching algorithm
Birth registration records of children reported to the NSHPC were identified on the
BDRD using a set of criteria (“matching algorithm”). A test dataset using the records of
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179 children reported to the NSHPC was used in the development of the matching 
algorithm (Table 6.1).
Table 6.1 Information available for the test dataset children (n=179)
Variable
Children with 
information available 
from NSHPC database 
n (%)
Child’s NHS number 179(100)
Child’s date of birth 179(100)
Child’s sex 178 (99)
Mother’s date of birth 175 (98)
Mother’s postcode district* of residence at delivery 163 (91)
Child’s birth weight 145 (81)
Mother’s country of birth 130(73)
Notes
♦postcode district is the first half o f  a postcode e.g. A12 is the postcode district o f  A12 3BC
NSHPC, National Study o f  HIV in Pregnancy and Childhood; NHS, National Health Service
The test dataset children were bom in England and Wales 1998-2004 and reported to the NSHPC by June
2004.
The general structure of the algorithm was a hierarchical set of match types, each one 
consisting of one or more variables. For each study subject, variables according to those 
in the first match type were compared with the BDRD to see if the subject matched with 
any birth registration records. If a match for the subject was not made, the second match 
type was used, and so on, until either a match was made or the end of the algorithm was 
reached. The aim in selecting match types for the algorithm was to maximise the number 
of subjects where a unique correct match with a birth registration record was made, and 
to minimise the number of subjects where incorrect or multiple matches were made.
Variables both in the NSHPC database and the BDRD that were suitable for use in the 
algorithm were: child’s National Health Service (NHS) number, date of birth and sex;
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and mother’s date of birth and postcode district of residence at delivery (postcode district 
is the first half of a postcode, e.g. A12 is the postcode district of A12 3BC).
Child’s birth weight, mother’s country of birth and the variables used in the algorithm 
(see previous paragraph) were provided for the matches made using the algorithm 
(output dataset). For the purposes of selecting match types for the algorithm, matches 
were considered correct if they agreed on at least one of the following not in the relevant 
match type: child’s birth weight, mother’s date of birth, mother’s postcode district of 
residence at delivery or mother’s country of birth; and incorrect if they did not agree on 
any. The finalised algorithm is shown in Table 6.2.
Table 6.2 The matching algorithm used in the Office for National Statistics 
flagging study
Match type 1) Child’s date of birth, sex and NHS number
Match type 2) Child’s date of birth, sex and mother’s date of birth
Match type 3) Child’s date of birth and mother’s date of birth
Match type 4) Child’s date of birth, sex and mother’s postcode district of residence at delivery
Match type 5) Mother’s date of birth, sex and mother’s postcode district of residence at delivery 
Match type 6) NHS number 
NHS, National Health Service
When the finalised algorithm was used on the test dataset, 166 (93%) of the 179 subjects 
were matched uniquely and correctly on type 1. Eight subjects were matched uniquely 
and correctly on type 2, one on type 4, one on type 5 and one on type 6. Two matches 
were made for one subject on type 2 and two for one subject on type 3; and for both the 
correct match could be identified.
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Several observations were made in the development of the algorithm. A match type with 
child’s date of birth, sex and NHS number (match type 1) was effective at making unique 
correct matches for subjects. However, despite all subjects in the test dataset having an 
NHS number recorded, 7% (13/179) of subjects were not matched on type 1. This was 
because data was missing or did not match between the NSHPC database and the BDRD. 
A match type consisting of only NHS number was important if mother’s date of birth and 
child’s date of birth were either missing or did not match between the databases. 
However, this match type was only used at the end of the algorithm as an error in NHS 
number would be less likely to lead to an incorrect match at that stage than if it was near 
the beginning. If a subject was a twin and was not matched on type 1 but there were 
multiple matches on another match type that included its sibling, birth weight had to be 
used to identify the correct match.
6.2.2 Confirmation of matches made using matching algorithm
Introduction
NHS number was not available for all children reported to the NSHPC. To assess 
whether matches made using the algorithm without NHS number would be the same as 
those made with NHS number, the algorithm was used on the test dataset with NHS 
number excluded. As NHS number was provided in the output dataset, matches made 
without NHS number could be compared with those made with it. Matches were 
identified as correct if NHS number was the same; and incorrect if it was different. This 
exercise only applied to the 166 subjects that matched on type 1 with NHS number (see 
Appendices 4.1 and 4.2).
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Unique matches
Of the 166 subjects that were matched on type 1 with NHS number, without NHS 
number 121 (121/166, 73%) were matched uniquely and correctly on type 2 and five 
(5/166, 3%) on type 4. However, seven (7/166, 4%) subjects were matched uniquely and 
incorrectly on type 2, 3 or 4 (Appendix 4.1).
Of the 126 subjects that were matched uniquely and correctly on type 2 or 4, 125 also 
agreed on at least one of: child’s birth weight (within lOg), mother’s country of birth or 
mother’s postcode district of residence at delivery (the latter not included for type 4). 
However, of the seven subjects that were matched uniquely and incorrectly on type 2, 3 
or 4, all disagreed on at least one of the above three variables. Only one of the seven 
subjects agreed on any of them (mother’s postcode district of residence at delivery not 
included for type 4), and in this case mother’s country of birth was the UK (Appendix 
4.1).
No matches
One subject had no match, and this was because mother’s date of birth and mother’s 
postcode district of residence at delivery were missing in the test dataset (Appendix 4.1).
Multiple matches
Thirty two (32/166, 19%) subjects had multiple matches on either type 2 or type 4. These 
included the correct match for 30 subjects (Appendix 4.2). Correct and incorrect matches 
for the 32 subjects could generally be related to how many variables they agreed or 
disagreed on, of: child’s birth weight (within lOg), mother’s country of birth or mother’s 
postcode district of residence at delivery (the latter not included for type 4). However for 
four subjects, incorrect matches agreed on mother’s country of birth when it was the UK,
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and therefore there had to be agreement on another variable to distinguish correct from 
incorrect. For twin pairs, the correct match had to agree on child’s birth weight for it to 
be distinguished from the incorrect match (i.e. its sibling) (2 subjects). For one subject 
the correct match could not be distinguished from incorrect (Appendix 4.2).
Confirmation of matches
If subjects that were matched uniquely without NHS number had then been flagged 
without any further confirmation, 5% (7/133) of them would have been flagged 
incorrectly. Furthermore, a relatively high proportion of the 166 subjects had multiple 
matches (32/166, 19%).
A stage was therefore built into the protocol to confirm non-type 1 matches made using 
the algorithm, determined by the agreement in the test dataset of: child’s birth weight 
(within lOg), mother’s country of birth and mother’s postcode district of residence at 
delivery (Appendices 4.1 and 4.2). A programme was written in SAS (SAS statistical 
software, version 8.02, SAS Institute, Cary, North Carolina, USA) for this confirmation, 
according to the criteria outlined in Appendix 4.3.
6.2.3 Protocol for flagging
The protocol established for flagging children reported to the NSHPC on the NHSCR for 
notifications of death and cancer registration over the long term, is shown in Figure 6.1. 
See Section 2.4 for the general methodology of flagging studies.
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Figure 6.1 Protocol for flagging children reported to the National Study of HIV 
in Pregnancy and Childhood on the National Health Service Central 
Register
Dataset o f  children to be flagged 
extracted from NSHPC database 
(input dataset) [1]
Matches made using matching 
algorithm (output dataset) (2]
Details o f  children 
identified on 
BDRD [41Confirmation o f  matches [3]
Event notifications [5]
Researcher
atlCH
NHSCR at 
ONS
GRO at ONS 
(BDRD)
Notes: GRO, General Register Office; NHSCR; National Health Service Central Register; ICH, 
Institute of Child Health; NSHPC, National Study of HIV in Pregnancy and Childhood; ONS, 
Office for National Statistics; BDRD, Births/Deaths Registration Database
6.3 Inclusion criteria for flagging children reported to the National Study 
of HIV in Pregnancy and Childhood (2005)
Data presented here relate to children reported to the NSHPC by June 2005. The 
inclusion criteria for the ONS flagging study in 2005 were children reported to the 
NSHPC who were:
• bom in England or Wales 2001-2004 and
• of any HIV infection status and
• of any ART exposure
The restriction was made on country of birth as the BDRD only includes births registered 
in England and Wales. Children were included regardless of reported HIV infection 
status as:
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• for indeterminate children, the majority are likely to have been exposed to ART; 
and once confirmation of infection status is reported to the NSHPC, the majority 
are likely to be uninfected
• for infected children, notifications of death and cancer registration reported from 
ONS enable clarification of information reported to the NSHPC through annual 
follow-up (see Section 2.2)
Children were included regardless of reported ART exposure as forms sent to the 
NSHPC at a later date could provide additional information about ART exposure 
(Appendix 3).
By June 2005 there were 2842 children who met the inclusion criteria for flagging (Table 
6.3). Of these, 2040 (72%) were uninfected, 85 (3%) were infected and 717 (25%) were 
of indeterminate status. Of the indeterminate children, 707 (707/717, 99%) were bom to 
women diagnosed with HIV infection before delivery. The majority of children were 
bom in England (2815/2842, 99%). A total of 2135 (2135/2842, 75%) children had been 
reported through both the obstetric and paediatric reporting schemes, 481 through 
obstetric only and 226 through paediatric only.
Table 6.3 Children born in England and Wales and reported to the National 
Study of HIV in Pregnancy and Childhood
Year of 
birth
Children reported 
by June 2005 (n)
Children with National Health 
Service (NHS) number supplied 
n (%)
2001 483 202 (42)
2002 606 334 (55)
2003 850 610(72)
2004 903 658 (73)
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6.4 Flagging of children reported to the National Study of HIV in 
Pregnancy and Childhood (2005)
6.4.1 Input dataset
A dataset on the 2842 children who met the inclusion criteria for flagging was extracted 
from the NSHPC database. This consisted of the variables in Table 6.4 as well as 
NSHPC study number and whether the child was a singleton or from a multiple birth. 
The dataset was checked for data inconsistencies; original forms were consulted and 
NSHPC respondents contacted for clarification as appropriate.
6.4.2 Output dataset
When the algorithm (see Table 6.2) was used on the input dataset, 1739 (1739/2842, 
61%) of the 2842 children who met the inclusion criteria for flagging were matched on 
type 1. A third (892/2842, 31%) of children were matched uniquely on types 2-6, 6% 
(179/2842) of children had multiple matches on types 2-5 and 1% (32/2842) had no 
match (see column [1] on Table 6.5).
Table 6.4 Information available for children to be flagged (n=2842)
Variable
Children with information 
available from the NSHPC 
database
n(%)
NHS number 1804 (63)
Date of birth 2842 (100)
Sex 2822 (99)
Birth weight* 1853 (65)
Mother’s date of birth 2800 (99)
Mother’s postcode district of residence at delivery 2769 (97)
Mother’s country of birth* 2706 (95)
*Not used in matching algorithm
NSHPC, National Study of HIV in Pregnancy and Childhood; NHS, National Health Service
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Table 6.5 Matching algorithm, confirmation of matches and flagging
Match type and 
number of 
matches made 
using algorithm
[1]
Children with 
type and number 
of matches made 
using algorithm 
n (%)
[2]
Children 
with 
confirmation 
of match 
n
[3]
Details sent 
to NHSCR 
n
[4]
Children 
flagged 
n (%)
Type 1 unique 1739 (61) - 1739* 1738 (65)
Type 2 unique 793 (28) 762 762* 759 (28)
Type 2 2 matches 96 (3) 82 82 82 (3)
Type 2 3 matches 10 (<1) 8 8 8(<1)
Type 2 4 matches 2 (<1) 1 1 1 (<1)
Type 3 unique 33 (1) 16 16 16(1)
Type 3 2 matches 8 (<1) 6 6 6 (<1)
Type 4 unique 56 (2) 29 29* 28(1)
Type 4 2 matches 35(1) 27 27 27(1)
Type 4 3 matches 14 (<1) 10 10 10 (<1)
Type 4 4 matches 8(<1) 6 6 6 (<1)
Type 4 6 matches 1(<1) 1 1 1 (<1)
Type 4 7 matches 1 ( d ) 1 1 1 (<1)
Type 5 unique 8 (<1) 6 6 6(<1)
Type 5 2 matches 4 (<1) 2 2 2(<1)
Type 6 unique 2(<1) 2 2 2 (<1)
No match 32(1) - 0 0(0)
Total 2842 (100) 959 2698 2693 (100)
* Five children could not be flagged (see Section 6.4.4). NHSCR, National Health Service 
Central Register
6.4.3 Confirmation of matches
The confirmation of matches programme was used on non-type 1 matches from the 
output dataset (see Appendix 4.3). Of the 892 children who were matched uniquely on 
types 2-6, 815 (91%) met the confirmation criteria; and of the 179 children who had 
multiple matches on types 2-5, 144 (80%) had a match that met the confirmation criteria 
(see column [2] on Table 6.5).
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6.4.4 Flagging
Details on the 959 children who met the confirmation criteria, plus the 1739 children 
who were matched on type 1, were obtained from the BDRD and were sent to the 
NHSCR (see column [3] on Table 6.5) (Figure 6.1).
There were five children who could not be flagged as their records on the NHSCR had 
been closed. This occurs in various situations, e.g. adoption. In total, 2693 (2693/2842, 
95%) of the 2842 children who met the inclusion criteria for flagging were flagged on 
the NHSCR (see column [4] on Table 6.5).
6.4.5 Characteristics of flagged and non-flagged children
Flagged and non-flagged children were compared in terms of the characteristics shown 
in Table 6.6. Univariable comparisons were tested with x2 tests.
There was a significant increase in the proportion of children flagged by year of birth 
from 2001 to 2004 (p=0.004), which is likely to be due to the increased availability of 
NHS number (see Table 6.3). There was no significant difference between children who 
were flagged and those who were not, in terms of antenatal ART exposure (p=0.452), 
gestational age (p=0.294) or maternal area of birth (p=0.663).
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Table 6.6 Characteristics of flagged and non-flagged children (n=2842)
Flagged 
n (%)
Non- 
flagged 
n (%)
x2
p value
Year of birth (n=2842)
2001
2002
2003
2004
443 (16) 
571 (21) 
811 (30) 
868 (32)
40 (27) 
35 (23) 
39 (26) 
35 (23) x2, 13.45, p=0.004
Maternal area of birth (n=2790)
Europe
Sub-Saharan Africa 
Other
377(14) 
2095 (79) 
175 (7)
19(13)
117(82)
7(5) X2, 0.82, p=0.663
Gestational age (n=2765)
>37 weeks 
<37 weeks
2237 (85) 
390(15)
113(82)
25(18) X2, 1.10,p=0.294
Antenatal antiretroviral 
therapy exposure (n=2782)
None
Monotherapy 
Double therapy 
3 or more drugs
173 (7) 
441 (17) 
55 (2) 
1970 (75)
13(9) 
23 (16) 
1 0 )  
106 (74) X2, 2.63, p=0.452
Note: data reported to the National Study of HIV in Pregnancy and Childhood by the end of 2005
6.5 Notifications of death and cancer registration in flagged uninfected 
children by the end of 2005
6.5.1 Children born before 2001
As outlined in Section 2.4, 329 children reported to the NSHPC bom 1996-1999 were 
flagged on the NHSCR in the late 1990s. A further 24 children bom 1998-2000 were 
flagged in 2005 during the development of the matching algorithm. Of the 353 children, 
79 (22%) were infected, 29 (8%) indeterminate and 245 (69%) uninfected.
For the 245 uninfected children, total length of time on the NHSCR and therefore
opportunity for death or cancer registration to be reported, by the end of 2005 was 2033
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child-years: 1578 child-years (median 8.1 years, range 5.0-10.0) in 194 children exposed 
to antenatal ART and 455 child-years (median 9.3 years, range 5.4-10.0) in 51 children 
not exposed to antenatal ART (n=37) or with missing exposure information (n=14). No 
notifications of death or cancer registration had been reported from ONS by the end of 
2005.
6.5.2 Children born 2001-2004
Of the 2693 children flagged in 2005, 81 (3%) were reported to be infected, 428 (16%) 
indeterminate and 2184 (81 %) uninfected by the end of 2005.
Total length of time on the NHSCR for the 2184 uninfected children by the end of 2005 
was 6023 child-years: 5732 child-years (median 2.6 years, range 1.0-5.0) in 2085 
children exposed to antenatal ART and 291 child-years (median 2.9 years, range 1.1-4.9) 
in 99 children not exposed to antenatal ART (n=82) or with missing exposure 
information (n=17).
No notifications of cancer registration had been reported from ONS by the end of 2005. 
There had been three death registrations reported from ONS by the end of 2005 (Table 
6.7), two of which had already been reported to the NSHPC by respondents. No child 
had evidence of cancer in their death registration.
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Table 6.7 Notifications of death registration in flagged uninfected children born 2001-2004
Child Antiretroviral therapy 
exposure
Gestational 
age (weeks)
Congenital 
abnormality reported 
to NSHPC? (System)
Cause of death Age at 
death
1 Antenatal: ZDV + 3TC + NVP 
Intrapartum: Missing 
Neonatal: ZDV
40 Yes (Circulatory) Congenital heart disease 8 months
2 None 39 No Congenital malformation 
of respiratory system
9 months
3 Antenatal: ZDV + 3TC + NVP 
Intrapartum: ZDV 
Neonatal: ZDV
26 No Tuberculosis 1 month
ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; NSHPC, National Study of HIV in Pregnancy and Childhood
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6.6 Key points
• a protocol was established to flag children reported to the NSHPC on the NHSCR for 
notifications of death and cancer registration
• the protocol included: a matching algorithm used to identify birth registration records 
on the BDRD and a programme used to confirm matches
• variables used in the matching algorithm were: child’s date of birth, sex and NHS 
number; and mother’s date of birth and postcode district of residence at delivery
• although NHS number was important in the identification of birth registration 
records, they could still be identified without it
• 95% of children reported to the NSHPC bom in England and Wales 2001-2004, had 
been flagged by the end of 2005
• there was no significant difference in antenatal ART exposure between children who 
were flagged and those who were not
• by the end of 2005, 2429 uninfected children reported to the NSHPC had been 
flagged: 245 bom 1996-2000 and 2184 bom 2001-2004
• total length of time on the NHSCR for the 2429 uninfected children was 8056 child- 
years
• by the end of 2005, there had been no notifications of cancer registration and three 
notifications of death registration in uninfected children
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Chapter 7 Follow up of uninfected children born to HIV
infected women in the UK: the CHART study
“I  think it is a good idea following up these children because it shows you have their 
interest at heart and would like to know and help them if  they do get any side effects from
the drugs. ”
[Mother of two children (aged 1 and 7 years)]
“Although I  strongly support research into the follow-up o f children exposed to anti HIV 
drugs I  am currently unwilling to give my permission for this to happen as I  feel that my 
decision o f when or whether to tell my child about my HIV status could be taken out of 
my hands. I f  you can assure me this won't happen I  will happily comply. ” 
[Mother of one child (aged 1 year)]
“People do not think through what it means- i.e. they do want to help/be followed up but 
change address, phones etc and CHART is not on their minds once they move on with 
children growing up. I  have never spoken to anyone who didn't think it important in 
principle; it's the intrusion in their lives which puts them off. ”
[Paediatric nurse]
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7.1 Introduction
The prevalence of HIV infection in pregnant women in the UK has increased in recent 
years, as have detection rates. In 2004 the prevalence of HIV among women giving birth 
in England and Scotland was 0.18%, and approximately 90% of HIV infected pregnant 
women were diagnosed prior to delivery (The UK Collaborative Group for HIV and STI 
Surveillance 2005). Interventions to reduce mother-to-child transmission (MTCT) have 
meant that MTCT rates have decreased to around 2% (European Collaborative Study 
2005c, Duong et al. 1999). These factors have resulted in a substantial increase in the 
number of uninfected children bom to HIV infected women in the UK. By the end of 
2004, the National Study of HIV in Pregnancy and Childhood (NSHPC) had recorded 
291 bom in 2000, 398 in 2001, 493 in 2002 and 593 in 2003. In 2005 over 95% of HIV 
infected pregnant women reported to the NSHPC were on antiretroviral therapy (ART) 
(Tookey 2005b).
The CHART study, a consented annual clinic-based follow-up of uninfected children 
bom to HIV infected women in the UK and reported to the NSHPC, was conducted to 
explore the feasibility of individualised follow-up to monitor adverse health events that 
could be related to ART exposure in fetal and/or early life. Enrolment in the CHART 
study is described in this chapter. Results from a survey among health professionals on 
their clinic practice regarding uninfected children and experiences with the CHART 
study, are also presented (see Section 2.6).
7.2 Methods
The initial approach for follow-up information on an eligible child was made through the
NSHPC paediatric respondent after the child’s infection status was reported. If it was
more appropriate, an alternative health professional aware of the mother’s HIV infection
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status was contacted, e.g. genitourinary (GU) physician, general practitioner (GP), health 
visitor. Health professionals were reminded on a regular basis about children whose 
enrolment status had not been confirmed. Parental consent was sought for enrolment, and 
an annual questionnaire on the child’s health and development was completed 
opportunistically by the health professional with the parent or carer. Demographic, 
perinatal and ART exposure information was prospectively collected through the 
NSHPC. Further details on the CHART study and the NSHPC are provided in Chapter 2.
Eligibility for enrolment in the CHART study
Children were eligible for enrolment in the CHART study if they were uninfected (see 
Appendix 3.3 for definition), bom in the UK to HIV infected women diagnosed before 
delivery, reported to the NSHPC by March 2005 and:
• reported from a “core” hospital (see below) and bom between January 1996 and 
December 2000 OR
• reported from any hospital in the UK and bom between January 2001 and April 2004 
Time scale of the CHART study
The CHART study was carried out between 2002 and 2005. Enrolment of uninfected
children bom since 1996 started in five hospitals in London in April 2002, and then in
six hospitals in Oxford, Sheffield, Leicester, Birmingham and London (2 hospitals) in
October 2002 (core hospitals) (see Figure 7.1 and Appendix 5). The core hospitals were
selected on the basis of number of reports made to the NSHPC and hospital location. Just
under half (334/777, 43%) of all uninfected children bom in the UK to HIV infected
women between 1996 and 2000, were reported from the 11 core hospitals. In January
2003, the CHART study was extended to include uninfected children bom since 2001
and reported from any hospital in the UK (Figure 7.1). In April 2005, all health
127
professionals who had been approached regarding enrolment of a child, and from whom 
no reply had been received, were contacted again and asked to provide information on 
the child’s enrolment status (e.g. enrolled, declined, lost to follow-up, could not enrol 
before end of study period etc). Study enrolment ceased in June 2005 and data collection 
ceased in August 2005.
Figure 7.1 Time scale of the CHART study
A B C  D E F
2002 2003 2004 2005
Notes
|  Uninfected children bom 1996-April 2004 reported to NSHPC by March 2005 from 11 core hospitals 
□  Uninfected children bom 2001-April 2004 reported to NSHPC by March 2005 from non-core hospitals
A=Enrolment started in 5 first phase core hospitals (April 2002)
B=Enrolment started in 6 second phase core hospitals (October 2002)
C=Enrolment started in non-core hospitals (January 2003)
D=Status clarification (April 2005)
E=End o f study enrolment (June 2005)
F=End o f  data collection (August 2005)
7.3 Enrolment in the CHART study
A total of 2104 children were eligible for enrolment in the CHART study (Table 7.1). Of 
these, 334 were bom between 1996 and 2000 and reported to the NSHPC from the 11 
core hospitals (median number of reports per hospital was 13, range 5-64). The 
remaining 1770 eligible children were bom between January 2001 and April 2004 and 
reported from 168 hospitals in the UK (median number of reports per hospital was 3, 
range 1-125).
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Table 7.1 Enrolment in the CHART study: April 2002-June 2005
Year of birth of child Total
1996* 1997* 1998* 1999* 2000* 2001 2002 2003 2004p n (%)#
Children eligible for CHART study 36 37 60 87 114 405 512 670 183 2104
Child enrolled 11 15 22 48 55 129 149 224 51 704 (33)
Child’s parent/carer declined enrolment 2 2 4 4 7 18 26 33 4 100 (5)
Health professional decided it 
inappropriate to approach parent/carer - - - - - 4 9 5 1 19(1)
Child died - 1 - - - - - 1 - 2 (<1)
Child’s mother died- no access to child - 2 1 1 - 1 - - - 5 (<1)
Child fostered/adopted- no access to child - 1 - - 1 1 2 1 - 6 ( d )
Child left the UK 1 1 3 3 4 10 17 16 4 59(3)
Child lost to follow-up 19 14 24 24 35 107 118 102 12 455 (22)
Health professional unable to contact 
family before end of CHART study 2 1 3 3 9 27 42 96 50
233 (11)
Health professional could not identify 
child from case identifiers provided 1 - 1 - - 4 4 3
1 14(<1)
Health professional unable to participate 
in CHART study - - - - - 47 62 95 26
230(11)
No response from health professional - - 2 4 3 57 83 94 34 277(13)
*Children reported from the core hospitals (see Appendix 5). NSHPC, National Study of HIV in Pregnancy and Childhood. #Percentage of eligible 
children. (3Bom January-April 2004.
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At the end of study enrolment in June 2005, 704 (33%) of the 2104 eligible children had 
been enrolled: 151 bom 1996-2000 and 553 bom 2001-2004 (Table 7.1 and Figure 7.2). 
Though the number of eligible children increased over the study period, the proportion 
enrolled also increased: 21% (89/424) at the end of 2002 (core hospitals only), 23% 
(262/1128) at the end of 2003 and 26% (514/1958) at the end of 2004.
Figure 7.2 Children eligible for the CHART study by enrolment status (n=2104)
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Overall, parents or carers of 5% (100/2104) of children declined enrolment (Table 7.1), 
thus of the parents and carers approached regarding enrolment, 88% (704/804) agreed to 
take part. A further 22% (455/2104) were reported to be lost to follow-up and 3% 
(59/2104) were known to have left the UK. Two children were reported to have died (one 
of sudden infant death syndrome (SIDS) and one of tuberculosis). The remaining 37% 
(784/2104) of children could not be enrolled because they had been reported from a 
hospital unable to participate in the CHART study (n=230), the health professional had
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not been able to access the family (timing issues, could not identify child, inappropriate 
to approach family about study, child fostered or adopted, mother had died) (n=277), or 
there had been no response from the health professional despite reminders (n=277).
Enrolled children
Of the 704 enrolled children, 47 (7%) were subsequently reported as lost to follow-up, 
and the parents or carers of 13 (2%) declined further follow-up. Of the remaining 
children, 203 (203/644, 32%) had subsequent questionnaires outstanding at the end of 
data collection: seven had not had a questionnaire completed for three years, 112 for two 
years, and 84 for one year. For children bom 1996-2000 the proportion enrolled was 
higher among younger children ( t^rend, 4.72, p=0.030), but for children bom 2001-2004 
enrolment remained relatively constant (% trend, 0.00, p=0.994).
Parents or carers who declined enrolment
The parents or carers of 100 children declined enrolment (100/2104, 5%), and reasons 
were provided by health professionals for 38 of them (Table 7.2).
Table 7.2 Reasons for child’s parent/carer declining enrolment in the 
CHART study (n=38)
Reason n
Issues with confidentiality* 14
Issues with acceptance of HIV diagnosis / does not want to O
be reminded of HIV diagnosis 7
Logistical reasons (too far to travel / leaving the UK) 4
Child well 2
Does not want further appointments for the child 5
Lack of time 4
* included: concern that either family members or their partner would find out about 
their HIV diagnosis, not wanting information on their child to leave the hospital, not 
being willing to talk about HIV over the telephone
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Loss to follow-up
Of the 22% (455/2104) of eligible children reported as lost to follow-up, reasons were 
provided by health professionals for half of them (Table 7.3). Health professionals 
reported 46 children as lost to follow-up because they had been discharged from the 
paediatric clinic; no contact details of alternative health professionals had been provided.
Table 7.3 Reasons for loss to follow-up of children eligible for the 
CHART study (n=221)
Reason n
Clinic non-attendance (paediatric/genitourinary clinic) 72
Family moved / contact details held by clinic not current / j ^
no longer registered at GP practice
Child discharged from paediatric clinic 46
Participation of health professionals 
Contacts
During the study period, 335 health professionals were contacted regarding study 
enrolment and data collection (Table 7.4). Alternative health professionals (i.e. not 
NSHPC paediatric respondents) were contacted regarding the enrolment of 135 children 
(35 were then enrolled); and the completion of subsequent questionnaires for 27 children 
(seven were then completed).
Health professionals unable to participate
Health professionals from 11 hospitals and general practices reported they were unable to 
participate in the CHART study, which meant that 11% (230/2104) of eligible children 
could not be enrolled (Table 7.1). Lack of resources was generally cited as a reason.
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Table 7.4 Health professionals contacted regarding enrolment of children in the 
CHART study
n (%)
Paediatrician 188 (56)
Community paediatrician 3(1)
Nurse (paediatrics) 22 (7)
GU physician 40(12)
Nurse (GU medicine) 13(4)
Midwife 4(1)
Health visitor 6(2)
GP 59(18)
Total 335
GU, genitourinary
Health professional decided it inappropriate to approach the family about the study 
Health professionals contacted regarding the enrolment of 19 children, reported that it 
would be inappropriate to approach the family about the study. Reasons given included: 
health of the mother, issues with HIV diagnosis, confidentiality, and previous difficulties 
with testing or treating the child.
7.4 Characteristics of children eligible for the CHART study
Of the 1770 eligible children bom 2001-2004, 76% (1322/1741) were bom to women 
from sub-Saharan Africa, with 17% (289/1741) bom to women from Europe. In terms of 
maternal HIV risk factor, injecting drug use was reported for the mothers of 2% 
(32/1671) of children, whereas being from an HIV high-prevalence area was reported for 
87% (1453/1671). Median maternal age at delivery was 29.8 years (range 14.5-53.3). A 
total of 96% (1687/1755) of children had been exposed to antenatal ART, mostly 
combination therapy (n=1358).
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The 334 eligible children bom 1996-2000 and reported from the 11 core hospitals had 
similar demographic characteristics to the younger children: 74% (244/328) were bom to 
women from sub-Saharan Africa and 21% (69/328) bom to women from Europe. 
Injecting drug use was reported for the mothers of 6% (21/327) of children, and being 
from a high-prevalence area was reported for 80% (260/327). Median maternal age at 
delivery was 30.1 years (range 17.4-41.4). A total of 89% (294/330) of children had been 
exposed to antenatal ART.
Characteristics of eligible children by enrolment status
Characteristics of eligible children, according to whether or not they were enrolled in the 
CHART study, are shown in Table 7.5. Enrolled children and non-enrolled children were 
similar in terms of maternal HIV risk factor (p=0.248), maternal area of birth (p=0.389) 
and gestational age (p=0.448) (Table 7.5). However enrolled children were more likely 
to have an older mother than those who were not enrolled (p=0.003); and enrolled 
children were more likely to have been exposed to antenatal ART (674/697, 97%) than 
non-enrolled children (1297/1378, 94%) (%2, 6.46, p=0.011).
Children whose parents or carers declined enrolment were less likely to have been 
exposed to antenatal ART (89/98, 91%), than those whose agreed to enrolment (674/697, 
97%) (x2, 7.70, p=0.006); there were no differences in terms of demographic 
characteristics.
Age at last contact
Median age at last contact for the non-enrolled children (reported on NSHPC paediatric 
forms) was 6 months (range 1-45). Median age at last contact for the enrolled children, 
reported through the CHART study, was 24 months (range 5-106).
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Table 7.5 Characteristics of eligible children by enrolment status (n=2104)
Enrolled 
n (%)
Non- 
enrolled 
n (%)
x2
p value
Maternal area of birth (n=2069)
Europe
Sub-Saharan Africa 
Other
115(16) 
540 (77) 
43 (6)
243 (18) 
1026 (75) 
102 (7) x2,1.89,p=0.389
Maternal HIV risk factor 
(n=1998)
From high prevalence area 
Injecting drug use 
Other*
587 (87) 
14(2) 
70(10)
1126 (85) 
39(3) 
162(12) X2, 2.79, p=0.248
Gestational age (n=1661)
>37 weeks 
<37 weeks
476 (82) 
101 (18)
910(84)
174(16) X2, 0.58, p=0.448
Maternal age at delivery (years) 
(n=2089)
<25
25-29
30-34
>35
105 (15) 
221 (31) 
227 (32) 
149 (21)
275(20) 
477 (34) 
403 (29) 
232(17) X2, 14.09, p=0.003
Antenatal antiretroviral 
therapy exposure (n=2075)
None
Monotherapy 
Double therapy 
3 or more drugs
23 (3) 
156 (22) 
17(2) 
501 (72)
81(6) 
290 (21) 
45 (3) 
962 (70) X2, 7.86, p=0.049
Note: data as reported to the National Study of HIV in Pregnancy and Childhood by the end of 
August 2005. *Contact with infected blood, HIV infected partner, blood transfusion recipient
7.5 The health professional survey: clinic practice and involvement in the 
CHART study
7.5.1 Survey respondents
By the end of the data collection period, questionnaires had been returned by 40 out of
the 46 health professionals contacted, a response rate of 87% (see Section 2.6 and
Appendix 7). Of the six health professionals who failed to return the questionnaire, four
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were from hospitals in London with a mean of 25 uninfected children bom between 
January 2001 and April 2004 and reported to the NSHPC by April 2005; and two were 
from hospitals outside London (4 and 13 uninfected children reported).
The majority of the 40 respondents were paediatricians (20, 50%) or paediatric nurses 
(15, 38%). Other respondents were: three neonatologists, an HIV physician, and a 
paediatric secretary. Health professionals’ views on the long-term follow-up of ART- 
exposed uninfected children (section C of the questionnaire) are presented in Chapter 8 
along with those of parents and carers.
7.5.2 Clinic practice regarding uninfected children
The annual number of uninfected children seen in clinic varied considerably between the 
40 hospitals (Table 7.6). Just under half the respondents reported that uninfected children 
were seen in a general paediatric (15, 38%) or a neonatal (3, 8%) clinic; and a small 
number (4, 10%) specified a paediatric infectious diseases or blood borne virus clinic. In 
the remaining hospitals, they were seen in a dedicated HIV clinic: either a paediatric (8, 
20%) or a family (10, 25%) clinic. Whether uninfected children were seen in an HIV 
clinic was not related to clinic caseload.
Table 7.6 Approximate number of uninfected children born to HIV infected 
women seen per year in clinic as reported by survey respondents
Uninfected children (n) Respondents
(n)
<10 10
11-30 18
31-50 7
>50 3
Not provided 2
Total 40
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To assess the multidisciplinary nature of the clinic, respondents were asked if they had 
regular discussion of issues relating to uninfected children with colleagues in other 
departments within their hospital. Three quarters (30, 75%) did so with colleagues both 
in the antenatal or obstetrics department and in the GU medicine or adult infectious 
disease department; and a further nine with colleagues in one of these two disciplines. 
One respondent (an HIV physician) discussed issues with colleagues in the paediatrics 
department.
In terms of the routine clinic follow-up protocol for a child bom to a woman diagnosed 
with HIV, there was little variation between hospitals as to when this was done. Of the 
39 respondents who supplied information on this, all offered clinic appointments at least 
once when the child was between six and eight weeks of age; and again at the age of 
three (36 respondents) or four months (1 respondent) or both (2 respondents). All but one 
of the respondents reported that it was clinic policy to invite children who had negative 
virological tests early in life to come back to clinic for a confirmatory antibody test 
between the ages of 12 and 18 months. Additional appointments were offered in some 
clinics: at six months (8 respondents), nine months (1 respondent) and yearly from 18 
months until five years of age (7 respondents).
7.5.3 Involvement in the CHART study
Of the 40 survey respondents, 35 had participated in the CHART study and therefore 
completed section B of the questionnaire (Appendix 7). Comments made by the 
respondents are in Appendix 8.
Seven respondents reported that their involvement in the CHART study had formally 
changed their clinic policy in terms of how uninfected children were followed up. In two
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hospitals, children had previously been discharged around 18 months of age, but with the 
introduction of the study, follow-up was extended beyond this age. In three hospitals, 
involvement in the study helped formalise annual follow-up. Twelve respondents 
considered that their involvement in the CHART study had informally changed clinic 
practice. Ways in which this occurred were: more time spent with parents to discuss the 
study and to complete the forms, more discussion with parents about exposure to ART, 
changes to the times of clinics, additional clinics arranged, and the offer of clinic 
appointments to children who would previously not have been seen after 18 months of 
age.
About a third (10/34, 29%) of respondents involved health professionals outside their 
clinic to assist with contacting parents and carers and enrolling children in the CHART 
study. Mostly these were GU physicians or nurses, though GPs, community 
paediatricians and nurses were also involved.
The approximate amount of time additional to routine clinical care that the respondent 
estimated that they and other colleagues had devoted to contacting parents and carers and 
enrolling children varied (Table 7.7). As expected, respondents in hospitals with more 
children who fitted the inclusion criteria for the CHART study tended to devote more 
time to it. One respondent commented that the forms were easy to complete within 
normal consultation time, but another felt “uneasy” asking families back to clinic for a 
“few simple questions” so they also did an examination on the child (Appendix 8).
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Table 7.7 Estimated time spent contacting parents/carers and enrolling
children into the CHART study
Time Respondents
(n)
Less than 1 hour per month 9
1-2 hours per month 16
1 hour per week 5
More than 1 hour per week 2
Not provided 3
Total 35
Contacting parents and carers about the CHART study
Three quarters of respondents usually approached parents and carers about the CHART 
study in the paediatric clinic, either when the child was brought to clinic for their 
confirmatory antibody test or at another time (Figure 7.3).
Figure 7.3 How health professionals usually approached parents/carers about 
the CHART study (n=35)
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53%
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a Opportunistically in 
paediatric clinic
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Respondents were asked about situations which made contacting parents and carers 
about the CHART study difficult (Table 7.8). Clinic non-attendance and loss of contact 
were considered especially problematic, particularly as some families moved or were 
moved away or changed their telephone number (see Appendix 8). Some families were 
reluctant to be contacted by the clinic staff, particularly once the child was discharged. 
Specific reasons given for this included the father or partner not being aware of the 
mother’s HIV status, and families not wanting to be reminded about HIV once their child 
was known to be uninfected. In addition, a number of respondents sometimes felt 
awkward when they tried to contact families who had already been discharged from the 
clinic. Other issues highlighted were lack of resources and large clinic caseload 
(Appendix 8).
Table 7.8 Frequency with which respondents thought certain situations made 
contacting parents/carers about the CHART study difficult (n=35)
Situation Frequently
n (%)
Sometimes
n (%)
Hardly 
ever 
n (%)
Never 
n (%)
Missing 
n (%)
Regularly does not 
attend scheduled 
appointments
12 (34%) 13 (37%) 2 (6%) 4(11%) 4(11%)
Lost contact with 
family 12 (34%) 16 (46%) 3 (9%) 2 (6%) 2 (6%)
Family known to have 
left the UK 2 (6%) 13 (37%) 6(17%) 7 (20%) 7 (20%)
Difficult family 
circumstances 3 (9%) 17 (49%) 2 (6%) 4(11%) 9 (26%)
Child discharged from 
clinic 9 (26%) 11 (31%) 7 (20%) 3 (9%) 5 (14%)
Lack of clinic staff 
time 7 (20%) 9 (26%) 3 (9%) 11 (31%) 5 (14%)
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Enrolment in the CHART study
Respondents were asked about why they thought parents and carers agreed to take part in 
the CHART study (Table 7.9). Over half of respondents indicated that wanting to keep in 
contact with health services was either frequently or sometimes important, slightly more 
so than concern over the safety of ART.
Table 7.9 Issues involved in parents/carers agreeing to take part in the 
CHART study: respondents’ views (n=35)
Issue Frequently 
n (%)
Sometimes 
n (%)
Hardly 
ever 
n (%)
Never 
n (%)
Missing 
n (%)
Concern over the 
safety of the 
antiretroviral therapy
9 (26%) 9 (26%) 5 (14%) 4(11%) 8 (23%)
Wanting to keep in 
contact with health 
services
3 (9%) 16 (46%) 6 (17%) 3 (9%) 7 (20%)
Feeling
uncomfortable about 
refusing
1 (3%) 8 (23%) 9 (26%) 6(17%) 11 (31%)
Respondents were then asked how often they thought several different issues were 
involved in parents and carers declining to take part in the CHART study (Table 7.10). 
Nearly half of respondents thought concern about data confidentiality was frequently or 
sometimes involved. Other issues mentioned were: the parent not wanting to be 
reminded of their illness, and families not wanting to come to clinic appointments in 
nursery or school time.
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Table 7.10 Issues involved in parents/carers declining to take part in the
CHART study: respondents’ views (n=35)
Issue Frequently 
n (%)
Sometimes 
n (%)
Hardly 
ever 
n (%)
Never 
n (%)
Missing 
n (%)
Not feeling that it is 
important 2 (6%) 9 (26%) 4(11%) 10 (29%) 10 (29%)
Not wanting to keep 
in contact with health 
services
4(11%) 10 (29%) 6 (17%) 9 (26%) 6(17%)
Difficult family 
circumstances 1 (3%) 12 (34%) 7 (20%) 6 (17%) 9 (26%)
Concern about data 
confidentiality 6(17%) 10 (29%) 3 (9%) 8 (23%) 8 (23%)
7.6 Key points
• just over 2100 uninfected children reported to the NSHPC from nearly 170 hospitals 
in the UK were eligible for enrolment in the CHART study
• at the end of the study period, a third of eligible children had been enrolled, 
parents/carers of 5% had declined enrolment, a quarter were lost to follow-up or had 
left the UK, and a third were not enrolled because the health professional was 
unwilling to contact the family
• of the enrolled children 7% were subsequently reported as lost to follow-up, and the 
parents/carers of 2% declined further follow-up
• confidentiality was the most frequently given reason for the parent/carer declining 
enrolment
• the family having moved or changed contact details was the most frequently given 
reason for loss to follow-up
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• the majority of eligible children were bom to women from sub-Saharan Africa, and 
only 3% of children were bom to women who had acquired HIV infection through 
injecting drug use
• 95% of eligible children had been exposed to antenatal ART, mostly combination 
therapy
• enrolled and non-enrolled children were similar in terms of demographic 
characteristics, but enrolled children were more likely to have been exposed to 
antenatal ART
• most health professional survey respondents were paediatricians or paediatric nurses
• the majority of respondents offered clinic appointments for uninfected children at 6-8 
weeks, 3 and/or 4 months and 12-18 months of age; a fifth of respondents then 
offered appointments annually until 5 years of age
• a fifth of respondents reported that their involvement in the CHART study had 
formally changed clinic policy in terms of how uninfected children were followed up, 
and a third reported that it had informally changed clinic practice
• a third of respondents had involved health professionals outside their clinic to assist 
with study enrolment
• three quarters of respondents usually approached parents/carers about the study in the 
paediatric clinic
• clinic non-attendance and loss of contact were considered situations that often made 
contacting parents/carers about the study difficult
• over half of respondents thought keeping in contact with health services was either 
frequently or sometimes involved in parents/carers agreeing to take part in the study
• nearly half of respondents thought concern about data confidentiality was either 
frequently or sometimes involved in parents/carers declining to take part in the study
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Chapter 8 Views of parents and carers on the long-term follow-
up of uninfected children
‘‘When you are pregnant you are worried about the virus passing to baby and not 
strongly about the effects o f the drugs. ”
[Mother of one child (aged 3 months)]
“We don't know the outcome o f these drugs so we shouldn't hesitate with investigations. " 
[Father of four children (aged 1,4, 14 and 15 years)]
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8.1 Introduction
Clinic-based follow-up of uninfected children may not always be appropriate for HIV- 
affected families. As was observed in the CHART study, some families declined and a 
large number of children were lost to follow-up before the health professional could 
approach the family about enrolment (see Chapter 7). Possible adverse effects associated 
with antiretroviral therapy (ART) exposure may not develop for many years, even into 
adulthood; therefore it is important that monitoring continues beyond the time when the 
family is in regular contact with HIV-related services. As there are strategies that could 
be used over the long term which involve the family and health professionals to a lesser 
extent than clinic-based follow-up, it is appropriate to obtain views of parents and carers 
to inform proposals for the future. In this chapter, results from a questionnaire survey 
with parents and carers of uninfected children are presented. Findings from the survey 
are compared with results from a related survey among health professionals (Section 
8.6). Further details on the surveys are provided in Chapter 2.
8.2 Survey respondents
There were 140 respondents in total; 137 from the 14 clinics involved in the survey and
three from Positively Women and Positive Nation. Seventy six respondents were
recruited from the six researcher clinics. The clinic attendance rates on the occasions
when the researcher was present were available for four of the five paediatric clinics
(Table 8.1). The overall attendance rate for each of the four clinics varied from 56% to
87%. Not all parents and carers who attended the clinic with their child met the inclusion
criteria as some only cared for an infected child and others for a young infant of
indeterminate status. Furthermore, due to the set up of individual clinics, some of those
who met the inclusion criteria left the clinic before they could be approached. The
response rate for those invited to participate in the six researcher clinics was 85% (76/89)
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(Table 8.1). The majority of respondents completed the questionnaire in the clinic 
(74/76, 97%). Two parents took the questionnaire home to complete, and both returned it 
by post.
The remaining 61 respondents were from eight non-researcher clinics (Table 8.2). The 
response rate for parents and carers invited in clinic to participate was 93% (43/46); with 
a much lower response rate for those who were sent the survey material (18/55, 33%).
8.3 Respondents and their children
Just over half of the 140 respondents (74, 53%) cared for one child bom to an HIV 
infected woman; a further 39 (28%) cared for two, 18 (13%) for three, and nine (6%) 
cared for four or more children. The majority of respondents (127/139, 91%) were 
mothers of the children in their care, 11 respondents were fathers and one respondent 
was an aunt.
A total of 135 respondents reported their own country of birth. Of the maternal 
respondents, 11 (11/123, 9%) were bom in the UK, 105 (105/123, 85%) in sub-Saharan 
Africa (see Table 8.3) and the remainder in Jamaica (2), New Zealand (1), Iraq (1), 
Russia (1) and Portugal (1). Of the 12 non-matemal respondents, four were bom in the 
UK and the rest in sub-Saharan Africa (Ghana, Angola, Republic of the Congo, Rwanda, 
Uganda and Zimbabwe).
Most respondents (134/138, 97%) expected that the children in their care would continue 
to live in the UK; and of the four who did not, three thought they would leave the UK 
within five years and one did not know when they would leave.
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Table 8.1 Attendance rates and response rates in researcher clinics involved in the parent and carer survey
Hospital* 
(type of 
clinic)
Data collection 
period
Number 
of clinics 
visited by 
researcher
HIV-affected children booked for 
clinics that the researcher visited Parents/carers who fitted inclusion criteria#
Booked
(n)
Attended
(n)
Attendance 
rate (%)
Total
(n)
Invited to 
participate 
(n)
Completed
questionnaire
(n)
Response 
rate (%)
1 (PAED) October 2004 - April 2005 7 34 19 56 16 15 12 80
2 (PAED) November 2004 - June 2005 11 N/A N/A N/A N/A 29 26 90
3 (PAED) December 2004 - February 2005 4 44 28 64 16 13 10 77
4 (PAED) February 2005 - June 2005 4 22 15 68 16 12 9 75
5 (PAED) February 2005 - March 2005 2 23 20 87 9 7 7 100
5 (GU) May 2005- June 2005 5
Not
applicable
Not
applicable
Not
applicable N/A 13 12 92
Total October 2004 - June 2005 33 - - - - 89 76 85
*The hospitals involved in the parent and carer survey are listed in Appendix 9 
PAED, paediatric clinic; GU, genitourinary clinic; N/A, information not available
#Parent/carer who cared for at least one uninfected child bom in the UK to an HIV infected woman who took antiretroviral therapy during 
pregnancy
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Table 8.2 Response rates in non-researcher clinics involved in the parent and carer survey
Hospital* 
(type of 
clinic)
Data collection 
period
Parents/carers who fitted inclusion criteria# 
and were invited to participate in clinic
Parents/carers who fitted inclusion criteria# 
and were sent survey information
Invited to 
participate (n)
Completed 
questionnaire (n)
Response 
rate (%)
Sent survey 
information (n)
Returned 
questionnaire (n)
Response 
rate (%)
3 (GU) June 2005 - August 2005 17 17 100 - - -
6 (PAED) December 2004 - July 2005 9 9 100 - - -
7 (PAED) January 2005 - May 2005 4 2 50 - - -
8 (PAED) January 2005 - March 2005 2 1 50 4 2 50
9 (PAED) Febmary 2005 - April 2005 - - - 10 3 30
10 (PAED) March 2005 - July 2005 6 6 100 5 3 60
11 (PAED) December2004 - - - 8 1 10
12 (PAED) March 2005 - April 2005 8 8 100 28 9 32
Total December 2004 - August 2005 46 43 93 55 18 33
*The hospitals involved in the parent and carer survey are listed in Appendix 9 
PAED, paediatric clinic; GU, genitourinary clinic
#Parent/carer who cared for at least one uninfected child bom in the UK to an HIV infected woman who took antiretroviral therapy during 
pregnancy
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Table 8.3 Country of birth of maternal respondents born in sub-Saharan
Africa (n=105)
Country n %
Cameroon 3 3
Democratic Republic of the Congo (Zaire) 4 4
Ghana 11 10
Ivory Coast 3 3
Kenya 6 6
Nigeria 9 9
Rwanda 3 3
Sierra Leone 3 3
South Africa 5 5
Uganda 21 20
Zambia 7 7
Zimbabwe 19 18
Other* 11 10
* Angola (1), Burundi (2), Ethiopia (2), Gambia (1), Malawi (2), Republic of the Congo 
(1), Somalia (2)
Generally there was only one respondent per family, but five of the fathers and the aunt 
who participated came from the same family unit as a maternal respondent. There were a 
total of 239 children cared for by the respondents and the median age of the children was 
two years (range 4 weeks to 17 years) (Figure 8.1).
Every family included at least one uninfected child because of the inclusion criteria, but 
in fact most of the 239 children were uninfected (206/239, 86%); eight were infected and 
the infection status of 25 children was not known (indeterminate status or not tested) 
(Figure 8.1). Results of blood tests were not requested on the questionnaire. A total of 46 
children were bom outside the UK (46/233, 20%) and all of these had at least one 
younger sibling who was bom in the UK. Of the eight infected children, six were bom 
outside the UK.
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Figure 8.1 Age and infection status of the children cared for by the respondents
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8.4 Contact with health services
As clinic-based follow-up is dependent on the relationship between families and service- 
providers, respondents were asked about their contact with and disclosure to health 
professionals. For the 132 respondents with no infected children, those whose youngest 
child was less than two years of age were more likely to still visit the paediatric or family 
clinic for their children’s care (84/88, 95%) than those whose youngest child was aged 
two years or older (20/42, 48%) (x2, 40.66, p<0.001).
Almost all respondents took their children to a general practitioner (GP) in addition to 
HIV-related follow-up in clinic (135/139, 97%). Disclosure of HIV status to the GP was 
relatively common: 81% (109/135) of respondents reported that their GP knew about 
HIV in the family. A further 18 respondents had not told their GP, and seven respondents 
did not know if their GP knew. Whether disclosure to the GP had occurred was not 
associated with the age of the youngest child cared for.
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All 124 maternal respondents who reported where they received their own HIV care 
from, went to either a genitourinary (GU) or a family clinic. Of the 12 non-matemal 
respondents, eight went to a GU clinic for their HIV care, two specified they were not 
HIV infected and two did not supply any information.
8.5 Views on long-term follow-up
Introduction
Four possible long-term follow-up options involving clinic contact, telephone contact, 
postal contact and no direct contact (data linkage), were described in the survey 
questionnaire (Table 8.4). For each option the following were outlined: the involvement 
of the parent/carer, clinic staff and researchers; who would need to know the 
parent/carer’s contact details; who would receive information on the child’s health. 
Through the information sheet (Appendix 10), researchers at the Institute of Child Health 
were introduced, so that words such as “us” and “we” could be used in the description of 
the options.
Options were chosen to provide a range of intensity of contact that the parent or carer
would have with the clinic and researchers. As the CHART study protocol represented
an intensive type of contact and as survey respondents would not necessarily have been
approached about enrolment in the study, two of the options (clinic and telephone) were
based on the CHART study protocol (see Section 2.3 and Chapter 7). As lack of clinic
resources was a factor in enrolment and sustainability of the CHART study, direct postal
contact between the family and researchers was proposed in one option. Linkage
between health records and routinely available health data does not involve direct
contact, and was the least intensive form of contact outlined in the questionnaire. This
option related to a general data linkage study and not particularly the Office for National
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Statistics flagging study (Chapter 6). Respondents were asked a series of questions on
the four options (see Appendix 11).
Table 8.4 The four follow-up options presented in the survey questionnaire
OPTION A (CLINIC CONTACT)
• You and/or your child would be asked to come to the family or paediatric clinic 
once a year.
• Clinic staff would ask you general questions about your child’s health.
• The answers would be put on a form and sent to us. Neither your name nor your 
child’s name would be on the form.
• You would need to inform the clinic of any change in your contact details.
OPTION B (TELEPHONE CONTACT)
• Clinic staff would telephone you once a year and would ask you general questions 
about your child’s health.
• The answers would be put on a form and sent to us. Neither your name nor your 
child’s name would be on the form.
• You would not need to attend the clinic to take part, but you would need to inform 
the clinic of any change in your telephone number.
OPTION C (POSTAL CONTACT)
• The clinic staff would give us your contact details when your child was 
discharged. We would keep these in strict confidence.
• We would send you a short form about your child’s health once a year, for you to 
complete and send back to us.
• There would be no reference to HIV on anything you were sent.
• You would need to inform us of any change in your address.
OPTION D (NO DIRECT CONTACT)
• We would not need to have any regular direct contact with you or your child and 
we would not know your or your child’s name or address.
• Every child in the UK is given an NHS number at birth. The clinic would give us 
your child’s NHS number which we could relate to routinely available health 
information.
• You would not have to keep in contact with the clinic after your child was 
discharged.
Importance of follow-up
Nearly all of the respondents (131/139, 94%) agreed with the statement: “it is important
to follow up uninfected children to see if there are any side effects from anti-HIV drugs”
(Figure 8.2). Some of them added further comments supporting this and their reasons
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included: the uncertainty of whether side effects would occur in the future, reassurance 
for the parent, and a way of children helping others in the same situation. Two 
respondents thought follow-up was important, but only if there was a health problem 
identified, and two more respondents suggested specific problems that may affect a child 
exposed to ART: weight loss and fertility problems (see Appendix 12).
Figure 8.2 Importance of follow-up: respondents’ agreement (n=140)
“It is important to follow up uninfected children to see if there are any side effects from 
anti-HIV drugs ”
□  Strongly agree
□  Agree
■  Disagree
□  Strongly disagree
□  Missing_________
Acceptability
Respondents were asked which option or options presented in the questionnaire (Table 
8.4) they thought acceptable. All respondents except one considered at least one of the 
options acceptable: 60% (84/140) thought one acceptable, 19% (26/140) two, 11% 
(15/140) three and 10% (14/140) all of them. Overall, annual clinic-based contact was 
considered to be the most appropriate with 61% (86/140) finding it acceptable to come to 
the clinic (option A) and 48% (67/140) to be telephoned by the clinic (option B). Fewer 
respondents found postal contact with the researchers (option C) (51/140, 36%) or the no
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direct contact option (option D) (33/140, 24%) acceptable (Table 8.5). Whether 
respondents reported option A acceptable was not associated with family characteristics: 
age of the youngest child (less than two years versus two years or older) (x2, 1.12, 
p=0.289), whether the respondent was bom in the UK (x2, 2.37, p=0.123) or the number 
of children they cared for (one versus two or more) (x2, 1.52, p=0.218). The same was 
also observed for option C and option D. Respondents who had two or more children 
were more likely to find option B acceptable (34/66, 52%) than those with one child 
(21/74, 28%) (x2, 7.83, p=0.005), though there was no association with other family 
characteristics.
There was no relationship between whether respondents found clinic-based contact 
acceptable and the clinic they were recruited from: of the 115 respondents who 
considered either option A or option B acceptable, there was at least one from each of the 
14 clinics in the survey.
Table 8.5 Follow-up options that respondents found acceptable
Option(s) n (%)
All 4 options 14(10)
A + B + C 11(8)
A + B + D n o
A + C + D 3(2)
B + C + D 0(0)
A + B 12(9)
A + C 6(4)
A + D 1(1)
B + C 3(2)
B + D 2(1)
C + D 2(1)
A only 38 (27)
B only 24(17)
C only 12(9)
D only 10(7)
None of them 1(1)
Total 140
Notes: A=clinic contact, B=telephone contact, C=postal contact, D=no direct contact
154
As previously mentioned, the four options varied in terms of the intensity of contact that 
the family would have with the clinic and researchers. Each option was given a score to 
reflect this: A=4, B=3, C=2 and D=l. Based on the combination of options that the 
respondent found acceptable, an intensity score was calculated. There was no significant 
difference in the mean intensity score between: respondents whose youngest child was 
aged less than two years and those whose youngest child was two years or older (4.88 
versus 4.86, t=0.03, p=0.974); respondents bom in the UK and those bom abroad (5.66 
versus 4.83, t=1.12, p=0.263); respondents who cared for one child and those who cared 
for two or more (4.68 versus 5.05, t=-0.77, p=0.443).
Issues surrounding disclosure and confidentiality were raised by some respondents (see 
Appendix 12). Some were concerned that involvement in follow-up could mean that their 
HIV status would be disclosed to the child when either they had already decided not to 
disclose to their family, or had yet to decide whether to disclose. This was mentioned 
particularly in relation to clinic-based contact. Some respondents stated they did not want 
their child to know about their HIV status because it would be difficult for the child to 
“accept or understand”, they did not want to “harm or scare them” or they wanted their 
child to be “normal”. One respondent thought GPs should be aware of any follow-up as 
she wanted to keep “family health care as ‘normal’ as possible”, while another was 
“happy to help with research if totally anonymous”.
A quarter of respondents strongly objected to at least one option (31/136, 23%), in 
particular postal contact (15 respondents). Reasons for objecting were given by 25 of the 
respondents (Table 8.6). These were generally because they specifically wanted another 
type of contact for the child, they envisaged logistical problems or they were concerned 
about confidentiality with their child, family or neighbours.
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• "Once your child has been cleared the last thing you want is to come to hospital 
for these visits. Children grow up and will start asking questions. ”
• "Don’t want to be written to because I live with my sister and someone could 
open the letter. ”
Table 8.6 Follow-up options that respondents strongly objected to and reasons
given (n=31)
Options 
strongly 
objected to
Number of 
respondents 
(n)
Reason (n)
A only 2 Difficult to explain reason to child (2)
B only 4 Someone else could hear conversation (3) 
Prefer eye contact (1)
C only 11 Someone else could read information (6) 
Do not want details to leave clinic (2) 
Cannot read (1)
No reason given (2)
D only 9 Want to give consent (2)
Want to be seen in clinic (2)
Do not want child “labelled” (1) 
No reason given (4)
A + B 1 Do not like contact with medical professionals (1)
C + D 1 Do not want child on a “register” (1)
B + C 1 Want to be seen in clinic (1)
B + C + D 1 Want to be seen in clinic (1)
A + B + C 1 Work abroad (1)
Notes: A=clinic contact, B=telephone contact, C=postal contact, D=no direct contact
Parental permission
Respondents were asked if they thought parental permission would be needed before a 
child was included in option D (no direct contact). Of the 130 respondents who answered 
this question, 70% (n=91) indicated that it would be needed. In terms of when parents 
and carers should be asked for permission before a child was included in any type of 
follow-up, 40% of respondents (55/136) thought this should occur during pregnancy,
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10% (14/136) at birth and 38% (51/136) when the child was known to be uninfected. Ten 
respondents wanted the issue to be raised at more than one stage (see Appendix 12).
Contacting parents and carers
Respondents were asked whether, if a health problem associated with exposure to a 
particular antiretroviral drug was identified in children, parents and carers should be told 
about the risk. The majority of respondents thought they should be told regardless of 
whether there was any treatment available for the health problem (118/140, 84%) and a 
smaller number (n=19) only if there was a treatment available.
• “I f  there is something ahead you should contact the Mum (if I'm still alive). ” 
Three of the respondents did not think the parents and carers should be told of a risk.
• “I f  the children aren't ill, then they [the parents] shouldn't be told. ”
• “You would know if your child was ill but I  wouldn't want to know if  others were 
ill. ”
Of the 10 respondents who only found option D acceptable, nine of them still indicated 
that parents and carers should be told of a risk to the child’s health.
When asked how parents and carers should be contacted about any such risk, a letter
from the paediatric or family clinic was the most popular option (50/133, 38%) with 12
also specifying that they should be offered a clinic appointment. About a third of
respondents (43/133) stated a telephone call from the clinic was the most appropriate,
and a small number (n=9) both a telephone call and a letter from the clinic. A letter from
researchers outside the clinic was thought by nearly a fifth (23/133) to be the best way of
contacting the family. In terms of methods of contact, there were some apparent
contradictions within individuals. Of the 23 respondents who thought a letter from the
researchers to be the most appropriate channel for communication of a risk, only eight
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found follow-up option C acceptable; and of the 44 respondents who indicated that a 
telephone call from the clinic would be suitable, only 26 thought option B was 
acceptable.
Contact via parents and carers or young person?
As possible health problems associated with exposure to ART may not become apparent 
for many years, it was proposed in the questionnaire that at some stage it might be more 
appropriate for the clinic or researchers to have direct contact (options A-C) with the 
young person themselves rather than the parent or carer. Respondents were asked what 
they thought about this.
Eighteen out of the 105 respondents who answered this question (18/105, 17%) stated 
that the young person should be contacted directly by the clinic or researchers, and six of 
the 18 specified this would be appropriate when the child was: an adult (2), a teenager 
(1), “more mature” (1), 16 years old (1) or 18 years old (1). Five of the 18 respondents 
thought direct contact could only occur in the following situations: if the child knew 
about the mother’s HIV status (3), if the parent was dead (1), or if the parent had given 
permission (1) (see Appendix 12).
Most respondents (77/105, 73%) thought it should be up to the parent or carer to tell the 
clinic or researchers if and when the young person could be contacted. Some respondents 
gave reasons for this: they did not want anyone else contacting their child at all or 
without their permission, it was more appropriate if the parent discussed the subject with 
the child before anyone contacted them, they would not want to upset the child, the child 
might not know about their parent’s HIV status or the parent might not plan to tell them,
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and involving the parent would assist in the disclosure of their HIV status to the child 
(see Appendix 12).
Three respondents did not know how contact at a later stage should be done, two thought 
this would be the child’s choice, four did not want any direct contact and one did not 
want any direct contact after the child was five years old (see Appendix 12).
8.6 Views on long-term follow-up: health professional survey and parent 
and carer survey
Four of the questions on the importance and acceptability of long-term follow-up from 
the parent and carer survey questionnaire were included on the health professional survey 
questionnaire to compare responses (see Section 2.6 and Appendix 7). The description of 
the four follow-up options was adapted as appropriate. Details on the 40 health 
professional survey respondents are given in Chapter 7.
All of the health professionals agreed that “it is important to follow up uninfected 
children to see if there are any side effects from anti-HIV drugs”, similar to the 94% of 
parents and carers who agreed.
Half of the health professionals (22/40, 55%) indicated that parents should initially be 
asked during pregnancy for permission to follow up the child. Four (10%) thought 
permission should be asked for at birth and 14 respondents (35%) thought parental 
permission should be asked for when the child was known to be uninfected (see 
Appendix 8). The stage at which health professionals reported that parental permission 
should be asked was similar to what was observed with parents and carers (40%, 10% 
and 38% for the three stages respectively).
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All health professionals thought at least one of the options acceptable. They were 
generally more likely to find three (11/40, 28%) or four (6/40, 15%) options acceptable 
than the parents and carers (11% and 10% respectively). Option A was the option that 
most health professionals found acceptable (28/40, 70%) and was of a similar proportion 
to that of the parents and carers (61%) (x2, 0.984, p=0.321). However, option D was 
reported to be acceptable by a larger proportion of health professionals (21/40, 53%) than 
of parents and carers (33/140, 24%) (x2, 12.398, p<0.001) and similar was observed for 
option C (x2, 4.451, p=0.035). Health professionals from five of the 12 hospitals where 
the parent and carer survey was carried out found all of the options acceptable; and each 
option was found acceptable by at least one parent or carer in each hospital. In six of the 
seven remaining hospitals, parents and carers found options acceptable when the health 
professional did not (option A in 4 hospitals, B in 2, C in 3 and D in 1). Furthermore, in 
two hospitals, the health professional found options acceptable when none of the parents 
and carers did (option A and D in one hospital and C and D in the other).
There were some issues relating to options A and B that were highlighted by the health 
professionals: difficulties in dedicating clinic time and resources and the mobility of the 
families involved. Problems raised in terms of option C were perceived low response 
rates and difficulties in families receiving the documents, again due to their mobility and 
because many live in shared accommodation (see Appendix 8).
Nearly half of the health professionals strongly objected to at least one of the options in 
the questionnaire (15/34, 44%), a higher proportion than the parents and carers (31/136, 
23%) (x2, 6.266, p=0.012) (Table 8.7). Eight health professionals cited lack of clinic 
resources as a reason for objecting to option A or option B, however this was not 
associated with clinic caseload.
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• “ Unnecessary contact with clinic creates huge anxieties in families. Also difficult to 
justify in the present climate o f limited resources. ”
• “Quite a few o f our families live in accommodation where there are lots ofpeople 
and may not want to discuss things on the phone. ”
Table 8.7 Follow-up options that health professional survey respondents
strongly objected to and reasons given (n=15)
Options 
strongly 
objected to
Number of 
respondents 
(n)
Reason(s) (n)
A only 5 Lack of clinic time/resources (2)
Lack of clinic time/resources & parental confidentiality 
concerns (3)
B only 5 Time consuming & need interpreters (1) 
Time consuming & intrusive (1)
Intrusive (1)
Parental confidentiality concerns (1)
Families change telephone numbers often (1)
C only 2 Problematic to families(l)
Parental confidentiality concerns (1)
D only 2 Not enough contact (2)
A + B 1 Lack of resources (1)
Notes: A=clinic contact, B=telephone contact, C=postal contact, D=no direct contact
8.7 Key points
• most parent and carer survey respondents were bom in sub-Saharan Africa and 
were mothers of the children in their care
• median age of the children in the care of the respondents was two years
• of respondents with no infected children, those whose youngest child was aged 
less than two years were more likely to still visit the paediatric or family clinic 
than those whose youngest child was two years or older
• among respondents who took their children to a GP, most had told the GP about 
HIV in the family
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almost all parents and carers thought it was important to follow up uninfected 
children to see if there were side effects from ART
annual clinic-based contact was thought the most acceptable type of follow-up, 
though a third of respondents found postal contact with researchers acceptable 
and a quarter found data linkage acceptable
whether respondents found a particular type of follow-up acceptable was not 
generally associated with family characteristics
a quarter of parents and carers strongly objected to at least one type of follow-up, 
mostly postal follow-up
concerns regarding follow-up usually centred around disclosure, confidentiality 
and contact with health professionals
two thirds of parents and carers indicated that parental permission would be 
needed before a child was included in data linkage
the majority of respondents thought parents and carers should be told of a health 
problem associated with exposure to a particular antiretroviral drug 
over three quarters of respondents thought that direct contact should be through 
the parent or carer rather than with the young person; concerns over disclosure 
and appropriateness were cited
all health professional survey respondents thought it was important to follow up 
uninfected children to see if there were side effects from ART 
health professionals generally found more types of follow-up acceptable than 
parents and carers
about half of health professionals thought data linkage acceptable, a larger 
proportion than that of parents and carers
nearly half of health professionals strongly objected to at least one type of follow-
up, a larger proportion than that of parents and carers
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• concerns relating to follow-up raised by health professionals were clinic 
resources, confidentiality and mobility of HIV-affected families
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Chapter 9 Discussion
9.1 Background
The use of highly active antiretroviral therapy (HAART) has considerably altered the 
natural history of HIV infection in Europe. Mortality rates among HIV infected 
individuals have decreased and HIV has become a manageable chronic disease (Mocroft 
et al. 2003, CASCADE Collaboration 2000, European Centre for the Epidemiological 
Monitoring of AIDS 2005).
HIV infected women who are aware of their diagnosis may choose to become pregnant 
because they are in good health and are able to access appropriate interventions to 
prevent mother-to-child transmission (MTCT) (Fiore 2005, Newell et al. 2002). In 
addition, the introduction of antenatal HIV testing programmes has led to a considerable 
increase in detection rates among previously undiagnosed HIV infected women (The UK 
Collaborative Group for HIV and STI Surveillance 2005). With the use of interventions, 
MTCT rates of less than 2% can be achieved (Mandelbrot et al. 2001, European 
Collaborative Study 2005c). The increasing number of pregnancies among diagnosed 
HIV infected women, combined with the widespread administration of antiretroviral 
therapy (ART) in pregnancy and in the neonatal period, has resulted in an increasing 
number of uninfected children who were exposed to ART (European Collaborative Study 
2005c, Tookey 2005b).
In resource-rich settings, national guidelines have been established which recommend
the use of prophylactic ART to prevent MTCT; many HIV infected pregnant women also
require treatment for their own HIV infection (Public Health Service Task Force 2005a,
Hawkins et al. 2005, Newell et al. 2002). In Europe, estimates of MTCT rates in the
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absence of interventions range from about 15% to 30% (The Working Group on Mother- 
to-Child Transmission of HIV 1995, Ratcliffe et al. 1998); the different estimates are 
probably at least partly related to the background rates of breastfeeding and caesarean 
section delivery in different European settings. Therefore in order to protect the minority 
of HIV-exposed children who would be infected if no action were taken, all HIV infected 
pregnant women are advised to take ART; this means that virtually all of their children 
are exposed to the potential unwanted side effects of such treatment, alongside the 
undoubtedly beneficial effect of avoiding HIV infection.
As there are concerns about possible long-term effects of exposure to antiretroviral 
drugs, it is important to identify practical and effective means of monitoring these 
children (Mofenson and Munderi 2002). Long-term cohort studies, which could 
potentially identify associations between ART exposure and adverse outcomes, only 
include a fraction of the actual number of uninfected children exposed to ART. Active 
surveillance is more comprehensive in terms of the population covered, though the 
amount of information collected at an individual level is limited.
9.2 HIV-affected families in Europe
In the European Collaborative Study (ECS), there has been an increase in the proportion
of uninfected children bom to black women from sub-Saharan Africa who acquired their
HIV infection heterosexually, and a decrease in those bom to white women with a
history of intravenous drug use. In the mid 1980s, 5% of uninfected children in the ECS
paediatric centres were bom to black women and 93% were bom to white women.
However by the end of the study period, the proportion of children bom to black women
had increased to 46% and the proportion bom to white women had decreased to 47%
(Chapter 3). Similarly, in the early 1990s about two thirds of children reported to the
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National Study of HIV in Pregnancy and Childhood (NSHPC) were bom to women from 
sub-Saharan Africa, but this rose to about 80% in 2000-2004. National data collated by 
the European HIV/AIDS surveillance programmes show a similar picture (European 
Centre for the Epidemiological Monitoring of AIDS 2005). In the UK, three quarters of 
heterosexually acquired HIV infections diagnosed in 2004 were probably acquired in 
Africa (The UK Collaborative Group for HIV and STI Surveillance 2005).
Proxies for the early social environment of uninfected infants in the ECS were derived 
from maternal information collected during pregnancy (Chapter 3). This meant that only 
broad social circumstances were considered. No measures of maternal socio-economic 
status such as income, employment or housing were available. This was a limitation as 
HIV-affected families may be financially disadvantaged due to factors such as drug use 
or immigration problems, which could in turn affect access to services (Schrooten et al. 
2002, Dray-Spira and Lert 2003).
Most of the approximately 1700 uninfected infants enrolled in the ECS paediatric centres 
were looked after by one or both of their parents. Over the study period, there was a 
decrease in the proportion of children requiring alternative (non-parental) social care in 
the first year of life. This was probably due to the reduction in the number of drug-using 
women whose children were at an increased risk of placement in alternative care, which 
has also been observed elsewhere (Blanche et al 1996, Schable et al. 1995).
Furthermore, the improved health and quality of life of HIV infected individuals as a 
result of HAART has meant that parents are better able to care for their child (Mocroft et 
al. 2003). Parental care as the main source of social care of children bom to HIV infected 
women was also observed in a UK setting: almost all of the 140 respondents in the 
parent and carer survey were parents of the children in their care (Chapter 8).
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The stigma associated with HIV infection has been recognised since the beginning of the 
epidemic. Women can be particularly affected by HIV-related stigma in terms of being 
labelled as promiscuous, a drug-user or a prostitute (Bunting 1996). Fear of 
discrimination or isolation is likely to influence decisions about disclosure of HIV status 
to family and friends, as well as to health professionals (Anderson and Doyal 2004). 
There are also cultural differences in terms of how HIV is perceived (Erwin et al. 2002). 
Concerns over immigration status may act as a barrier to accessing both HIV and general 
health care (Erwin and Peters 1999, Pollard and Savulescu 2004). HIV infected African 
women living in Europe are less likely to disclose their HIV status to family and friends 
than women originating from Europe (Bungener et al. 2000), which could limit their 
access to support with caring for their child. Active drug users may also have poor access 
to health services because of psychosocial factors (Mok et al. 1996).
Medical confidentiality is fundamental in health service provision, though the level to 
which individual patients want it is likely to vary (Jenkins et al. 2005). In a large 
descriptive study of views on medical privacy among patients with one or other of six 
chronic conditions, individuals with HIV were the least likely to report that others knew 
about their condition (Kass et al. 2004). Concern over confidentiality was the most 
frequently cited reason for parents declining enrolment in the CHART study (Chapter 7). 
Respondents in the parent and carer survey also mentioned their anxieties about 
confidentiality and the risk of inadvertent disclosure, as issues which made long-term 
contact and follow-up problematic for them (Chapter 8). The following statements were 
representative of the opinions expressed.
“Am happy to help with research i f  totally anonymous. ” [Mother of one child (aged 1 
year)]
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‘7feel that keep the child under checks would bring some conflict. In my opinion I  have 
chosen not to disclose my HIV status to my family. ” [Mother of one child (aged 3 years)]
Although most respondents to the parent and carer survey reported that they had 
disclosed their HIV status to the family general practitioner (GP), this is not always the 
case with HIV-affected families (Anderson and Doyal 2004). Anecdotal reports from the 
CHART study suggested that the family GP and health visitor were not always aware of 
the mother’s HIV infection and therefore could not be contacted regarding enrolment of 
the child in the study (Chapter 7). Even if disclosure to the GP has taken place, HIV- 
affected families may still prefer to receive their care from the paediatric HIV clinic 
which offers familiarity and security (Boulton et al. 1999). The level to which 
individuals involve their GP is likely to vary, as suggested by one mother in the parent 
and carer survey:
“I think that GPs must be aware o f any follow-up programme. I  know some families with 
HIV are not always comfortable with this- but personally I  find it crucial to keep our 
family health care as 'normal' as possible- less explaining, and I  think less stigmatised. ” 
[Mother of one child (aged 6 years)]
The majority of respondents to the health professional survey reported offering clinic 
appointments at the standard ages recommended for testing children bom to HIV 
infected women, as outlined in the British HIV Association pregnancy guidelines 
(Hawkins et al. 2005). However, non-attendance both in paediatric and genitourinary 
(GU) clinics was a particular barrier to enrolling children in the CHART study; and 
where a reason had been provided for loss to follow-up, clinic non-attendance was 
reported for about a third of children. Conversely, over half of respondents to the health 
professional survey thought many parents agreed to take part in the CHART study 
because they were keen to keep in contact with familiar health services (Chapter 7). This 
dichotomy is summed up by a paediatrician in the health professional survey:
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“Two distinct groups o f patients exist: 1- who would like engaging medical contact with 
non specific concerns. 2- who would want to cut off with us as soon as possible. ” 
[Paediatrician]
Increasingly, hospitals are adopting a “family clinic” structure to care for HIV-affected 
families, where medical and psychosocial care for adults and their children (infected or 
uninfected) is integrated (Sharland et al. 2003). In a survey of service-providers from 15 
paediatric HIV centres in Europe, some of which were ECS centres, most reported the 
coordination of adult and paediatric clinic teams within their hospital (Thome et al. 
1999). In the health professional survey, all respondents reported regular discussion of 
issues relating to uninfected children with colleagues in the obstetric and/or GU 
departments within their hospital and a quarter reported that uninfected children were 
seen in a family clinic (Chapter 7).
Early in the epidemic, HIV-affected families in the UK were largely based in London. 
However, they now increasingly live outside London, due in part to the epidemic 
becoming more generalised in the heterosexual population but mainly because of a 
national programme for the dispersal of asylum seekers (National AIDS Trust 2006, 
Creighton et al. 2004). This has had a significant impact on the workload of GU clinics 
outside London in recent years (Rajamanoharan et al. 2004). The prevalence of HIV 
infection (diagnosed and undiagnosed) among women giving birth in England outside 
London, has increased since 2000 (see Figure 1.5). Some regions have been particularly 
affected, for example in the North West of England prevalence doubled from 0.046% in 
2003 to 0.089% in 2004 (The UK Collaborative Group for HIV and STI Surveillance 
2005). Reports of pregnancies in diagnosed HIV infected women reflect these trends in 
overall prevalence, with the proportion of pregnancies reported from regions outside
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London rising from 20% in 2000/1 to 47% in 2004/5 (Tookey 2005a). Furthermore, 
children eligible for the CHART study were reported from 168 hospitals across the UK.
HIV-affected families in the UK are generally a mobile population. They frequently 
move or are dispersed, sometimes at short notice (National AIDS Trust 2006). There is 
also considerable movement between the UK and other countries, either for temporary 
visits or for permanent moves. In the health professional survey, loss of contact with the 
family was reported as a major limiting factor to enrolling children in the CHART study:
“Difficulties with keeping in touch with families, often move frequently. ” [Paediatric 
nurse]
“ ...the difficulty for us health professionals was trying to contact some o f the 
carers/parents, due to high mobility o f our clients. ” [Paediatric nurse]
Although uninfected children bom to HIV infected women in Europe may come from 
families that share broad characteristics, they will have individual needs, and health and 
social services should cater for this (Thome et al. 1999).
9.3 Antiretroviral therapy exposure and the health of uninfected children
The proportion of uninfected children in the ECS who were exposed to ART in utero 
and/or in the neonatal period increased from 23% in 1994 to 100% in 2000 (Chapter 4). 
This was a reflection of the increased use of prophylactic ART across Europe after the 
results of the Pediatric AIDS Clinical Trial Group (PACTG) 076 trial were published 
(Connor et al. 1994). Furthermore, in utero exposure to combination therapy, 
predominantly HAART, increased from the mid 1990s. These trends have been observed 
in observational studies elsewhere in Europe (Bellon Cano et al. 2004, Barret et al. 2003) 
and in the USA (Cooper et al. 2002). In the UK, three quarters of children eligible for the
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CHART study (bom since 1996) were exposed to combination therapy in utero (Chapter 
7). HAART is now the standard treatment for HIV infected individuals, and it is 
recommended that pregnancy should not preclude the use of optimal therapeutic 
regimens (Public Health Service Task Force 2005a).
Congenital abnormalities
In the ECS there was no association observed between antenatal ART use and the 
presence or pattern of congenital abnormalities (Chapter 4). This is consistent with 
findings from studies which only addressed zidovudine (ZDV) exposure (Sperling et al. 
1998, Lipshultz et al 2000), as well as more recent analyses in which infants were 
exposed to HAART (European Collaborative Study 2005a, Townsend et al. 2006, Watts 
et al. 2004). Although these studies provide reassurance, ongoing monitoring of 
congenital abnormalities in ART-exposed children is required, particularly in view of the 
increasing number of antiretroviral drugs that are initiated before conception and in the 
first trimester of pregnancy (Tookey 2005b, European Collaborative Study 2005c).
The purpose of the Antiretroviral Pregnancy Registry (APR), a large-scale passive 
reporting system, is to detect any major teratogenic effects of antiretroviral drugs 
administered to pregnant women. By 2005, the APR had a sufficient number of first 
trimester exposures to detect a two-fold increase in risk of birth defects for nine 
antiretroviral drugs. No increases were detected for eight of them, though a high 
frequency of birth defects after first trimester exposure to didanosine (ddl) was noted 
(6.4%) (Antiretroviral Pregnancy Registry Steering Committee 2005).
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Adverse health events
The ECS finding that in the short-term uninfected children exposed to ART were no 
more likely to suffer from a serious adverse health event, including neurological or 
cardiac diseases, is encouraging. Furthermore, there was no evidence of excess mortality 
associated with exposure to ART (Chapter 4). This is in line with evidence from other 
studies (Chotpitayasunondh et al. 2001, Sperling et al. 1998). The investigation here did 
not involve specific tests for mitochondrial abnormalities, and thus findings from the 
French Perinatal Cohort Study could not be confirmed or rejected (Blanche et al. 1999). 
In contrast to a report from the French group, there was no observed association between 
ART exposure and febrile seizures in the first 18 months of life (Landreau-Mascaro et al. 
2002).
Prematurity and growth
The previously reported association between antenatal ART exposure and prematurity 
(European Collaborative Study and the Swiss Mother + Child HIV Cohort Study 2000) 
persisted in uninfected infants, with the risk being especially pronounced when protease 
inhibitors were part of the regimen (Chapter 4). The relationship between the use of 
illicit drugs in pregnancy and an increased risk of prematurity has long been established 
(Mauri et al. 1995), and this was also observed here, independent of ART exposure.
Although in multivariable regression models, children exposed to combination therapy 
were significantly smaller in terms of weight, height and head circumference than those 
who were not exposed or who were only exposed to monotherapy, this effect was small 
(adjusted coefficients -0.10, -0.12, -0.14 respectively) (Chapter 5). The effect was much 
smaller than that of maternal illicit drug use, where children bom to mothers with 
reported drug use in pregnancy were significantly lighter, shorter and had a smaller head
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circumference than those with no reported drug use (Ross et al. 1995). However, 
uninfected children bom prematurely and exposed to combination therapy generally 
reached a given centile for weight or head circumference earlier, than those in the same 
gestational age category who were either not exposed or who were only exposed to 
monotherapy. These findings are consistent with the hypothesised mechanism underlying 
the increased risk of prematurity with exposure to HAART, that prematurity is mediated 
through a cytokine balance resulting in premature labour, rather than being due to infant 
factors (Fiore et al. 2006). Although prematurity can be appropriately managed in 
resource-rich settings, since there is an association between extreme prematurity and 
infant mortality (European Collaborative Study 2004a) the situation should be 
monitored.
Malignancies
In the ECS there were no malignancies reported in uninfected children exposed to ART, 
similar to earlier findings from the PACTG (Culnane et al. 1999, Hanson et al. 1999) 
(Chapter 4). In much of the previously published work, only exposure to ZDV has been 
addressed (Chotpitayasunondh et al. 2001, Culnane et al. 1999). One of the strengths of 
the ECS is the large number of uninfected children exposed to combination therapy in 
utero. A limitation of the analysis of adverse health events carried out using data from 
the ECS was that the median length of follow-up was only just over two years (Chapter 
4). Nevertheless, since the analyses presented here were carried out, a longer period of 
follow-up has been accrued for a substantial number of children (European Collaborative 
Study 2005b). Other cohort studies such as the French Perinatal Cohort Study and the 
Women and Infants Transmission Study (WITS) in the USA end formal follow-up 
around two years of age (Le Chenadec et al. 2003, Paul et al. 2005).
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There were no notifications of cancer registration reported for the 2429 uninfected 
children who were flagged in the Office for National Statistics (ONS) flagging study 
(Chapter 6). However the median length of time on the National Health Service Central 
Register (NHSCR) for these children was only two and a half years. Therefore, 
observations to date cannot exclude an elevated risk of malignancies, since all the 
children flagged are relatively young and malignancies may develop at older ages, as 
was seen with in utero exposure to diethylstilbestrol (DES). Clear cell adenocarcinoma 
of the vagina and cervix was found in young women whose mothers had taken DES in 
pregnancy which was prescribed to prevent miscarriage and other complications 
(Schrager and Potter 2004).
9.4 Feasibility of follow-up studies
Research is needed in order to identify whether there are long-term adverse effects of 
exposure to ART, and cohort studies such as the ECS, the WITS and the French Perinatal 
Cohort Study, provide an opportunity to do this. Findings from these studies should be 
used to inform monitoring programmes, which could focus on a small number of health 
outcomes.
The CHART study was carried out to see if it was feasible to manage a consented clinic-
based monitoring system, within the appropriate ethical parameters, at a population level
based on reports of children made to the NSHPC (Chapter 7). Just over 2100 children
were eligible for enrolment in the CHART study. Of the parents and carers who were
actually approached regarding enrolment, nearly 90% agreed to take part, but overall
only a third of eligible children were enrolled by the end of the study period. As
reporting to the NSHPC is anonymous and there is no direct contact with families, the
CHART study was dependent on a network of health professionals which included over
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330 individuals by the end of the study period. About a third of eligible children could 
not be enrolled because the health professional had not been willing to contact the family 
or there had been no response from the health professional despite reminders. This raises 
the issue of whether health professionals are the most appropriate channel for long-term 
follow-up of these generally well children.
The amount of effort that health professionals put into attempting to contact the family 
about the CHART study before they reported the child as lost to follow-up was variable. 
Some considered that a child was lost to follow-up if they had been discharged from the 
paediatric clinic, whereas others reported having tried telephoning or writing to the 
family, making home visits and accessing other health professionals likely to be in 
contact with the family.
In some cases a child’s uninfected status was reported to the NSHPC after the child 
had been discharged from the paediatric clinic following a negative antibody test 
(usually around 12-18 months of age). As the NSHPC paediatric respondent was then no 
longer in close contact with the family, this made it more difficult for them to approach 
the parent about enrolment in the CHART study. This was particularly important in 
situations where the health professional felt they could only speak to the parent about the 
study at a clinic appointment. Some health professionals also reported that families were 
lost to follow-up even before the antibody test.
“In retrospect I  should have discussed it more regularly at clinic visits but many had 
only had 1 or 2 negative tests and were indeterminate status. By the time they are known 
to be negative they are then not in regular contact until 18/12 [18 months] and many o f 
these are lost to follow up/move. ” [Paediatrician]
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Health professionals were not paid for their involvement in the CHART study, and lack 
of resources meant that some were unable to take part at all. The amount of clinic staff 
time that was available for enrolment and data collection would have varied between 
hospitals. In some of the large hospitals, dedicated paediatric HIV clinic staff were 
available to manage the study on a local level. Only a fifth of respondents in the health 
professional survey reported that lack of clinic staff time was a major factor which made 
enrolment difficult. An important consideration was the increase in the number of 
eligible children reported to the NSHPC during the CHART study, which far exceeded 
that predicted before the start of the study. This was due mainly to the significant 
increase in the prevalence of HIV infection in pregnant women from 2000 (see Figure 
1.5) and also the widespread introduction of routine antenatal testing across the UK also 
from 2000 (NHS Executive 1999), both of which occurred after the CHART study had 
been planned. Health professionals in clinics where caseloads increased rapidly over the 
CHART study period reported difficulties in enrolling children:
“The entire workload has rested with a single paediatric consultant (myself) and the 
paperwork and parent liaison has been a nightmare. We are a particularly busy unit and 
a smaller unit with fewer children would find this a lot easier. ” [Paediatrician]
The most frequently given reason for loss to follow-up of children eligible for enrolment 
in the CHART study was that the family had moved or changed their contact details: a 
quarter of eligible children were lost to follow-up or were known to have gone abroad. 
Similarly, in the PACTG 219 study, a long-term observational study of children enrolled 
in the PACTG 076 trial, loss to follow-up is estimated to be about 10% per year 
(Culnane et al. 1999). Even among the children who were actually enrolled in the 
CHART study, 7% were subsequently reported as lost to follow-up within a relatively 
short space of time.
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It was reassuring to find that enrolled and non-enrolled children in the CHART study 
were similar in terms of their baseline demographic characteristics, which were available 
through routinely collected data from the NSHPC. However, as enrolment and continued 
data collection through the CHART study was carried out in an opportunistic way, it is 
possible that children with more severe or chronic conditions who require continued 
contact with health services were more likely to be enrolled.
The CHART study demonstrated the difficulties involved in monitoring the health of 
these children at a population level. It became clear that regular clinic-based contact 
would not be feasible over the long term or on a national basis. However, it was 
important to assess this as the protocol was non-invasive, consented and involved health 
professionals known to the family, and also because both families and health 
professionals express the opinion that ongoing contact is desirable.
The ONS flagging study highlighted the effectiveness of using routinely collected data to 
monitor health outcomes in uninfected children exposed to ART (Chapter 6). As long as 
systems remain in place, notifications of death and cancer registration in flagged children 
will continue to be reported to researchers at the NSHPC from ONS. The protocol that 
has been established will make it possible to flag children reported to the NSHPC in 
future years. Since this process does not require the involvement of health professionals, 
it is likely to be a relatively inexpensive way of monitoring major outcomes in 
uninfected children exposed to ART. It is also relatively unbiased in that 95% of eligible 
children could be flagged, and there were no significant differences in terms of ART 
exposure between children who were flagged and those who were not.
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However, a limitation of the ONS flagging study is that only notifications of death and 
cancer will be available. Non-fatal clinical symptoms suggestive of mitochondrial 
abnormalities, such as neurological or cardiac diseases would not be captured through 
this mechanism (Blanche et al. 1999).
The now widespread use of the National Health Service (NHS) number in the UK, 
coupled with electronic transfer and storage of data, offers new opportunities for data 
linkage studies (Connecting for Health 2006a). Possible additional data sources that 
could be linked with data collected in the NSHPC include primary care datasets such as 
the General Practice Research Database (GPRD) (General Practice Research Database 
2006), hospital episode statistics (HES) (Hospital Episode Statistics 2006) and disability 
and disease registers (Hutchison and Harpin 1998). Clearly, further work would be 
needed to explore whether these would be viable, as well as research into the health 
outcomes that should be targeted. The ONS flagging study has support under Section 60 
of the Health and Social Care Act 2001 from the Patient Information Advisory Group 
(PIAG), which enables the collection of patient identifiable information without 
individual patient consent. New data linkage studies would have to be approached with 
appropriate ethical and legal consideration.
9.5 Acceptability of follow-up studies
Almost all respondents in the parent and carer survey were supportive of the rationale for 
follow-up, and while expressing a preference for certain strategies, generally did not 
dismiss others (Chapter 8). Whether respondents found a particular follow-up strategy 
acceptable was not generally associated with demographic characteristics. It is likely that 
factors such as confidence, confidentiality concerns, anxiety about discrimination and
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acceptance of HIV diagnosis (if infected) are related to an individual’s preference for 
follow-up strategies.
Contradictory views were expressed both within and between individuals, particularly 
with respect to whether and how contact should be maintained, and it would be 
impossible to select one particular strategy which would suit all individuals involved. 
Individual opinions sometimes reflect confusion and bias (Wendler 2006) and it would 
be extremely challenging to decide which opinions were “correct”.
Clinic-based contact was found acceptable by most respondents, which could reflect the 
fact that it is familiar to them, but could also be indicative of the age of their children. A 
clinic that has provided services for the family, possibly over several years, is likely to 
also provide the reassurance that respondents would not feel in a different situation 
(Sharland et al 2003, Boulton et al. 1999). In a survey of parents of hepatitis C infected 
children, the favourable option for long-term follow-up of children was for them to 
continue to see a paediatrician and then transfer to adult care at an appropriate time. This 
was in preference to ongoing postal or telephone contact (Personal communication, L 
Pembrey, 2006). A third of respondents in the health professional survey strongly 
objected to clinic-based contact, citing concerns about confidentiality, the mobility of 
HIV-affected families and a lack of clinic resources (Chapter 8).
Despite reassurances that no reference to HIV would be made on any literature, one in 10 
respondents to the parent and carer survey strongly objected to postal contact (Chapter 
8). Health professionals involved in the CHART study also reported that some HIV- 
affected families do not give permission for letters to be sent home (Chapter 7). This is 
mainly due to confidentiality concerns, particularly when families are living in shared
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accommodation or when the HIV infected woman’s family or partner is unaware of her 
HIV status.
“Problem with postal contact is that may be opened by another family member- many 
asylum seekers in multi-occupation. Even if  no mention o f HIV it may trigger awkward 
questions.” [Paediatrician]
Concern about long-term follow-up having the potential to lead to disclosure of maternal 
HIV status to the child, was raised by some respondents to the parent and carer survey.
In a European multi-centre survey, which included some ECS centres, around 10% of 
HIV infected parents had told their children about their HIV diagnosis (Thome et al. 
2000). Disclosure of parental HIV status has been shown to be associated with the 
increased age of the child, the increased length of time since the parent’s HIV diagnosis 
and the severity of the parent’s illness (Lee and Rotheram-Borus 2002, Thome et al. 
2000, Nostlinger et al. 2004). In a cohort of children bom to HIV infected mothers in the 
UK, infected children were more likely to know their mother’s diagnosis than uninfected 
children (Mok and Cooper 1997), but this has not been observed in other settings 
(Thome et al. 2000). The disclosure process is complex, and is likely to involve more 
personal factors such as the existing relationship between the parent and child, 
anticipated stigma and uncertainty about the future. There is also the consideration of 
how life events, such as morbidity, may alter opinions. The following statements from 
HIV infected mothers show the diversity of views held on disclosure:
“I think once a teenager reaches a certain age I  not sure I  would tell my children I  have 
HIV i f  I ’m still alive so I  would not want to harm or scare them in any way but that’s a 
long way ahead o f me, things change. ” [Mother of two children (aged 2 and 4 years)]
“I think it should be up to the parent to tell the clinic i f  they can contact the young 
person as it would necessitate the mother's disclosure o f her own HIV status and this is a 
very personal, individual matter. ” [Mother of one child (aged 1 year)]
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“I think that is important to do a follow up, but at the same time if  the child is uninfected 
it is difficult for them to maybe accept or understand about all this, so would be better to 
leave this subject (or burden as it is at the moment) out o f their life. ” [Mother of one 
child (aged 2 years)]
Long-term follow-up strategies that are dependent on disclosure are likely to encounter 
difficulties on an individual level. If health risks to an ART-exposed individual can be 
screened for or treated, this raises the issue of whether disclosure of maternal HIV status 
and the fact that the young person was exposed to ART should occur regardless of 
parental consent. There needs to be a discussion on balancing the rights of the HIV 
infected mother to privacy and confidentiality, and the rights of the ART-exposed child 
or adult to appropriate screening or care as appropriate. This should occur within a broad 
population perspective, rather than on an individual case basis.
The majority of respondents thought that parents and carers should be told of a health 
problem associated with exposure to a particular antiretroviral drug, which suggests the 
importance that parents attach to information about their child’s health (Thome et al. 
1999) (Chapter 8). Nevertheless, actually carrying this out would be challenging, 
particularly as in some individuals there were inconsistencies between the types of 
follow-up strategies they found acceptable and how they would want to be contacted.
The type of information communicated to the family would have to be decided, such as 
whether findings from research were provided or whether they were only contacted if 
screening could be offered to the ART-exposed child or young adult.
A quarter of respondents in the parent and carer survey and half of the respondents in the 
health professional survey found data linkage acceptable. Two thirds of parents thought 
that parental permission should be sought before a child was included in any monitoring 
system relying on data linkage. In the Millennium Cohort Study (MCS), a UK cohort of
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nearly 19 000 children bom 2000-2002 which over-sampled from disadvantaged and 
ethnic minority localities, consent for linkage to birth register and/or hospital maternity 
data was obtained from over 90% of mothers. However, consent was less likely among 
minority ethnic group mothers (Tate et al 2006). Although HIV infected mothers are 
likely to be different in terms of their views regarding confidentiality, the finding from 
the MCS could have implications for data linkage studies of uninfected children in the 
UK that involved parental consent, as currently the majority of their mothers are of non­
white ethnicity.
The median age of the children of the respondents in the parent and carer survey was two 
years, which limits the extension of the findings to parents with older children (Chapter 
8). The low attendance rate in the paediatric clinics involved in the survey is consistent 
with the large number of children who were reported as lost to follow-up in the CHART 
study due to non-attendance (Chapter 7). It also demonstrates the difficulty in accessing 
HIV-affected families for the purposes of this survey, and indeed any follow-up strategy 
that relies on clinic attendance. Furthermore, families who attended clinics and therefore 
were available to take part in the survey could have been more compliant than those who 
did not attend, which could have introduced selection bias to the survey.
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9.6 Recommendations
In the UK, follow-up of ART-exposed uninfected children bom to HIV infected women 
should take place both on an individual level and a population-based level (see Figure 
9.1).
Figure 9.1 A general model for the follow-up of uninfected children exposed to 
antiretroviral therapy
Follow-up
Data linkage
Population Individual
Clinic contact / 
central source of 
information
Individual level
Clinic contact
• The child should attend the paediatric clinic for blood tests and assessments up to 18 
months of age, as recommended in the British HIV Association pregnancy guidelines 
(Hawkins et al. 2005)
• Paediatric clinic staff should encourage the parent/carer to stay in touch with the 
clinic once their child has been confirmed uninfected, and to contact the clinic if they 
have any concerns about their child’s health
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• Paediatric clinic staff should support the parent/carer in disclosing the mother’s HIV 
status and the child’s ART exposure to both relevant health professionals, and to the 
child when they are of an appropriate age
• GU clinic staff should take an active role in supporting the parent in the disclosure 
process
Central source o f information for families
• There should be a central source of information for families with ART-exposed 
children
• Information provided should include: findings from research into possible adverse 
side effects of ART exposure, how the parent/carer or the ART-exposed individual 
could report any adverse side effects, details of support groups and clinical care for 
HIV-affected families, and advice on how to disclose the mother’s HIV status and the 
child’s ART exposure to both relevant health professionals and to the ART-exposed 
individual
• This resource could be accessed through telephone or postal contact or from a 
website; and details should be provided to the woman during her own care and during 
her child’s paediatric follow-up
• This resource could be incorporated with information about other drug exposures in 
pregnancy, in an attempt to normalise maternal HIV infection and the child’s ART 
exposure
Population-based level
• Children bom to HIV infected women in the UK should be reported to the NSHPC, 
as recommended in the British HIV Association pregnancy guidelines (Hawkins et
• The ONS flagging study should continue
• The feasibility of using other routine data sources that could be linked to data 
collected in the NSHPC, should be explored
• A data linkage study should contain the facility to contact the family or the ART- 
exposed individual should a significantly increased risk of a serious condition be 
identified. Contact would have to be approved through the appropriate channels, be 
subject to strict data security measures and would only be used for serious conditions 
where there was an appropriate screening tool or treatment available
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Appendix 2 The European Collaborative Study forms
2.1 Maternal information
2.2 Perinatal information
2.3 Laboratory investigations
2.4 Medical examination
2.5 Assessment
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ECS3
INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
MATERNAL INFORMATION AT DELIVERY
Centre
Mothers Study Number 
Child Study Number
Mother’s date o f birth (day, month, year)
Country o f b ir th ....................................................................................................................................................
Marital Status
Single (1), Married (2), Divorced, Separated, W idowed (3), Cohabiting (4)
Ethnic Group
Asian (1), White (2), Black (3), Oriental (4), Other (5)
Age when leaving full-time education, years................................................................................................
Obstetric History
Number o f previous livebirths .........................................................................................................................
Number o f previous stillbirths .........................................................................................................................
Number o f previous m iscarriages....................................................................................................................
Number o f previous term inations....................................................................................................................
Mothers Risk Group
History o f intravenous Drug Abuse (Y/N)
Trimester o f last use: pre-conception (0), 1st (1), 2nd (2), 3rd (3), unknown (9)
Needle sharing? never (1) past (2) present (3) unknown (9)
Sexual partner o f Bisexual (Y/N)
Sexual partner o f Haemophiliac (Y/N)
Sexual partner o f Intravenous Drug Abuser (Y/N)
Sexual partner o f Other high risk group (Y/N)
(Specify) .................................................................................................................................................................
O th e r .........................................................................................................................................................................
Mothers HIV History
Date o f first HTV+ test (day, month, year)
Current clinical status
Current HTV staging ( C D C ) ..............................................................................................................................
Specify symptoms ................................................................................................................................................
Date of o n s e t ..........................................................................................................................................................
Details of treatment during pregnancy
Has the woman received any antiretroviral therapy at any time during this pregnancy? Y/N  
Please give details o f both ART and other prophylaxis (eg. TM P-SMX)
Drug Date started Date stopped Currently taken? 
(yes/no)
2 1 1
ECS 3
PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
Page 2 
MATERNAL INFORMATION 
Laboratory investigations during pregnancy and at delivery:
Centre Number 
M others Study Number 
Child Study Number
1-2
6
3-5
Virology
Date: Date: Date:
HIV-DNA PCR Pos / Neg Pos / Neg Pos / Neg
HIV-RNA PCR copies/ml copies/ml copies/ml
Sample type Plasma / Serum Plasma / Serum Plasma / Serum
Assay used
Other laboratory investigations
Date: Date: Date:
Total lymphocytes
CD4 (109/litre)
CD8 (1 O’/litre)
IgG (gm/litre)
IgA (gm/litre)
IgM (gm/litre)
p24 Ag
HIVEUsa
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ECS3
INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
PERINATAL INFORMATION Centre
Mothers Study Number 
Child Study Number 
Child's date of birth (day, month, year)
Sex (M, F) 
Gestational age (weeks) 
Birthweight (gm) 
OFC (cm
Hospital where delivery took p lace ...................................................................
Obstetrician (initals)..........................................................................................
Antiretroviral therapy during labour/delivery Y/N
If yes, which drug?................................................................Orally / IV?
Delivery
Caesarean Section: Elective (1), Emergency (2)
If Caesarean Section, reason............................................................................
Vaginal: Spontaneous (3), vacuum (4), forceps (5)
Presentation: breech (Y/N)
Duration of labour 1st stage (if known).............................................................
Duration of labour 2nd stage (if known)...........................................................
Time from rupture of membranes to delivery (if known)...................................
Scalp Electrodes (Y/N)
Episiotomy or vulvovaginal tear (Y/N)
Perinatal Problems (Y/N). Specify Details:
Hepatomegaly..................................................................................................
Splenomegaly...................................................................................................
Drug Withdrawal Symptoms.......................... „.................................................
Thrombocytopenic Purpura............................... ..............................................
Infection: suspected (1) confirmed (2 ) .............................................................
Transfusion........................................................................................................*
Congenital Abnormalities.................................................................................. *
Other.................................................................................................................
Disposition
with parents (1) fostered (2) adopted (3)
remained in hospital (4) other (5) .......................................................*
if remained in hospital, say w hy:.......................................................
Feeding: breast (1) bottle (2) breast and bottle (3)
was breast feeding tried and abandoned? Y/N
Died? Y/N
Date of death: (day/month/year)
Postmortem results, if available............................................................ *
ITXI
□
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Take sample required; Please record laboratory results on yellow form 9 | 2
PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
Centre
LABORATORY INVESTIGATIONS Mothers Study Number
Child Study Number
Assessment at:
0-7 days, 3w, 6 w, 4.5m, 6 m, 9m, 12m, 18m, 24m, and then annually if 
child presumed not infected, or 6  monthly if infected
Ring findings and specify as appropriate:
Date blood drawn:_____ / _____ / ______
day month year 
HIV / ELISA + / - Specify system used
antibodies .......................................................................................................
Western blot + / -
Virus culture
+ / - Specify identification system(s) ..........................................................
+ / - Specify identification system(s) ..........................................................
Viral load
DNA-PCR .....................................................................................................
RNA-PCR .....................................................................................................
Antigen assay + / -
Specify identification system ........................................................................
Other tests (eg IVAP, PCR, IgM) Specify method and result
+ / -  ............................................................................................................
+  / -  ............................................................................................................
IgG (gm/litre)
IgA (gm/litre)
IgM (gm/litre)
T4 (109/litre)
T8  (109/litre)
Absolute lymphocyte (109/litre)
Neutrophil (109/litre)
Platelet (109/litre)
Haemoglobin (gm/dl)
Toxo IgG Latex (at 9 months to exclude congenital infection) (+/-)
Tetanus IgG (at least 1 month after third DT/DPT)
CMV IgG (+/-)
1-2
3 -5
for office use only
I I I I I
1 3 -1 4
1 5 -1 6
1 7 -1 8
1 9 -2 0
21-22
2 3 -2 4
2 5 -2 6
2 7 -2 9
3 0 -3 2
3 3 -3 5
7 -1 2
3 6 -3 8
39-41
4 2 -4 4
4 5 -4 8
4 9 -5 2
5 3 -5 6
5 7 -6 0
6 1 -6 4
68
I
6 5 -6 7
69-71
7 2
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ITPT3'74
ECS3
INTENSIVE PROSPECTIVE STUDY OF CHILDREN BORN TO HIV POSITIVE MOTHERS
MULTI CENTRE EEC STUDY
MEDICAL EXAMINATION
Please circle or complete as appropriate
Assessment a t : 3w, 6 w, 3m, 4.5m and 6  m
Centre
Mothers Study Number 
Child Study Number 
Date of Examination 
Weight (kg) 
Height (cm) 
OFC (cm)
1-2
3-5
7-12
13-16
17-20
21-23
Recurrent fever of unknown origin requiring medical attention..................................Y/N
Chronic or Recurrent diarrhoea requiring medical attention....................................Y/N
Specify organism....................................................................................................... .......
Bacterial infection .............................................................................................................Y/N
If yes, specify:
Septicaemia, Meningitis, Urinary tract infection, Pneumonia, O ther......................
Communicable D ise a se ...................................................................................................Y/N
Measles (1) Mumps (2) Rubella (3) Varicella (4) Zoster (5) Other (6 ) ..............
Complications.......................................................... ..........................................................
Skin Infection requiring medical attention......................................................................Y/N
Staph (1) Strep (2) Herpes (3) Candida (4) Other (5 )...........................................
Non-infectious skin eruption .........................................................................................Y/N
Petechiae/Purpura (1) Eczema (2) Kaposi Sarcoma (3) Other (4 )......................
Palpable Lymph N o d es .................................................................................................... Y/N
Axillary (1) Postoccipital (2) Cervical (3) Inguinal (4) Epitrochlear (5) Other (6 )
Chronic parotid swelling .................................................................................................Y/N
Oral Candida persistent or recurrent despite therapy..................................................Y/N
Upper respiratory tract infection .................................................................................. Y/N
Chronic otitis media (1) Sinusitis (2 ) Chronic purulent rhinitis (3) Other (4).......
Lower respiratory tract d isease  confirmed by X-ray..................................................Y/N
Lymphocytic intersitial pneumonitis or Pulmonary lymphoid hyperplasia (1)
Pneumonia (2) Bronchiolitis (3) Other (4 )...................................................................
specify organism, if known...............................................................................................
Opportunistic Infection .................................................................................................... Y/N
PCP(1) CMV (2) Toxo (3) Candida (4) Mycobacterium (5) Other (6 ) .............
Hepatomegaly.......................................................................................................................Y/N
Splenom egaly.................................................................................... 2 1 5 ..........................
□ For office use only
28-30
31-33
34-35
o 36-38
41-43
44-46
49-50
151-53
54
| 7 | 1 | 57-58
ECS3 page 2
Please circle or complete as appropriate 
Medical Examination
Date of Examination / ___ / ___ Centre
Mothers Study Number 
Child Study Number
1-2
3 -5
Neurological abnormality................................................................................................Y/N
encephalopathy (static/progressive) (1 ) ....................................................................
seizures (2) paresis (3) pathologic reflexes (4) increased tone (5) 
decreased tone (6 ) abnormal gait (7) other (8 ) ........................................................
Other Findings on exam Specify....................................................................................Y/N
Developmental Asessm ent
Gross motor Pass (1 ) Fail (2 )
Fine motor/adaptive Pass (1 ) Fail (2 )
Language Pass (1 ) Fail (2 )
Personal/social Pass (1 ) Fail (2 )
Loss of developmental m ilestones.............................................................................. Y/N
specify..............................................................................................................................
Neonate
Has the baby received any anti-retroviral therapy to reduce
the risk of vertical transmission?...................................................................................... Y/N
If yes: which drug(s)?.............................................................................................
for how long?.............................................................................................
Treatment
Has this child been enrolled in an anti-retroviral treatment trial...................... Y/N
If yes: which trial? ......................................................................................... .......
Current treatment (excluding the above)
IVGG, AZT, DDi, Other..................................................................................................
Hospital Admission(s)...................................................................................................... Y/N
(Indicate dates of admission/discharge and diagnoses for each hospitalization)
Immunisations given since last v isit...............................................................................Y/N
DPT (1) DT(2) Oral Polio (3) Killed Polio (4) Measles (5) MMR (6 )
Hepatitis B (7) Other (8 ) ...............................................................................................
Abnormal reactions..................................................................................................Y/N
Child care
mother / father / other relative / fostered / adopted / hospital / institution
Breast Feeding....................................................................................................................Y/N
If stopped, when .............................................................................................................
Health of Mother ......................................................................................................................
Is mother alive / dead?
if dead, was death HIV-related? ...........................................................................Y/N
cause of death ................................................................................................................
Mother's current HIV staging (CDC) ..........................................................................
defining sym tom s...........................................................................................................
date of diagnosis.............................................................................................................
current treatment? .........................................................................................................
216
8-10
1 1 -1 3
1 4 -1 6
For office use only
2 4
2 2 -2 3
2 5 -2 6
2 7
|28
2 9-31
3 2 -3 6
37-41
4 2
4 3 -4 6
4 7 -5 0
5 5
5 6
5 1 -5 2
5 3 -5 4
5 7 -5 8
6 2 -6 3
6 4 -6 8
6 9 -7 3
7 4 -7 5
m 7 6 -7 7
ECS.1
PROSPECTIVE STUDY OF CHILDREN BORN TO HIV +VE MOTHERS
Assessment: 9 ,1 2 ,1 8  and 24 months; thereafter annually for antibody -ve, 
uninfected children and 6-monthly for infected children
Please circle or tick as appropriate
Centre number 
Mother Study number 
Child Study number 
Weight (kg) 
Height (cm) 
Head circumference (cm)
1-3
4 -6
12,5 
£  1 6 -1 8
Is child alive?
Date of assessment (day, month, year) 
Name of paediatrician (initials) ............
Y/N 19 For office use only
I I I I 2 0 -2 5
I 2 6 -2 7
Is this child HIV infected?....................................................................................Y/N
Has this child developed AIDS? (CDC d e f ) .....................................................Y/N
If AIDS has been diagnosed since previous report,
specify date of diagnosis ....................................................................................
AIDS indicator d isease .........................................................................................
Care
mother / father / other relative / fostered / adopted / hospital / institution
Is mother alive / dead?
if dead, was death HIV-related? .................................................................. Y/N
cause of d e a th ........................................................................................................
Preschooling/Schooling
Does this child require special educational provisions................................ Y/N
if yes, specify..........................................................................................................
Treatment
Has this child been enrolled in an anti-retroviral treatment trial ...............Y/N
if yes, which trial? .................................................................................................
Current treatment (excluding the a b o v e )...............................................................
Intravenous gammaglobulin/AZT/DDi/other, specify ....................................
Communicable diseases .................................................................................Y/N
if yes, specify: measles / whooping cough / varicella / tuberculosis / mumps / zoster
n 3 0 -3 5
3 6 -3 8
□3 9
4 2
4 3 -4 4
4 5
4 6 -4 8
4 9 -5 3
5 4 -5 8
□59
ECS .1 (page 2) Centre ......................  M other.......................  C h ild ........................ D a te ......... / ...... /.
Oral Candida since last visit (persisting > 2m or recurring despite therapy) 
if yes, date on onset (day, month, year)..................................................................
Y / N
Hospital admission(s) Y / N
(indicate dates of admission/ discharge and diagnoses for each hospitalization)
Since the last visit, has this child had any of the following abnormalities:
yes/no date clinical method
presentation of diagnosis
diagnosis
renal Y / N
hepatic Y / N
gastro-intestinal Y / N
cargo-vascular
00
Y / N
central nervous system Y /N
respiratory Y / N
malignancy Y / N
other, specify
Y /N
Please complete this section, if the child has died
Date of death .........................................................................
Cause of death .......................................................................
Post mortem results.............................................................
2 -7
9 -1 2
1 3 -1 6
1 9 -2 41 7 -1 8
2 5 -3 0
3 1 -3 2 3 3 -3 8
3 9 -4 4
4 5 -4 6 4 7 -5 2
5 3 -5 8
5 9 -6 0 6 1 -6 6
6 7 -7 2
7 3 -7 4 7 5 -8 0
8 1 -8 6
8 7 -8 8 8 9 -9 4
9 5 -1 0 0
101-102 1 0 3 -1 0 8
1 0 9 -1 1 4
1 1 5 -1 1 6 1 1 7 -1 2 2
1 2 3 -1 2 8
1 2 9 -1 3 4
1 3 5 -1 3 7
1 3 8 -1 4 0
1 4 1 -1 4 3
Appendix 3 The National Study of HIV in Pregnancy and Childhood
forms
3.1 Pregnancy notification
3.2 Outcome of notified pregnancy
3.3 Paediatric notification
3.4 Follow-up to establish infection status
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NSHPC confidential pregnancy notification
MREC approval ref; MREC/04/2/009
CONFIDENTIAL form date
Tick boxes, complete, ring, or delete as appropriate 01/05
H o sp ita l................................................. Your re f (eg woman’s hospital number, local code or sou nd ex)................................................
W om an’s date o f  birth /  /  Previous liv eb irth s...............  stillbirths ............. m iscs /term s............
Ethnic origin Q  W hite Q  Black African Q  Black Caribbean Q  Black other
]  Indian Subcontinent \^ \ Oriental \^ \ Other or m ixed, s p e c ify .......................................
<*■**•«“................ 2r<lisss",“~ □□□□
PREGNANCY LM P _____
] Continuing to term E D D  /  /
| Spontaneous abortion or □  termination on /  /  at   w eek s gestation
If spontaneous abortion or termination, any congenital abnormality? \^ \ N o  Y es Please specify  overleaf
W ere an tenatal booking b loods taken  at th is m a tern ity  u n it?  1 | N o  □  Y es
PROBABLE SOURCE OF INFECTION
I I From high prevalence country, s p e c ify   Date arrived U K /lreland /  /
I I Injecting drug use \^ \ Transfusion recipient \^ \ Other, sp ec ify ................................................................
| Infected partner, specify  his likely risk factor ...............................................................................................................................
INFECTION STATUS IDENTIFIED
I I During this pregnancy: voluntary antenatal testing /  other setting, sp ec ify  ...................................
I I Known prior to this pregnancy: tested at G U M  C lin ic /  GP / Drug C lin ic /  other ........................
D ate o f  first p ositive test   I f  type 2 on ly , p lease tick here [
CLINICAL STATUS & DRUG TREATM ENT DURING PREG NANCY
I I Asym ptomatic Q  Symptomatic, not stage C d isease □  CDC Stage C d isease, date o f  onset /  /
D etails ..............................................................................................................................................................................................................................
W as th is w om an on drug treatm en t w h en  sh e b eca m e p reg n a n t?  \^ \ N o  Y es Started /  /
If  Y es, specify d ru g (s ) ...................................................................................................................  Continuing? Q  N o  O  Y es
.........................................................................................................................................................................  Date stopped /  /
D ru g treatm en t changed or started  d u rin g  p regn an cy?
I I N o  Q  N ot yet decided Q  Drug treatment declined Q  Y es, changed or started, details below:
D r u g (s ) ................................................................................................................................................................  D ate started or
.............................................................................................................................................................................  due to  start /  /
RECENT TEST RESULTS
Viral lo a d  copies/m l ( ......................... logio).t e s t ..................................................... Date
CD4________ % no.___________  C D 8 % no._____________ Total lym phocytes n o ._____________
Form completed by: Name   Date
Position Telephone  Em ail___
PLEASE ADD ANY ADDITIONAL INFORMATION OR COMM ENTS OVERLEAF.
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NSHPC outcome of notified pregnancy
MREC approval ref: MREC/04/2/009________________________________________________________
C O N F ID E N T IA L  form date
Tick boxes, complete, ring, or delete as appropriate 01/05
Your r e f ........................................... W om an’s date o f  birth /  /  Hospital o f  d e liv e ry .........................................................
PREGNANCY OUTCOME
Date /  /  G esta tion  (w ks) Q  Livebirth Q  Stillbirth Q  Miscarriage Q  Termination
B irthw eight (kg) \^ \ M ale \^ \ Female Hospital n o ..................................... N H S n o .............................................
2 nd tw in: B W  (kg) Q  M ale Q  Fem ale Hospital n o ..................................... N H S n o .............................................
| Elective CS Q  Planned vaginal delivery Q  Unplanned vaginal delivery, re a so n ......................................................
]  Emergency CS, reason ........................................................................................................................................................................................
C om plications: Pregnancy (eg  pre-eclampsia)? N o  Y es, s p e c ify ......................................................................................
Perinatal infections? \^ \ N o  Y es, s p e c ify ..............................................................................................
Congenital abnormalities? \^ \ N o  Q ]  Y es, s p e c ify ...................................................................................................
Postcode at delivery i— i j— i j— 11— | I— I j— I ■ ■
(leave off last letter) I 11___11___11 I I____ 11 I Paediatrician..............................................................................................
MATERNAL CLINICAL STATUS AT DELIVERY if woman has died,
Asymptomatic [ [ ]  Symptomatic, not stage C disease | |CDC Stage C disease Date o f  death /  /
Details
D R U G  T R E A T M E N T  D U R IN G  P R E G N A N C Y  ( if  not enough space for all d rugs, con tin u e overleaf)
A nte-p artum  treatment? Q  N o  [ ^ ]  Yes: date started (or gest w eek) date stopped (or gest w eek)
Antiretrovirals:
Drug 1   /  /  ________ /  / ______________
Drug 2 .........................................................  /  /  _______  /  /  _______
Drug 3 ................................................................  /  /  ________ /  / ______________
Drug 4 ................................................................  /  /  ________ /  / ______________
Drug 5   /  /  ________ /  /  ________
A ny other significant ante-partum drugs (eg  PCP prophylaxis, TB treatment, prescribed m ethodone, illicit drugs)
Drug 6 ................................................................  /  /  ________ /  /  _______
Drug 7 ................................................................   /  /  I I
In tra-partum  antiretroviral treatment?
I I N one Q  Oral ............................................................... Intravenous Drug(s)............. .
P ost-partum  antiretroviral(s) for in fant? Q  N o Q  Y es Q  N ot known 
If yes, date treatment started /  /  D ru g (s ) ...................................................
MATERNAL TEST RESULTS CLOSE TO TIME OF DELIVERY just before delivery if possible 
Viral load .........................................copies/m l Test   Date /  /
C D 4________ % no.___________ CD8 % no.___________  Total lym phocytes n o ._____________ /  /
Form completed by: Nam e  Date / /
Position______________________  Telephone_________ ^  Email
NSHPC confidential paediatric notification
LONDONM REC/04/2/009 : □ : V  y g  ; : , __________________
o f f ic e  u se  o n ly ___________________________________________________________________________________________________________________________________________ A /a y  2005
C S T U  M S T U  S U  P A E D  H O S P
P a ed ia tr ic ia n __________________________________________  H o sp ita l________________________________________
C O N F ID E N T IA L  P lease com p lete this form  as far as you can , even if  you do not have all deta ils requested
A PAEDIATRIC DETAILS
NHS no .......................................................  Hospital no .........................................  Initials  Soundex ..................
Dale o f birth / /  □  Male □  Female Home postcode □  □ □ □  □ □
------------------------1— 1 1— 1 (leave o ff last letter)
Ethnic origin Q ]  White | | Black African | | Black Caribbean | [Black other
Indian Subcontinent [ ^ ]  Oriental \^ \ Other or mixed, specify ........................... .
 __  Home postcode at birth i— 11— 1 I— 11— i i— 11— |
Bom in |__ | UK/Ireland Hospital o f b irth ...........................................  (leave off last letter) I— 11— 11— 11— I I— 11— I
or | | Abroad Country o f birth   and date arrived in UK/Ireland /  /
B HOW WAS THIS CHILD IDENTIFIED AS INFECTED OR AT RISK OF INFECTION?
1 1 Mother known to be infected in pregnancy 1 1 Child symptomatic
□  Mother/other family member found to be infected (specify relationship)..................................................................................
□  n k  I 1 Other, specify ..............................................................................................................................................................
Date o f child’s first lab investigation /  /  | 1 not yet done 1 1 tests refused □  NK
If you are aware o f siblings reported to us, please give dates o f birth or other ref: .........................................................................
C PERINATAL DETAILS
Mode of delivery \^ \ vaginal ( ^ ]  elective CS \^ \ emergency CS \^ \ NK G estation   B irthw eight..............
Any perinatal infections? 1 | No □  Yes, sp ec ify ...............................................................................................................................
Any congenital abnormalities? 1 1 No □  Yes, sp ec ify ...............................................................................................................................
Any other problems? 1 1 No □  Yes, sp ec ify ...............................................................................................................................
Anti-retroviral treatment for mother and/or baby to reduce risk of vertical transmission? \^ \ No \^ \ Yes, specify below
Antenatally? 1 1 NK 1 | No 1 | Yes, sp ec ify ....................................................................................................................................
Intrapartum? \^ \ NK U n o  1 | Yes, sp ecify .....................................................................................................................................
Post-partum (baby)? NK □  No □  Yes, sp ecify ....................................................................................................................................
Was the child breastfed? □  no  I I Yes, and breastfed for how long? (w k s).......................................... NK if breastfed
D PROBABLE SOURCE OF INFECTION
1. Exposed to maternal infection? \^ \ Yes, please give mother's details below \^ \ No, go to question 2 below NK
a) Mother’s date o f birth /  /  b) No. of previous livebirths..................stillbirths  miscarriages/terms.................
c) Mother’s country o f birth ...................................................................... and if not UK/Ireland, date arrived /  /
d) Mother diagnosed Q  after the birth o f this child Q  while pregnant with this child Q  before this pregnancy
e) Maternal infection probably acquired Q  in UK/Ireland Q  abroad, specify ................................................ Q ]  NK where
and likely exposure (tick all that apply)
I I injecting drug use \^ \ transfusion recipient
I I sexual exposure, specify partner’s probable risk factors if known ...........................................................................................................
I I mother to child transmission \^ \ no information on mother’s exposure
2. Other exposure risk for child? Q  No Q  Yes, please give details
□  blood/blood products abroad, please specify country and year ...
□  sexual exposure □  other, please specify........................... .............................................................
Thank you for completing the attached form. Please return it in the freepost envelope to:
Surveillance Studies Group, Centre for Paediatric Epidemiology & Biostatistics, Institute of Child Health, 
30 Guilford St, London WC1N 1BR.
If you have any queries phone us on 020 7829 8686.
Please complete this box and keep this page for your own records to help identify the 
child when you receive a follow-up form
Child’s name or other identification...................................................................................................................
Hospital number...........................................................  Study number (CSTU) ....................................
IN FECTIO N  STATUS
INFECTED
a) definitive
1. Child has Stage C disease (see definitions overleaf)
2. The detection of virus by PCR (at any age) on two separate specimens taken at different times
3. Antibody positive after the age of 18 months, or at any age if not bom to an infected woman
b) presumptive
The detection of virus by PCR (at any age) on one occasion
NOT INFECTED
a) definitive
Any one of the following and no evidence (viral, immunological or clinical) of infection:
1. One negative antibody test after the age of 12 months
2. Two consecutive negative antibody tests on separate samples taken at different times in children 
under 12 months
3. Two separate, consecutive, negative PCR results after one month of age -  at least one of these to be 
after 3 months of age
4. One negative PCR result and one negative antibody test on separate occasions after the age of 3 months
b) presumptive (in a non-breastfed child)
Either of the following and no evidence (viral, immunological or clinical) of infection:
1. One negative antibody test under the age of 12 months
2. One negative PCR after the age of one month
Indeterminate
A child bom to an infected woman where the child’s own infection status is not yet determined
Definitions of specific manifestations of infection requested
Manifestation Definition
Asymptomatic LIP* (see overleaf for definition of LIP) 
Severe bacterial infection 
Failure to thrive
Regression of developmental milestones
CXR abnormalities only; no respiratory signs or symptoms 
Single severe bacterial infection (state how diagnosed) 
Failure to thrive, not yet meeting definition overleaf 
Consistent regression over at least 3 months
P.T.O. for definitions of Stage C indicator diseases
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NSHPC follow-up to establish infection status
M RFC ref: MREC04/2/009
o f f ic e  u se  o n ly  ___________________________________________________________________________________________________________________  July 2005
C S T l !  M S T U  S U  P A E D  H O S P
Paediatrician .............................................................................. H o sp ita l..........................................................................................................
C O N F ID E N T IA L  P lease  c o m p le te  th is  form  as fa r  as you  can , even  if  y o u  d o  n ot h a v e  a ll d e ta ils  req u ested  
P le a se  c o m p le te  o r  a m e n d  th e se  c h ild  d e ta ils
Date o f  birth /  /  Q  M ale | | Fem ale In it ia ls   soundex if  a v a ila b le ...............
Current home postcode | 11 11 11 I I 11 11
Hospital n o .........................................  N H S n o.......................................  (leave off last letter) —  —  —  —  —  —
T h e last report w e  had on  th is ch ild  related  to  ex a m in a tio n  on  /  /  w h en  h is/h er  in fe c t io n  s ta tu s
h a d  n o t y e t  b een  c o n f ir m e d . I f  y o u  h ave m ore recent in form ation , p lea se  co m p le te  a ll se c tio n s  o f  th is form .
I f  y o u  h ave not seen  th is ch ild  s in ce  the last report p lea se  tick  here Q ,  co m p le te  the se c tio n  on  IN F E C T IO N  
ST A T U S, p rovid e any test resu lts not p rev io u sly  rep o rted  and co m p le te  the se c tio n  on  F O L L O W  U P  ST A T U S.
INFECTION STATUS & LABORATORY INVESTIGATIONS
D o you consider this child to be \^ \ infected not infected indeterminate (defin itions overleaf)
P lea se  p rovid e date o f  sam p le and ring typ e o f  test and resu lt for all d ia g n o stic  tests  s in c e  /  /
sample date type of test result sample date type of test result
1. / / antibody / PCR +  / - 4. / / antibody / PCR +  / -
2. / / antibody /  PCR +  / - 5. / / antibody /  PCR +  / -
3. / / antibody / PCR +  / - 6. / / antibody /  PCR +  / -
NB If this child is  now known to be infected we will contact you again for information on viral load, 
T-cell subsets and antiretroviral therapy.
THERAPY & CLINICAL DETAILS
PCP prophylaxis? d j  No Q  Y es, specify ........................................................
Date o f  last examination /  /  and, if taken at that time: W eight (kg)
A ny other serious infections or conditions? d l  N o  d l  Y es, specify ...........
FOLLOW UP STATUS
Date o f  last contact /  /  I I A live d l  Lost to fo llow  up d l  Known to have left UK/Eire
I I Being seen elswhere (please give details overleaf) d  Dead, date o f  death /  /  and if  dead
Certified cause a) d isease or condition directly leading to d ea th .................................................................................................... .
o f  death b) secondary c a u se (s ) .........................................................................................................................................................
Post-mortem? d l  N ot done d l  Done. Please attach a copy i f  possible.
C om pleted by: N a m e__________________________________  Position____________________________  Date
Tel n o _________________________________________________  Email_____________________________ _____________________
date started /  /
. .  Height ( c m ) ...............
Appendix 4 The Office for National Statistics flagging study: tables
and figure
4.1 Matches made when the matching algorithm was used without NHS number as 
compared to type 1 matches made when it was used with NHS number: unique 
matches and no matches
4.2 Matches made when the matching algorithm was used without NHS number as 
compared to type 1 matches made when it was used with NHS number: multiple 
matches
4.3 Confirmation of matches made using the matching algorithm
225
4.1 Matches made when the matching algorithm was used without NHS number as compared to type 1 matches made when it was used
with NHS number: unique matches and no matches (n=134)
Matches w ith o u t NHS 
number
Subjects
(n)
Reason for unique incorrect 
match/no match
Confirmation of correct/incorrect match without NHS number: do 
MCOB, BW\\f and PCD agree? (subjects)
Unique correct match 
on type 2 121 -
Agreed on 3 variables (53)
Agreed on 2 variables and 1 input variable missing (34)
Agreed on 2 variables and disagreed on 1 variable (12)
Agreed on 1 variable and 2 input variables missing (12)
Agreed on 1 variable, disagreed on 1 variable and 1 input variable missing (8) 
Agreed on 1 variable and disagreed on 2 variables (1)
Disagreed on 1 variable and 2 input variables missing (1)
Unique correct match 
on type 4# 5 -
Agreed on 2 variables (3)
Agreed on 1 variable and 1 input variable missing (1)
Agreed on 1 variable, disagreed on 1 variable and 1 input variable missing (1)
Unique incorrect 
match on type 2 4
Input MDOB differed from 
output MDOB on type 1 with 
NHS number
Disagreed on 3 variables (2)
Disagreed on 2 variables and 1 input variable missing (2)
Unique incorrect 
match on type 3 2
Input MDOB differed from 
output MDOB on type 1 with 
NHS number
Disagreed on 2 variables and 1 input variable missing (1) 
Disagreed on 2 variables and agreed on 1 variable* (1)
Unique incorrect 
match on type 4# 1
Input MDOB and PCD differed 
from output MDOB and PCD 
on type 1 with NHS number
Disagreed on 1 variable and 1 input variable missing (2)
No match 1 Input PCD and MDOB missing -
N otes: M D O B , m other’s c ate o f  birth; PC D, m other’s p ostcode district o f  residence at delivery; M C O B , m other’s country o f  birth; B W , ch ild ’s birth w eight.
M atches w ere identified  as correct/incorrect i f  N H S  num ber o f  the m atch found w ith  the algorithm  u sed  w ithout N H S  num ber w as the sam e/different as that found  
w ith  the algorithm  used  w ith N H S  number. *M C O B w as U K . #T yp e 4  m atch includes PC D , therefore not included  in  the confirm ation o f  correct/incorrect m atch. \j/ 
w ithin  lOg.
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4.2 Matches made when the matching algorithm was used without NHS number as compared to type 1 matches made when it
was used with NHS number: multiple matches (n=32)
Matches without NHS number Subject
(n)
Confirmation of correct/incorrect match without NHS number: do MCOB, BW\[/ 
and PCD agree?
Two matches on type 2: one correct 19
1) Correct match agreed on at least one available variable & incorrect match did not 
agree on any available variables (14 pairs)
2) Correct match disagreed on MCOB, agreed on 1 variable and 1 input variable was 
missing & incorrect match agreed on MCOB*, disagreed on 1 variable and 1 input 
variable was missing (2 pairs)
3) Correct match disagreed on 1 variable and 2 input variables were missing & 
incorrect match disagreed on 1 variable and 2 input variables were missing (1 pair)
4) Twin pairs: correct match agreed on MCOB, PCD, BW & incorrect match agreed 
on MCOB, PCD and disagreed on BW (2 pairs)
Two matches on type 2: both incorrect 1 Both possible matches disagreed on 3 variables
Three matches on type 2: one correct 1 Correct match agreed on at least one available variable & incorrect matches did not agree on any available variables
Two matches on type 4: both incorrect# 1 Both possible matches disagreed on 1 variable and 1 input variable was missing
Two matches on type 4; one correct# 6
1) Correct match agreed on at least one available variable & incorrect match did not 
agree on any available variables (5 pairs)
2) Correct match disagreed on MCOB and agreed on BW & incorrect match agreed 
on MCOB* and disagreed on BW (1 pair)
Three matches on type 4: one correct# 4
1) Correct match agreed on at least one available variable & incorrect matches did 
not agree on any available variables (3 pairs)
2) Correct match agreed on MCOB and BW & one incorrect match disagreed on 
MCOB and BW and the other incorrect match agreed on MCOB* and disagreed on 
BW (1 pair)
Notes: M DOB, mother’s date o f  birth; PCD, mother’s postcode district o f  residence at delivery; M COB, mother’s country o f  birth; BW , child’s birth weight. Matches were 
identified as correct/incorrect i f  N H S number o f  the match found with the algorithm used without NH S number was the same/different as that found with the algorithm used  
with N H S number. *MCOB was UK. #Type 4 match includes PCD, therefore not included in the confirmation o f  correct/incorrect match. \j/ within lOg.
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4.3 Confirmation of matches made using the matching algorithm
Type 1 match
(unique)
Flag
match
Flag
match
Matching
algorithm
No match
Type 6 m atch4 or type 
5 match
Type 2 or type 
3 match
Match agreed Match did
on at least one not agree on
variable (BW, any variables
MCOB* or (BW,
PCD) MCOB or
PCD)
Do not
match
matches
did not
agree on
variables
MCOB
or PCD)
Do not 
flag any 
matches
X
Unique Multiple Unique Multiple
match for matches for match for matches for
subject subject subject subject
More than 
one match for 
subject that 
agreed on at 
least one 
variable 
(BW#, 
MCOB* or 
PCD)
I
Match agreed Match did
on at least one not agree on
variable (BW any variables
or MCOB*) (BW or
MCOB)
Flag
match
Do not
match
All
matches 
for 
subject 
did not 
agree on 
any 
variables 
(BW or 
MCOB)
Flag match 
that agreed 
with the most 
variables
More than 
one match for 
subject that 
agreed on at 
least one 
variable 
(BW# or 
MCOB*)
Match agreed 
on at least one 
variable (BW, 
MCOB* or 
PCD)
I
Match did 
not agree on 
any variables 
(BW, 
MCOB or 
PCD)
Flag
match
Do not
m atch
Flag match
Do not that agreed
flag any with the most
matches variables
N otes: PCD, m other’s postcode district o f  residence at delivery; M C O B, m other’s country o f  birth; BW , ch ild ’s birth w eight. * If agreed on M CO B and M C O B w as 
U K  then does not count as an agreem ent. # I f  tw in or triplet, m ust agree on BW . B W  considered to agree i f  w ithin lOg.
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Appendix 5 The main hospitals involved in the CHART study
Core hospitals (1st phase)
St Thomas’ Hospital, London:  
St Mary’s Hospital, London:  
Newham General Hospital, London:  
St George’s Hospital, London:  
Royal Free Hospital, London: 
Core hospitals (2nd phase)
Whinns Cross Hospital, London: 
Sheffield Children’s Hospital. Sheffield: 
Leicester Royal Infirmary, Leicester: 
Northwick Park Hospital. Harrow: 
John Radcliffe Hospital. Oxford: 
Birmingham Heartlands Hospital. Birmingham: 
Other large hospitals
King’s College Hospital. London: 
Homerton University Hospital, London: 
University Hospital Lewisham, London: 
Chelsea and Westminster Hospital, London: 
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Appendix 6 The CHART study forms
6.1 Follow-up status form
6.2 Questionnaire
6.3 Parent’s information sheet
6.4 Health professional’s information sheet
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Follow up of uninfected children born to 
_________ HIV infected women (CHART)
For office use only
CSTU: MSTU: CONTACT: HOSP:
Please tick the appropriate statement(s) and sign this form.
1) O  The child’s parent / carer has been contacted about this study.
Has the parent agreed to take part in the study?
I I Agreed
How was consent given? Signed consent form Q  Verbal consent I I 
Where is the consent form stored? Q  Parent’s notes in this clinic
I I Child’s notes in this clinic 
I I Elsewhere, specify.........................
I I Not agreed If possible, please specify reason:
I I No reply Please explain:
2) The parent / carer has not been contacted about the study because:
□  The child has left the UK
□  The child is lost to follow up (because?...................................................................
I I The child / parent has been discharged from this clinic
Please provide contact details for another health professional who is aware o f the 
mother’s H IV  status:...............................................................................................
I I Other Please explain:
Signed.............................................................................Date
Phone number..........................................................................
Email.......................................................................................
 2 231--------
Follow up of uninfected children born to HIV infected women 
(CHART) - Questionnaire for child’s parent/carer_____
For office use o n ly ______________ ____________________________________________________________________________________________________
CSTU MSTIJ CONTACT HOSP
CONFIDENTIAL
1 )  Child details. Please supply any m issing information, or make any corrections.
Date o f  birth /  / _________  EH  Male E Z  Female Initials
Hospital n o   N H S no
The last information w e had on this child was dated /  /
This questionnaire should be com pleted by a health professional. Please tick boxes and com plete as appropriate.
The questions in bold print are to be addressed to the parent/carer. It may help to consult the ch ild ’s Parent Held Record.
2 )  Family. Who does the child currently live with? (Tick all that apply) 
Z] Mother EZI Father [ZZ1 Other relative, sp ecify ............................................................
If the child is not with his/her family, has s/he been: 
Z| Fostered ZU  Adopted [ZZI Other, sp ecify ..............
We would like to know how your child is doing in terms of general health, growth and development 
(since we last collected information on  ), and we have some questions for you.
3) Grow th. Please measure and/or w eigh this child today.
Height (cm )......................................... Weight (k g )   Date /  / _________
If this w as not possible, please supply the ch ild ’s m ost recent measured or estimated height and/or weight.
Height (c m )................................... Date /  / _________  1 | Measured | | Estimated | | Not known
Weight ( k g ) ................................... Date   |ZZI Measured [ZZI Estimated □  Not known
4 )  Developmental progress. Does your child attend: (Tick all that apply)
□  School I 1 Nursery | | Childminder 1 1 Other, specify.......................................................................................
Does your child receive any extra help at nursery or school? ZZI Not applicable [ZZ No □  Yes, specify
Does your child have any problems with, or do you have any concerns about their:
Walking/movement [ZZI No (ZZI Yes, sp ecify ............................................................................................
Speech [Z ] No EZ] Yes, sp ecify ............................................................................................
Hearing/ears [Z J No EZ] Yes, sp ecify ............................................................................................
Sight/eyes ZZI No EH  Yes» sp ecify ............................................................................................
Behaviour [ | No EH  Yes> sp ecify ............................................................................................
Other □  No □  Yes, sp ecify ..........................232-...........................................................
5) General Health. Do you think your child is generally fit and healthy? Q  Yes Q  No, specify
Since we last collected information, has your child been seen by your general practitioner, been referred 
to a specialist, been admitted to hospital or been taking on-going medication for: (Tick all that apply)
G eneral M edical or H ospital On-going
practitioner other specialist adm ission m edication
Chest infections □ □ □ □
Wheezing or asthma □ □ □ □
Fits or convulsions □ □ □ □
Other problems □ □ □ □
Please give full details of all the conditions ticked.
6) Do you have any concerns about your child’s growth, general health and progress that are not already 
mentioned above?
□  No □  Yes, sp ec ify ....................................................................................................................................................................................................
Contact details of the health professional who should be sent child’s next follow-up questionnaire
Email____________________________________   Telephone number__________________________
Where was the questionnaire completed? In clinic [^] Over the phone [^] Elsewhere, specify...................................
Was the child present? No Yes
Was the child’s Parent Held Record consulted while the questionnaire was completed? Q  No Q ] Yes
Is there anything else about this child’s health or development not mentioned above? [ ] No □  Yes, specify
Form completed by
7) Please thank the parent/carer for helping us with our study. The rest of the questions are for the health professional.
Date Occupation
CHART - Parent’s information sheet
We would like to invite you to take part in a study (the CHART study) in which 
uninfected children bom to mothers with HIV infection are being followed up.
Why do we need to follow up these children?
Most pregnant women with HIV take anti-HIV drugs during pregnancy and nearly all 
babies bom to HIV infected women are given these drugs in the first few weeks of 
life. As a result most babies bom to HIV infected women are not infected themselves. 
We do not think there are any serious side effects for children who are exposed to this 
treatment in the womb and in early life. However to make sure this is the case we 
would like to follow up all uninfected children bom to mothers with HIV, whether or 
not their mothers had treatment in pregnancy.
How will this be done?
We would like to keep in touch with you and your child over the long term, and to 
collect information about your child’s general health, growth and development once a 
year. One member of the clinic team currently responsible for your care or your 
child’s care will complete a questionnaire with your help, at a convenient time. If your 
child has any serious health problem we may need to contact the specialists looking 
after him/her for further information. In this case we would ask your permission to do 
this.
Do I have to take part in the CHART study?
Taking part in this study is completely voluntary. You can decide, now or at a later 
stage, that you do not wish to take part. This will not affect any present or future 
treatment or care for you or your child.
What are the potential benefits?
This study will not bring any immediate benefits to your child. However it is 
important to find out whether using these anti-HIV drugs in pregnancy and infancy 
has any unexpected side effects, which could be avoided in the future. If any such 
problems are identified which require further treatment or tests, we would be able to 
contact you.
What are the risks and discomforts?
There are no physical risks or discomforts to you or your child from taking part in this 
study.
Who will have access to the questionnaire information?
The questionnaire will be forwarded to the researchers at the Institute of Child Health 
in London but it will not include your name. All information will be held in strict 
confidence.
Who do I speak to if any problems arise?
If you have any concerns about the study a member of the clinic team will be happy to 
discuss them with you.
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For office use only
CSTU MSTU CONTACT HOSP
CHART - Consent form
For the parent/carer:
Please read and sign this form.
I have read the parent’s information sheet on the CHART study.
I am willing to participate in the study and to answer some questions about my 
child’s health.
Parent/carer: Signed..............................................................Date
Health professional: Signed............................................................. Date
Consent form to be 
kept in the clinic
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Follow up of uninfected children born to 
HIV infected women (CHART) 
Health professional’s information sheet
Background
The use of antiretroviral therapy (ART) during pregnancy for the prevention of 
vertical transmission of HIV has resulted in a substantial reduction in the number of 
HIV infected children. As pregnant women increasingly use this therapy and neonates 
are usually given ART in the first few weeks of life, a large number of uninfected 
children are being bom that have been exposed to these drugs. However, there has 
been little research on any possible long-term adverse effects of in utero and neonatal 
exposure to antiretroviral drugs. It is important to monitor the effects of this exposure 
and to identify and investigate any possible side effects.
Follow up of children exposed to antiretroviral therapy in pregnancy
In the UK and Ireland, pregnant women known to be HIV infected are reported 
through the Royal College of Obstetricians and Gynaecologists (RCOG) to the 
National Study of HIV in Pregnancy and Childhood (NSHPC), based at the Institute 
of Child Health in London. In a parallel scheme, paediatric cases of HIV infection and 
children bom to HIV infected women are notified through the British Paediatric 
Surveillance Unit (BPSU) of the Royal College of Paediatrics and Child Health, and 
are followed up to ascertain infection status and progression to AIDS. The reports are 
linked and contribute the paediatric data to the overall surveillance of HIV and AIDS.
Originally, once children bom to HIV infected women were confirmed to be 
uninfected, no further follow up information was sought. For infected children (and 
those of indeterminate status) annual follow up information was requested from 
notifying paediatricians.
We are now extending annual follow up in the UK by collecting information on 
children who are confirmed uninfected (the CHART study). This will be done by a 
health professional completing a questionnaire on the child’s general health, growth 
and development in consultation with the child’s parent/carer. In the unlikely event of 
a major health problem being identified, we may need further medical information on 
the child from their records within the unit. If specialists outside this team need to be 
contacted for information, we will ask for parental permission to do so.
In most cases the information on the antiretroviral therapy exposure will already have 
been prospectively obtained through the obstetric and paediatric surveillance.
Parental consent
The health professional (obstetrician or genitourinary physician) looking after the 
woman during pregnancy should have already discussed the risks and benefits of 
therapy with her and indicated that she will be asked for permission for her uninfected 
child to be followed up.
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On the questionnaire, there is space for further details about the child’s general health, 
growth and development. The health professional should use this where applicable.
Each follow up questionnaire relates to the period since the last one was completed, or 
since confirmation of uninfected status if it is the first. The health professional may 
want to refer to the previous questionnaire to avoid duplicating information.
Notes on completing the questionnaire
Box 1- We will fill in information that we have to identify the child. The health 
professional should supply any missing information, or make any corrections to 
this. Information is being sought relating to the period since the date specified. 
Please supply the child’s NHS number if available.
Box 2- The relatives that the child lives with should be specified. If the child does 
not live with their own family, please give details of their current carer.
Box 3- The health professional should weigh and measure the child (without shoes 
and outdoor clothing) when the questionnaire is filled in. If this is not possible, 
they should supply the most recent measured or estimated height and weight. This 
may be taken from the Parent Held Record or the child’s clinic records.
Box 4- We would like to know about any extra help that the child receives relating 
to their learning and development. If the child has problems with walking, speech, 
hearing, sight or behaviour for which a specialist opinion has been sought or the 
parent/carer has concerns, please give details.
Box 5- We are interested in any problems that have required medical attention, a 
stay in hospital or on-going medication. We would like to know the frequency with 
which these serious illnesses have occurred or whether they are a chronic 
condition. Please supply the names and addresses of the relevant hospitals or 
specialists.
Box 6- This allows the parent/carer to mention any concerns they have that have 
not been included in the rest of the questionnaire.
Box 7- This is for the health professional to complete. If they have any information 
on the child’s health, growth and development that has not been given in the rest of 
the questionnaire, they should include it here. It is important to date and sign the 
form and let us know to whom we should send the next follow up questionnaire.
The top copy of the questionnaire should be returned in the freepost envelope to: 
Claire Hankin, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child 
Health . The bottom copy should be kept in 
the parent or child’s notes.
The parent/carer should be encouraged to bring in their Parent Held Record, which 
may assist in the completion of the questionnaire. Ideally this questionnaire will be
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Antiretroviral therapy-exposed uninfected children
born to HIV-infected women
M A questionnaire for health professionals
Name............................................................Position....................................
Hospital..............................................................................Date completed.
When the CHART study was established in 2002, part of the remit was to a ssess  the 
feasibility of following up uninfected children. We would like to know what your clinic 
practice is regarding uninfected children. We would also like to hear about your experience 
with the CHART study, particularly how you approached the families and issues that you 
feel may have affected enrolment. ____ ______
A) CLINIC INFORM ATION
1) Approximately how many uninfected children born to HIV-infected women are 
seen in your clinics?
...........................per month/year (delete as appropriate)
2) What best describes the clinic where uninfected children are generally seen?
General paediatric clinic I I
Paediatric infectious d iseases clinic I I
Paediatric HIV clinic I I
Family HIV clinic (for children and adults) I I
Other, specify...........................................................  HH
3) Do you regularly discuss issues relating to uninfected children with colleagues in 
the following departments in your hospital?
Yes No
Genitourinary/Sexual Health department O  I I
Antenatal/Obstetric department O  I I
Other, specify............................................................ d l  d ]
4) What is your routine clinic follow u p  protocol for a child born to a woman 
diagnosed with HIV before or during delivery? (e.g. 6 weeks, 3 months etc.)
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9a) How have vou usually approached parents/carers about the CHART studv?
9b) How often have vou used other wavs to approach oarents/carers about the
CHART study?
9a) 9b)
(tick one) (tick all that apply)
Usually Sometimes Hardly ever Never
At child’s confirmatory test □ □ □ □
Opportunistically in paediatric clinic □ □ □ □
Opportunistically in adult clinic □ □ □ □
Over the phone □ □ □ □
In the parent/carer’s home □ □ □ □
Other, specify................................. □ □ □ □
10) How often have the followina situations made contactina oarents/carers about
the CHART study difficult?
Frequently Sometimes Hardly ever Never
Regularly DNA scheduled □ □ □ □
appointments
Lost contact with family □ □ □ □
Family known to have left the UK □ □ □ □
Difficult family circumstances □ □ □ □
Child discharged from clinic □ □ □ □
Lack of cfinic staff time □ □ □ □
Other, specify................................... □ □ □
11) How often have the followina issues olaved a part in oarents/carers aareeina to
take part in the CHART study?
Frequently Sometimes Hardly ever Never
Concern over the safety of the □ □ □ □
antiretroviral therapy
Wanting to keep in contact with □ □ □ □
health services
Feeling uncomfortable about refusing □ □ □ □
Other, specify......... ......................... .....□ □ □ □
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15) When do you think parents/carers should be asked for permission for the child 
to be included in follow-up?
During pregnancy 
At birth
When child is known to be uninfected 
Other, specify..................................
□□□□
In the parent/carer questionnaire we describe several different ways of following up 
uninfected children, including the CHART protocol. Please read the four options and 
answer the questions on the following page. Any new system  would have to be approved 
through the appropriate channels.
OPTION A (CLINIC CONTACT)
• You would ask the parent/carer and/or the child to come to the family or paediatric clinic 
once a year.
• You would ask them general questions about the child’s health.
• The answers would be put on a form and sent to us. Neither the parent/carer’s name 
nor the child’s name would be on the form.
• The parent/carer would need to inform you of any change in their contact details.
OPTION B (TELEPHONE CONTACT)
• You would telephone the parent/carer once a year and would ask them general 
questions about the child’s health.
• The answers would be put on a form and sent to us. Neither the parent/carer’s name 
nor the child’s name would be on the form.
• The parent/carer would not need to attend the clinic to take part, but they would need to 
inform you of any change in their telephone number.
OPTION C (POSTAL CONTACT)
• You would give us the parent/carer’s contact details when the child was discharged. We 
would keep these in strict confidence.
• We would send the parent/carer a short form about the child’s health once a year, for 
them to complete and send back to us.
• There would be no reference to HIV on anything they were sent.
• They would need to inform us of any change in their address.
OPTION D (NO DIRECT CONTACT)
• We would not need to have any regular direct contact with the parent/carer or the child 
and we would not know the parent/carer’s or the child’s name or address.
• Every child in the UK is given an NHS number at birth. You would give us the child’s 
NHS number which we could relate to routinely available health information.
• The parent/carer would not have to keep in contact with the clinic after the child was 
discharged.______________________________________ ______________________________
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Appendix 8 Comments from the health professional survey
questionnaires 
Comments on the CHART study
“Difficulties with keeping in touch with families, often move frequently. Also, most 
families feel happy at 18/12 when discharged, feel bad asking them to keep in touch for 
longer. ” [Respondent 12]
“Families are often busy may need to phone several times after a while you feel bad 
hounding them” [Respondent 14]
“When parents are discharged they want to get away from us as fast as possible and 
start to live a ‘normal ’ life. As for us contacting them, they stress out at us i f  a new 
partner is on the scene and knows nothing about the mother's status. These are things I  
have had to worry about and some mothers have put the phone down on me saying 
‘never contact me again ’. ” [Respondent 15]
“People do not think through what it means- i. e. they do want to help/be followed up but 
change address, phones etc and CHART is not on their minds once they move on with 
children growing up. I  have never spoken to anyone who didn't think it important in 
principle; it's the intrusion in their lives which puts them off. ” [Respondent 14]
“Two distinct groups o f patients exist: 1- who would like engaging medical contact with 
non specific concerns. 2- who would want to cut off with us as soon as possible. ” 
[Respondent 16]
“This was a very important study, the difficulty for us health professionals was trying to 
contact some o f the carers/parents, due to high mobility o f our clients. With older 
children, parents/carers were very suspicious when we contacted them, and will often 
DNA appointments. ” [Respondent 17]
“In retrospect I  should have discussed it more regularly at clinic visits but many had 
only had 1 or 2 negative tests and were indeterminate status. By the time they are known 
to be negative they are then not in regular contact until 18/12 and many o f these are lost 
to follow up/move. ” [Respondent 04]
“To enrol before 3/12 old so have opportunity to discuss while still in close contact. ” 
[Respondent 05]
“Problem for paeds is we discharge them after the 12-15/12 bloods, completing a form 
for you then. Our HIV clinic have agreed to continue handing out Qs. ” [Respondent 29]
“I apologise for not recruiting my children. This was due to fact I  don't routinely see 
after 18/12. Did explore getting GU team to do it- interested but I  failed to take it 
forward fast enough. [Respondent 30]
“Two major barriers to enrolling into the study: 1. family discharged from clinic and do 
not want on-going involvement or move/are moved away. 2. lack o f time and resources 
to undertake extra work commitment to this. ” [Respondent 06]
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"Despite relatively simple study, this has proved difficult to carry out here with poor 
secretarial resources and DNA appointments. Clinics already very busy. ” [Respondent 
37]
“Although it is difficult for us to have time to follow up these children and to keep track 
of the families-1 think it would be virtually impossible for centres e.g. out o f London- 
who do not have dedicated paed HIV staff. ” [Respondent 27]
“We didn’t encounter many problems because o f our small cohort offamilies- they were 
all more than willing to help. ” [Respondent 40]
“The entire workload has rested with a single paediatric consultant (myself) and the 
paperwork and parent liaison has been a nightmare. We are a particularly busy unit and 
a smaller unit with fewer children would find this a lot easier. ” [Respondent 09]
“I  think it is important to carry on even though I  am bad at filling out the forms. ” 
[Respondent 13]
“All but one agreed. Reasons for agreeing not discussed but seemed to understand need 
for checking no unexpected side effects. ” [Respondent 29]
“Forms have been relatively easy to complete and generally can be done so during 
regular consultation time. ” [Respondent 08]
“I f  there are going to be long term and subtle side effects, CHART questionnaire is too 
simple to unearth these. Overall I  feel slightly uneasy bringing children all the way to the 
clinic and send back after a few simple questions. So I  also examine them thoroughly 
[Respondent 16]
“I  would be happy to continue recruiting into the study as I  feel the data that is 
generated will guide service development. ” [Respondent 22]
Comments on the follow-up options presented in the questionnaire
“I think the concept o f long term follow-up needs to be raised when women are being 
either started on treatment or when/during pregnancy and then reiterated at all other 
visits for baby follow up i.e. birth, 6 weeks, 3 months and 18 months. ” [Respondent 14]
“Parents could be informed about study during clinic visits so that when child is 
uninfected they will be expecting follow up studies. ” [Respondent 18]
“Options A-C all unfunded at present. I  have warned parents that long term contact may 
occur. " [Respondent 11]
“I would prefer that follow-up did not take place from clinic. Difficulties in dedicating 
time etc. " [Respondent 12]
“All OK- but option A is not achievable for 100% o f the families therefore is it useful as 
so many are lost to follow up. ” [Respondent 27]
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“There is a significant issue with respect to clinician and clinic time. As length o f follow 
up proposed increases number o f contacts will grow. I  deal with relatively low numbers 
but for a large patient load this is likely to become unmanageable. Personally I  find it 
difficult to allocate outpatient slots as I  am seeing these patients in the context of a busy 
neonatal follow up programme and as patient numbers increase this problem will 
escalate. A non clinic contact is therefore attractive. I  think phone and post contacts may 
well be difficult to achieve given the mobility o f many o f these patients. ” [Respondent 
28]
“Problem with postal contact is that may be opened by another family member- many 
asylum seekers in multioccupation. Even if  no mention o f HIV it may trigger awkward 
questions. My own experience ofpostal follow up would suggest you'll get very few  
answers not because o f genuine refusal but just never received it. D is probably best 
option if there is enough useful info held centrally but no good if  only tracks mortality 
[Respondent 29]
“Would be delighted to give you details to follow families directly- appreciate this needs 
different ethics agreement. ” [Respondent 37]
“Seeing in clinic is ideal but at present to do this would involve me using 2 whole clinics 
for this and I  do not think our Trust would agree to this. ” [Respondent 30]
“Re option C-1 would be happy to ask families at last visit when uninfected but I  do not 
think you will get good response as it is not something they can continue to feel 100% 
commitment to and that’s what you need- other things become more important naturally 
over time” [Respondent 14]
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Appendix 9 The hospitals involved in the parent and carer survey
Chelsea and Westminster Hospital, London:  
Homerton University Hospital. London:  
King’s College Hospital, London: 
Newham General Hospital. London: 
Northampton General Hospital, Northampton: 
Princess Anne Hospital, Southampton: 
Princess Royal Maternity Hospital, Glasgow: 
St George’s Hospital, London: 
St James’ University Hospital, Leeds: 
St Thomas’ Hospital, London: 
University Hospital of Wales. Cardiff: 
Wexham Park Hospital, Slough: 
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Appendix 10 The parent and carer survey information sheet
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Parents and carers’ views on long-term follow-up
INFORMATION SHEET
We are researchers at the Institute of Child Health in London and we would like to 
ask you to complete a short questionnaire about you and your child. We would like to 
know your views on the long-term follow-up of uninfected children born to women 
with HIV.
What do we mean by “long-term follow-up”?
We are trying to find the best way to keep in contact with uninfected children and 
their families throughout childhood.
Why should we follow up uninfected children?
Most children born to HIV infected women in the UK are themselves uninfected. For 
example, in 2001 there were about 500 children born in the UK to HIV infected 
women. Of these about 475 were uninfected.
Most uninfected children have been exposed to anti-HIV drugs because their mother 
took them when she was pregnant. It is unlikely that these drugs have serious side 
effects. However, we want to ask your views on ways to keep in contact with these 
children in case any side effects are found in the future.
Who should complete the questionnaire?
A parent or a carer (such as a grandparent) of an uninfected child born in the UK to 
an HIV infected woman who took anti-HIV drugs when she was pregnant.
Who would see the completed questionnaire?
Only the researchers at the Institute of Child Health would see  the completed 
questionnaire. You will NOT be asked for your name. No information about you or 
your child collected by the clinic would be linked to anything you write on the 
questionnaire.
Do I have to take part?
No. Taking part is completely voluntary. If you do not want to take part, your own 
care and the care of your child will not be affected in any way. However completing 
this questionnaire means that you can tell us what you think about how we should 
keep in contact with these children.
How to contact one of the researchers:
The contact person is: Claire Hankin, Centre for Paediatric Epidemiology and 
Biostatistics, Institute of Child Health,  
If you have decided to complete the questionnaire, please then put it in the 
envelope provided, seal it and return it to the researcher in the clinic.
We do NOT need to know your name. Please do NOT write your name on the 
questionnaire.
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Parents and carers’ views on long-term follow-up
ANONYMOUS QUESTIONNAIRE
Date: / / Clinic:
SECTION 1: YOU AND YOUR CHILD
1) How many children who were born to an HIV infected woman are in your care?
2) For the child/children, please tell us their age, their HIV infection status and
whether they were born in the UK. Continue on last page if necessary
Age Infection status Born in the UK?
Infected Uninfected Not known Yes No
  □  □  □  □  □
  □  □  □  □  □
  □  □  □  □  □
  □  □  □  □  □
3) What is your relationship to the child/children? Tick all that apply
Mother O
Father O
Aunt/Uncle
Grandparent Q
Adoptive/Foster parent Q
Other (please specify) Q .....................................................................
4) Which country were you born in?
5) Looking to the future, do you expect the child/children to continue living in 
the UK?
Yes O
No O  If NO, when might they leave the UK ?.....................................
6) How often do you visit the family or paediatric clinic for the child/children’s
care?
No longer visit clinic O
Less than once a year I I
1-4 times a year O
More than 4 times a year Q
7) Have you always visited the same family or paediatric clinic with the
child/children?
Yes □
No Q If NO, how many have you been to?...............
8) Do you ever take the child/children to a GP?
Yes Q
No Q  I f  NO, go to question 10
11) Parental permission would be needed before a child was included in options A,
B or C (direct contact).
If we used option D (no direct contact), do you think parental permission 
would also be needed?
Yes O
No □
12) When do you think parents/carers should be asked for permission for the
child to be included in follow-up?
During pregnancy □
At birth □
When child is known to be uninfected □
Other (give details below) □
13) How much do you agree with the following statement:
It is important to follow up uninfected children to see if there are any side 
effects from anti-HIV drugs
Strongly agree Q
Agree □
Disagree I I
Strongly disagree O
14) Which option(s) would be acceptable to you?
Tick one box for each option
Yes No
Option A (Clinic contact) □ □
Option B (Telephone contact) □ □
Option C (Postal contact) □ □
Option D (No direct contact) □ □
15) Do you strongly object to any of the options?
Yes Q]
No O  I f  NO, go to question 17
16) Which option(s) do you object to, and why? Continue overleaf if necessary
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Appendix 12 Comments from the parent and carer survey 
questionnaires 
Importance of follow-up
“I  think it is a good idea following up these children because it shows you have their 
interest at heart and would like to know and help them if  they do get any side effects from 
the drugs. ” [Mother of two children (aged 1 and 7 years)]
“We don't know the outcome o f these drugs so we shouldn't hesitate with investigations. ” 
[Father of four children (aged 1,4, 14 and 15 years)]
“I strongly feel that it's very important to follow up on our children since nobody knows 
what the long term effects o f these drugs can be. ” [Mother of two children (aged 3 and 7 
years)]
“I  think it’s a good idea because they are strong drugs and it's known that pregnant 
women shouldn't take drugs. Nobody knows what kind o f effects the drugs have in the 
future or not. This would enable them to help other children. ” [Mother of two children 
(aged 3 months and 2 years)]
“I think it's important because you don’t know the side effects. I  think about it sometimes 
but not very often. ” [Mother of three children (aged 1, 3 and 6 years)]
“Sometimes when my son is ill I  think all the negative things but i f  he's followed up my 
mind can be clear. I  think following them up is a good idea. ” [Mother of one child (aged 
1 year)]
Need for follow-up?
“I f  they think there are problems then it [follow-up] is important. I f  there aren't side 
effects then it is wasting time. ’’ [Mother of four children (aged 2, 3, 11 and 14 years)]
“When the baby is healthy and doesn't have any problems she doesn't need to be coming 
to the hospital. She's doing well but you never know i f  she will get a problem. ” [Mother 
of one child (aged 3 months)]
“When you are pregnant you are worried about the virus passing to baby and not 
strongly about the effects o f the drugs. ” [Mother of one child (aged 3 months)]
“I f  child is uninfected I'd like to leave it at that, rather than being reminded o f the 
illness. ” [Mother of one child (aged 6 months)]
Specific child health concerns
“I sometimes think she’s too skinny and wonder if  i t ’s the drugs. My other babies are 
chubby. ” [Mother of three children (aged 1, 3 and 12 years)]
“I  think once the drugs have come out o f the child’s system I  would have thought there 
would be no such risk again, but for children could it make them as teenagers not being 
able to have children later on in life? ” [Mother of two children (aged 2 and 4 years)]
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Disclosure and confidentiality
“Although I  strongly support research into the follow-up o f children exposed to anti HIV 
drugs I am currently unwilling to give my permission for this to happen as I  feel that my 
decision o f when or whether to tell my child about my HIV status could be taken out o f 
my hands. I f  you can assure me this won't happen I  will happily comply. ” [Mother of one 
child (aged 1 year)]
“I think that is important to do a follow up, but at the same time i f  the child is uninfected 
it is difficult for them to maybe accept or understand about all this, so would be better to 
leave this subject (or burden as it is at the moment) out o f their life. ” [Mother of one 
child (aged 2 years)]
“I'm happy about the system they have now, the advice and the care that you get when 
you are pregnant. But I'm not happy about coming back to the clinic because they 
[children] will start asking questions and I'm not ready to tell them about my situation 
until they are 16. " [Mother of four children (aged 2, 3, 11 and 14 years)]
“I f  baby is negative until 3rd test, I  as a mother won’t be able to explain what happen 
(prefer kept a secret) but i f  risks happens on his health then I  decide then how to explain 
to him and what to do. ” [Mother of one child (aged 1 year)]
“I think once a teenager reaches a certain age I  not sure I  would tell my children I  have 
HIV if I ’m still alive so I  would not want to harm or scare them in any way but that’s a 
long way ahead o f me, things change. ” [Mother of two children (aged 2 and 4 years)]
“Ifeel that keep the child under checks would bring some conflict. In my opinion I  have 
chosen not to disclose my HIV status to my family. Therefore I  do not feel comfortable i f  
my children were to know my status from continuous check-up. [Mother of one child 
(aged 3 years)]
“I  wouldn't want this to be hanging over his head because I  am HIV. I  want him to be 
normal. ” [Mother of three children (aged 6, 14 and 17 years)]
“Am happy to help with research i f  totally anonymous. " [Mother of one child (aged 1 
year)]
“I think that GPs must be aware o f any follow-up programme. I  know some families with 
HIV are not always comfortable with this- but personally I  find it crucial to keep our 
family health care as 'normal' as possible- less explaining, and I  think less stigmatised. ” 
[Mother of one child (aged 6 years)]
Timing of follow-up
“I want to know in pregnancy what kind o f follow up is coming up. ’’ [Mother of one 
child (aged 1 year)]
“When you ask parents depends on how it's done. It depends on how you supply the 
information. I f  someone is struggling with their pregnancy you're not going to get the 
best feedback. It might not be appropriate to ask them when they are pregnant. ” [Father 
of one child (aged 1 year)]
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“I wouldn’t have time to bring him to clinic because most times I  come on Tuesdays and 
he's at school ” [Mother of three children (aged 6, 14, and 17 years)]
Contact via parent/carer or direct with child/young person?
Age of child/young person
“Ask the person themselves once they are 18. They will know about their parents’ illness 
when they are grown up. ” [Mother of one child (aged 3 months)]
“Depends on the age o f the child. The parents should be responsible enough to explain 
to the child at a reasonable age. By the time they are 16 they should know about the 
parent's diagnosis. I  would then be happy for them to be contacted directly. ” [Mother of 
two children (aged 6 weeks and 5 years)]
“I  think that when they are still young it would be important to contact the carer. But 
once they ’re more mature then it's fine to contact them without the carer there. ” [Mother 
of two children (aged 1 and 7 years)]
“Once they are an adult you can contact them directly. ” [Father of one child (aged 3 
months)]
“Depending on age. Some teenage children prefer their independence- yes- direct 
contact can be better. ” [Mother of four children (aged 3, 10, 14 and 16 years)]
“Contact still through the parents even when they are adults. ” [Mother of three children 
(aged 3, 8 and 9 years)]
“Should still contact the parent even when the child is older. ” [Mother of one child 
(aged 5 months)]
Permission
“Go direct to child. No need to ask for permission from mum. ” [Mother of one child 
(aged 2 years)]
“Researcher or clinic should only contact young person directly once permission has 
been sought from parent. It should be done in consultation with family doctor. ” [Mother 
of one child (aged 6 years)]
Contacting child/voung person
“The mother should be contacted rather than him directly. She's known him from birth. ” 
[Mother of three children (aged 1, 3 and 6 years)]
“I wouldn't want someone contacting my child. I'd rather it be left for me to be in control 
of it. ” [Mother of one child (aged 1 year)]
“I would like to know first. You might go to him first and he might not like it. I  don't want 
to do anything to upset my child. ” [Mother of one child (aged 1 year)]
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“The parent should be contacted first, no matter what the situation is, then the parent 
can speak to him/her about it in private. I  think it better, i f  it comes from the parent. ” 
[Mother of two children (aged 2 and 6 years)]
Child/voung person’s choice
“That's for him to decide. I  will tell him what happened- that I  took the drugs- and he 
can decide what to do for his future. ” [Mother of two children (aged 2 and 16 years)]
“I don't know. I f  they are grown up then it's up to them. ” [Mother of four children (aged 
2, 3, 11 and 14 years)]
Vital status of parent
"If I ’m still alive I  want it through me but i f  she knows then it can be through her. ” 
[Mother of three children (aged 1, 3 and 12 years)]
"It should be up to the parent/carer to tell the clinic or researchers when they can 
contact the young person. A young person should only be contacted i f  the parents are no 
longer around (dead). ” [Mother of three children (aged 1, 3 and 8 years)]
"If the monitoring can continue I  don't have a problem, but I  wouldn't want him to be 
contacted directly. I f  we are alive let it pass through us. ” [Father of four children (aged 
1,4, 14, and 15 years)]
Disclosure to child/voung person
"It depends on whether the carer or parent have been open about it the child can be 
contacted directly but i f  not the parent has to discuss it first with the child before he is 
called in to be seen or talk by the doctor. ” [Mother of two children (aged 1 and 8 years)]
"I think it should be up to the parent to tell the clinic i f  they can contact the young 
person as it would necessitate the mother's disclosure o f her own HIV status and this is a 
very personal, individual matter. " [Mother of one child (aged 1 year)]
“This entirely depends on how much is known by the children about parent’s condition. 
Each case is individual but no contact without prior permission should ever occur. ” 
[Father of three children (aged 1, 2 and 12 years)]
“The clinic or researchers must not under any circumstances break the news o f a 
parents infection to a young person. I  think it is the parents/carer responsibility to do so 
when they feel the time is right. ” [Mother of two children (aged 1 and 3 years)]
"Contacting the parents is better because he doesn't know about the Mum's illness. " 
[Father of two children (aged 2 and 6 years)]
"It should be up to the parent to tell the clinic when appropriate, as many people may 
not want to let their children know i f  they remain uninfected. ” [Mother of one child 
(aged 4 months)]
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